Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 5379 |
| CHEMBL ID | 31 |
| CHEBI ID | 5280 |
| SCHEMBL ID | 22591 |
| MeSH ID | M0209340 |
| Synonym |
|---|
| AB00171654-13 |
| AB00171654-14 |
| BRD-A74980173-001-02-8 |
| gatifloxacin & gamma interferon |
| MLS000040259 |
| am-1155 |
| gatiflo |
| zymar |
| zymaxid |
| cg-5501 |
| bonoq |
| SPECTRUM_001909 |
| SPECTRUM5_001468 |
| NCGC00178525-01 |
| BSPBIO_002697 |
| 112811-59-3 |
| gatifloxacin |
| C07661 |
| am 1155 |
| gtfx |
| 3-quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo- |
| tequin |
| am-1155 (*sesquihydrate*) |
| pd-135432 |
| bms-206584 |
| cg 5501 |
| 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid |
| MLS000759493 |
| 1-cyclopropyl-6-fluoro- 8-methoxy-7-(3-methylpiperazin-1-yl)- 4-oxo-quinoline-3-carboxylic acid |
| DB01044 |
| gatifloxacin anhydrous |
| 1-cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid |
| cpd000043336 |
| NCGC00095126-02 |
| NCGC00095126-01 |
| gatilox |
| bms 206584-01 |
| (+-)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid |
| gatispan |
| gaity |
| gatifloxacin [usan:inn] |
| pd 135432 |
| gatiquin |
| smr000043336 |
| KBIOGR_001613 |
| KBIO3_001917 |
| KBIO2_007578 |
| KBIOSS_002448 |
| KBIO2_002442 |
| KBIO2_005010 |
| SPECTRUM4_001127 |
| SPECTRUM3_000999 |
| SPECTRUM2_000487 |
| SPBIO_000353 |
| SPECTRUM1504272 |
| HMS2090K10 |
| HMS2093G06 |
| AC-1944 |
| bdbm50117914 |
| zymer |
| nsc-758701 |
| CHEMBL31 , |
| gatifloxacin (tn) |
| zymer (tn) |
| D08011 |
| gatifloxacin (inn) |
| CHEBI:5280 , |
| gatifloxacinum |
| 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
| gatifloxacino |
| HMS1922J15 |
| KINOME_3137 |
| 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid |
| STK801620 |
| NCGC00068236-02 |
| A802657 |
| AKOS004119932 |
| NCGC00068236-04 |
| NCGC00068236-05 |
| NCGC00068236-06 |
| NCGC00068236-03 |
| HMS3259P06 |
| BBL010485 |
| nsc758701 |
| pharmakon1600-01504272 |
| dtxsid5045704 , |
| dtxcid3025704 |
| tox21_110984 |
| cas-112811-59-3 |
| HMS2233D20 |
| CCG-39529 |
| 81485y3a9a , |
| unii-81485y3a9a |
| nsc 758701 |
| gatifloxin |
| tequin in dextrose 5% in plastic container |
| tymer |
| 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
| FT-0626635 |
| FT-0631189 |
| NCGC00068236-08 |
| S1340 |
| AKOS016340697 |
| HMS3372J10 |
| HMS3372J12 |
| gatifloxacin [who-dd] |
| gatifloxacin [inn] |
| gatifloxacin [mi] |
| (+/-)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid |
| CS-1841 |
| HY-10581 |
| NC00702 |
| 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid |
| SCHEMBL22591 |
| tox21_110984_1 |
| NCGC00068236-07 |
| KS-1066 |
| G-2380 |
| gatifloxacin, antibiotic for culture media use only |
| XUBOMFCQGDBHNK-UHFFFAOYSA-N |
| 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid |
| 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid |
| MLS006011836 |
| HB3263 |
| c19h22fn3o4.1.5h2o |
| AB00171654_16 |
| AB00171654_17 |
| gatifloxcin |
| 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazino)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid |
| cg5501 |
| SR-01000610458-3 |
| mfcd00895399 |
| sr-01000610458 |
| SR-01000610458-2 |
| SBI-0206764.P001 |
| HMS3715N03 |
| rkl10068 |
| 3-quinolinecarboxylic acid,1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo- |
| FT-0668952 |
| gatifloxacin,(s) |
| gatifloxacin sesquihydrate,(s) |
| 1-cyclopropyl-6-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-3-quinolinecarboxylic acid |
| G0325 |
| BCP13408 |
| Q2365016 |
| AMY17781 |
| BRD-A74980173-001-06-9 |
| 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic a |
| gtpl10816 |
| gatifloxacin 100 microg/ml in acetonitrile |
| 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylicacid |
| EN300-19768783 |
| Z1824566854 |
| SY070194 |
Gatifloxacin is a 4th generation fluoroquinolone antibiotic used in the clinic to treat ocular infection. Its adsorption onto iron minerals influenced by coexisting trace elements [e.g., Cu(II)] has not been well investigated.
Gatifloxacin has a broad spectrum of antibacterial activity in vitro and good clinical and bacteriological efficacy in patients with indicated infections. The eye drop has a good therapeutic effect to the bacterial conjunctivitis.
Gatifloxacin has been reported to cause dysglycaemia, especially in the elderly and in diabetics. The eye drop has a good therapeutic effect to the bacterial conjunctivitis.
Gatifloxacin can cause both hypoglycemia and hyperglycemia in both diabetic and non-diabetic patients. Gatifl Oxacin showed lower resistance levels than moxiflOxacin.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Gatifloxacin could cause multi-system and multi-organ ADRs with wide variety of clinical manifestations. " | ( [Analysis of adverse drug reaction of gatifloxacin in Hunan province from Aug. 2003 to Jul. 2007]. Deng, S; He, Y; Long, L; Yin, T; Zhang, W, 2009) | 2.07 |
| "Gatifloxacin showed lower resistance levels than moxifloxacin." | ( [In vitro antibiotic susceptibility to fluoroquinolones]. Galvis, V; Rey, JJ; Tello, A; Villareal, D; Wong, CA, 2012) | 1.1 |
| "Gatifloxacin can cause both hypoglycemia and hyperglycemia in both diabetic and non-diabetic patients. " | ( Gatifloxacin acutely stimulates insulin secretion and chronically suppresses insulin biosynthesis. Inagaki, N; Kawasaki, Y; Nagashima, K; Seino, Y; Takahashi, A; Ueno, H; Yamada, C; Yamada, Y, 2006) | 3.22 |
Gatifloxacin-treated eyes demonstrated significantly less inflammation, infection, and culture-positive endophthalmitis (P < 0.05), compared to the control animals. GLUT1 promoter activity was stimulated by 2.8 and 3.8 folds. Glucose uptake was decreased by 41% and 52%, respectively.
Gatifloxacin appears to be safe for children, with no evidence of producing arthrotoxicity in 867 children exposed to the antibiotic. The drug is safe and efficacious in adults of any age with community-acquired pneumonia, including the elderly up to 100 years old.
Pharmacokinetics of a single 400-mg dose of gatifloxacin alone were characterized as follows (mean +/- standard deviation): peak concentration (Cmax), 3.
We studied the activities of clarithromycin and fluoroquinolones in combination with other antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex (MAC) The activity of meropenem combined with either polymyxin B or gatifloxacin was evaluated by the checkerboard method against Pseudomonas aeruginosa (10 strains) and Acinetobacter baumannii.
| Excerpt | Reference | Relevance |
|---|---|---|
| "The activity of gatifloxacin against Toxoplasma gondii, either alone or in combination with pyrimethamine or gamma interferon (IFN-gamma), was examined in vitro and in vivo." | ( Activity of gatifloxacin alone or in combination with pyrimethamine or gamma interferon against Toxoplasma gondii. Araujo, FG; Khan, AA; Remington, JS; Slifer, TR, 2001) | 1.04 |
| " In the chequerboard method, the quinolones were tested in combination with ten antimicrobial agents (macrolides, aminoglycosides, beta-lactams, vancomycin, rifampicin and chloramphenicol) against five bacterial strains (one strain each of Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Enterococcus faecalis and Streptococcus pneumoniae)." | ( Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents. Bonner, DP; Fung-Tomc, J; Gradelski, E; Kolek, B; Minassian, B; Valera, L, 2001) | 0.69 |
| "We studied the activities of clarithromycin and fluoroquinolones (gatifloxacin, sitafloxacin, levofloxacin) in combination with other antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex (MAC)." | ( Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex. Sano, C; Sato, K; Shimizu, T; Tomioka, H, 2002) | 0.81 |
| "Studies were undertaken in order to assess the anti- Mycobacterium tuberculosis (MTB) activities of newly developed fluoroquinolones in combination with other antituberculous drugs." | ( Anti-Mycobacterium tuberculosis activities of new fluoroquinolones in combination with other antituberculous drugs. Sano, C; Sato, K; Shimizu, T; Tomioka, H, 2002) | 0.31 |
| "A new C-8-methoxyl fluoroquinolone, gatifloxacin (GFLX), and a new C-8-chloro fluoroquinolone, sitafloxacin (STFX), in combination with other drugs were examined for their activities against extracellular growing MTB organisms and those replicating in RAW264." | ( Anti-Mycobacterium tuberculosis activities of new fluoroquinolones in combination with other antituberculous drugs. Sano, C; Sato, K; Shimizu, T; Tomioka, H, 2002) | 0.59 |
| " Both GFLX and STFX exhibited combined activities against intramacrophage MTB, when used in combination with rifampin, rifalazil, isoniazid, pyrazinamide, ethambutol, streptomycin, or clofazimine." | ( Anti-Mycobacterium tuberculosis activities of new fluoroquinolones in combination with other antituberculous drugs. Sano, C; Sato, K; Shimizu, T; Tomioka, H, 2002) | 0.31 |
| " The silicon slides were covered by dense and black stained material in the blank group; the black stained material as mildly less in the group treated with anti-alginate serum, and much less in the group treated with gatifloxacin, and the BF was thin and only slightly stained black in the group treated with anti-alginate combined with gatifloxacin." | ( Influence of anti-alginate serum combined with gatifloxacin on mucoid pseudomonas aeruginosa biofilm morphology. Chai, D; Chen, Q; Li, X; Pei, F; Wang, R, 2002) | 0.76 |
| "Anti-alginate serum affects the structure and morphology of the biofilm of mucoid Pseudomonas aeruginosa and destroys the biofilm structure when combined with gatifloxacin." | ( Influence of anti-alginate serum combined with gatifloxacin on mucoid pseudomonas aeruginosa biofilm morphology. Chai, D; Chen, Q; Li, X; Pei, F; Wang, R, 2002) | 0.77 |
| "To study the in vitro interaction of gatifloxacin in combination with gentamicin and with the beta-lactams cefepime, meropenem and piperacillin against clinical isolates of Stenotrophomonas maltophilia, Pseudomonas aeruginosa, Burkholderia cepacia, extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae, vancomycin-resistant Enterococcus faecium (VRE) and methicillin-resistant Staphylococcus aureus (MRSA)." | ( In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms. Dawis, MA; France, KA; Isenberg, HD; Jenkins, SG, 2003) | 0.91 |
| " Several regimens of gatifloxacin in combination with rifampicin were compared with isoniazid plus rifampicin in a mouse tuberculosis model." | ( Gatifloxacin in combination with rifampicin in a murine tuberculosis model. Cynamon, M; Shoen, C; Sklaney, MR, 2007) | 2.1 |
| "Gatifloxacin in combination with rifampicin is a promising combination for potential evaluation in human clinical trials." | ( Gatifloxacin in combination with rifampicin in a murine tuberculosis model. Cynamon, M; Shoen, C; Sklaney, MR, 2007) | 3.23 |
| " When the three FQs were individually combined with CLR in vitro, mild antagonism was observed for 53 to 57% of the tested isolates." | ( In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. Fukushima, K; Higashiyama, Y; Hirakata, Y; Kohno, S; Kohno, Y; Miyazaki, Y; Ohno, H; Yanagihara, K, 2007) | 0.34 |
| "The antimicrobial activity of meropenem combined with either polymyxin B or gatifloxacin was evaluated by the checkerboard method against Pseudomonas aeruginosa (10 strains) and Acinetobacter baumannii (10 strains)." | ( In vitro evaluation of the antimicrobial activity of meropenem in combination with polymyxin B and gatifloxacin against Pseudomonas aeruginosa and Acinetobacter baumannii. Cardoso, CL; Carrara-Marrone, FE; Gales, AC; Garcia, LB; Guelfi, KC; Tognim, MC, 2008) | 0.79 |
| "In this study, it was aimed to investigate the effects of quinupristin/dalfopristin in combination with vancomycin and gatifloxacin against Staphylococcus aureus and Enterococcus faecium isolates." | ( [In vitro activities of quinupristin/dalfopristin in combination with vancomycin and gatifloxacin against Staphylococcus aureus and Enterococcus faecium clinical isolates]. Ermertcan, S; Gülden, E, 2009) | 0.79 |
| "3% solutions alone or when treatment was combined with steroids, and to correlate these concentrations with the minimum inhibitory concentrations (MIC) for the most common endophthalmitis-causing organisms." | ( Aqueous humor concentrations of topical fluoroquinolones alone or in combination with a steroid. Campos, M; Cruz, AC; Gomes, RLR; Lima, AAS; Melo, LAS; Suenaga, EM; Viana, RG, ) | 0.13 |
The pharmacokinetic parameters (Cmax, AUCo-t, tmax) of this drug have been evaluated. The oral bioavailability of gatifloxacin was 72·96 ± 1·10 %. After an oral administration in humans, the majority is excreted in the urine as the unchanged form.
| Excerpt | Reference | Relevance |
|---|---|---|
| "The pharmacokinetics of gatifloxacin (400 mg orally) and the influence of the antacid aluminum magnesium hydroxide (20 ml of Maalox 70) on the bioavailability of gatifloxacin in 24 healthy volunteers were assessed." | ( Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. Koeppe, P; Lober, S; Lode, H; Mignot, A; Rau, M; Schreiber, G; Ziege, S, 1999) | 0.93 |
| " The absolute bioavailability of gatifloxacin after oral administration was 96%, consistent with bioequivalence of the 400-mg intravenous and oral doses." | ( Interchangeability of 400-mg intravenous and oral gatifloxacin in healthy adults. Duncan, G; Grasela, DM; Kaul, S; Kollia, GD; LaCreta, FP; Randall, DM, 2000) | 0.84 |
| " The drug has high oral bioavailability (96%), and, therefore, oral and intravenous formulations are bioequivalent and interchangeable." | ( Clinical pharmacology of gatifloxacin, a new fluoroquinolone. Grasela, DM, 2000) | 0.61 |
| " Bioavailability is 96%, with a plasma half-life of approximately 8 hours in individuals with normal renal function." | ( Gatifloxacin, an advanced 8-methoxy fluoroquinolone. Fish, DN; North, DS, 2001) | 1.75 |
| " Gatifloxacin is absorbed well from the gastrointestinal tract (oral bioavailability is almost 100%)." | ( Gatifloxacin: a review of its use in the management of bacterial infections. Hurst, M; Onrust, SV; Ormrod, D; Perry, CM, 2002) | 2.67 |
| " Moreover, the rate of absorption was not affected by food intake." | ( Oral bioavailability of gatifloxacin in healthy volunteers under fasting and fed conditions. Göhler, K; Guillaume, M; Mignot, A; Stahlberg, HJ, 2002) | 0.62 |
| "Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate, such as morphine." | ( Minimal interaction between gatifloxacin and oxycodone. Grant, EM; Nicolau, DR; Nightingale, C; Quintiliani, R, 2002) | 0.61 |
| " Bioavailability testing indicated that although the 90% confidence intervals (CIs) for the ratio of the geometric means of the calcium-fortified juice and water arms' AUC stayed within the range of 80% to 125%, those for Cmax did not." | ( Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers. Amsden, GW; Victory, JM; Wallace, AW, 2003) | 0.62 |
| "Sequential intravenous-to-oral antimicrobial therapy with highly bioavailable antiinfective agents such as the fluoroquinolones may improve patient safety and decrease cost of infection management." | ( Bioavailability of gatifloxacin by gastric tube administration with and without concomitant enteral feeding in critically ill patients. Barletta, JF; Devlin, JW; Kanji, S; Kruse, JA; McKinnon, PS, 2003) | 0.65 |
| " Bioavailability was determined as the ratio of NG/intravenous area under the concentration-time curve (AUC infinity ) measured by the trapezoidal method." | ( Bioavailability of gatifloxacin by gastric tube administration with and without concomitant enteral feeding in critically ill patients. Barletta, JF; Devlin, JW; Kanji, S; Kruse, JA; McKinnon, PS, 2003) | 0.65 |
| " More research is needed to identify those patients in whom gatifloxacin bioavailability is reduced and for whom an empirical increase in gatifloxacin dose should be considered." | ( Bioavailability of gatifloxacin by gastric tube administration with and without concomitant enteral feeding in critically ill patients. Barletta, JF; Devlin, JW; Kanji, S; Kruse, JA; McKinnon, PS, 2003) | 0.89 |
| " After an oral administration in humans, gatifloxacin is well absorbed and distributed, and the majority is excreted in the urine as the unchanged form." | ( [Antibacterial property and clinical effect of gatifloxacin, a novel quinolone antibacterial agent]. Hosaka, M, 2003) | 0.84 |
| "Studies have shown that the bioavailability of gatifloxacin is decreased with concurrent administration of antacids containing aluminum or magnesium; dietary supplements containing zinc, magnesium, and iron; multivitamin preparations containing minerals; and sucralfate." | ( Coadministration of gatifloxacin and multivitamin preparation containing minerals: potential treatment failure in an elderly patient. Huang, A; Mallet, L, 2005) | 0.91 |
| " At the 10-mg/kg dose, the bioavailability was similar between the suspension and tablet formulation." | ( Pharmacokinetics of gatifloxacin in infants and children. Blumer, JL; Bradley, JS; Capparelli, EV; Damle, BD; Grasela, DM; Jacobs, RF; Kearns, GL; Reed, MD, 2005) | 0.65 |
| " The pharmacokinetic parameters (Cmax, AUCo-t, tmax) of this drug have been evaluated to compare the single dose (400mg) bioavailability of gatifloxacin with the reference formulation." | ( A study to determine the pharmacokinetics of gatifloxacin following a single oral dose. Banerjee, SN; Chakraborty, M; Chakravarty, M; Chattaraj, TK; Ghosh, A; Jayakumar, M; Mandal, U; Musmade, P; Pal, TK; Rajan, DS; Roy, K, 2004) | 0.79 |
| "To determine the effect of Ensure on the relative oral bioavailability of gatifloxacin in healthy volunteers." | ( Effect of ensure on the oral bioavailability of gatifloxacin in healthy volunteers. Goldman, M; Kays, MB; Lagvankar, S; Overholser, BR; Sowinski, KM, 2005) | 0.81 |
| "The poor bioavailability and therapeutic response exhibited by conventional ophthalmic solutions due to rapid pre-corneal elimination of the drug may be overcome by the use of in situ gel-forming systems that are instilled as drops into the eye and then undergo a sol-gel transition in the cul-de-sac." | ( Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Ding, P; Li, J; Liu, H; Liu, Z; Nie, S; Pan, W, 2006) | 0.56 |
| " Intestinal permeation study also revealed the decreased bioavailability of gatifloxacin relatively to the presence of aluminium hydroxide." | ( Interaction characteristics and thermodynamic behaviour of gatifloxacin by aluminium hydroxide. De, PK; Ghoshal, G; Mallick, S; Mondal, A; Pattnaik, S; Saha, A; Swain, K, 2007) | 0.81 |
| "The poor bioavailability and therapeutic response exhibited by conventional ophthalmic solutions due to rapid precorneal elimination of the drug may be overcome by the use of gel system." | ( Study on the ocular pharmacokinetics of ion-activated in situ gelling ophthalmic delivery system for gatifloxacin by microdialysis. Li, J; Li, X; Liu, Z; Pan, W; Yang, XG, 2007) | 0.56 |
| " In conclusion, gatifloxacin liposomal hydrogel is a suitable delivery system for the improvement of the ocular bioavailability of gatifloxacin." | ( Optimization of gatifloxacin liposomal hydrogel for enhanced transcorneal permeation. Hosny, KM, 2010) | 1.05 |
| " These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes." | ( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010) | 0.36 |
| "Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)." | ( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010) | 0.36 |
| " Gatifloxacin showed better bioavailability and sustained action in aqueous humor and corneal tissue from the nanoparticles compared to the commercial eye drops." | ( Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/prednisolone bitherapy. El-Leithy, IS; Ibrahim, HK; Makky, AA, 2010) | 1.5 |
| " Such clarification may lead to the development of strategies to overcome efflux and enhance its bioavailability at target site." | ( Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance. Kwatra, D; Mitra, AK; Pal, D; Vadlapatla, RK; Vadlapudi, AD, 2010) | 0.71 |
| "This study aims to improve gatifloxacin bioavailability to the eye using solid-lipid nanoparticles (SLN)." | ( Part I: Development and optimization of solid-lipid nanoparticles using Box-Behnken statistical design for ocular delivery of gatifloxacin. Abul Kalam, M; Ali, A; Aljuffali, IA; Alshamsan, A; Aqil, M; Mishra, AK; Sultana, Y, 2013) | 0.89 |
| "The successful ophthalmic delivery system is reliant on the diminution in the precorneal loss of drugs by increasing the corneal contact time and increasing the transcorneal permeability, which may enhance the bioavailability of drug to the eyes." | ( Delivery of gatifloxacin using microemulsion as vehicle: formulation, evaluation, transcorneal permeation and aqueous humor drug determination. Aljuffali, IA; Alshamsan, A; Kalam, MA; Mishra, AK; Sultana, Y, 2016) | 0.81 |
| ", solubility in an aqueous medium and lipophilic properties, which have an effect on the bioavailability of five selected fluoroquinolones." | ( Experimental and theoretical studies on the molecular properties of ciprofloxacin, norfloxacin, pefloxacin, sparfloxacin, and gatifloxacin in determining bioavailability. Betlejewska-Kielak, K; Biernacka, J; Grudzień, M; Kłosińska-Szmurło, E; Mazurek, AP; Pluciński, FA, 2014) | 0.61 |
| "The developed system is a viable alternative to conventional eyedrops of GTN due to its ability to enhance bioavailability through its longer precorneal residence time." | ( Therapeutic Effectiveness in the Treatment of Experimental Bacterial Keratitis with Ion-activated Mucoadhesive Hydrogel. Kant, S; Kesavan, K; Pandit, JK, 2016) | 0.43 |
| "The present investigation aimed at improving the ocular bioavailability of gatifloxacin by prolonging its residence time in the eye and reducing problems associated with the drug re-crystallization after application through incorporation into cationic polymeric nanoparticles." | ( Development of gatifloxacin-loaded cationic polymeric nanoparticles for ocular drug delivery. Al-Kassas, R; Deo, S; Duxfield, L; Englebretsen, V; Rupenthal, I; Sultana, R; Swift, S; Wang, R, 2016) | 1.02 |
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| " Two modified melittin peptides displayed rapid bactericidal properties against antibiotic-resistant strains, low innate resistance development by pathogenic bacteria, remained nonimmunogenic for T lymphocytes, and increased bioavailability in tear fluids." | ( Rational Substitution of ε-Lysine for α-Lysine Enhances the Cell and Membrane Selectivity of Pore-Forming Melittin. Agrawal, R; Barathi, VA; Beuerman, RW; Chan, LW; Jie, TY; Koh, SK; Lakshminarayanan, R; Leng, ET; Mayandi, V; Sebastian, TM; Somaraju Chalasani, ML; Ting, DSJ; Urf Turabe Fazil, MH; Varadarajan, J; Verma, NK; Xi, Q; Zhou, L, 2020) | 0.56 |
Gatifloxacin should be avoided in the same patient population, and the recommended dosage of 400 mg/day should not be exceeded. The optimized microemulsion possessed good stability and showed greater adherence to corneal surface.
| Role | Description |
|---|---|
| antiinfective agent | A substance used in the prophylaxis or therapy of infectious diseases. |
| EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | A topoisomerase inhibitor that inhibits DNA topoisomerase (ATP-hydrolysing), EC 5.99.1.3 (also known as topoisomerase II and as DNA gyrase), which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. |
| antimicrobial agent | A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| quinolinemonocarboxylic acid | Any aromatic carboxylic acid that contains a quinoline moiety that is substituted by one carboxy substituent. |
| N-arylpiperazine | |
| organofluorine compound | An organofluorine compound is a compound containing at least one carbon-fluorine bond. |
| quinolone | |
| quinolone antibiotic | An organonitrogen heterocyclic antibiotic whose structure contains a quinolone or quinolone-related skeleton. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 31.6228 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 64.0919 | 0.0040 | 23.8416 | 100.0000 | AID485290; AID489007 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 25.1189 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 25.1189 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
| endonuclease IV | Escherichia coli | Potency | 1.2589 | 0.7079 | 12.4324 | 31.6228 | AID2565 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 56.2341 | 0.1000 | 20.8793 | 79.4328 | AID588456 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 19.9526 | 0.0126 | 10.6917 | 88.5700 | AID887 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 26.6032 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
| TDP1 protein | Homo sapiens (human) | Potency | 18.8467 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 9.4392 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
| AR protein | Homo sapiens (human) | Potency | 26.8325 | 0.0002 | 21.2231 | 8,912.5098 | AID743035; AID743063 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 28.1838 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 9.4392 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 29.8470 | 0.3758 | 27.4851 | 61.6524 | AID743220 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 26.6032 | 0.0002 | 29.3054 | 16,493.5996 | AID743079 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 28.1838 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 39.8107 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 39.8107 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 0.1059 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.6315 | 4.4531 | 9.3000 | AID1473740 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.2000 | 5.6774 | 10.0000 | AID1473741 |
| Bile salt export pump | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 0.1100 | 7.1903 | 10.0000 | AID1473738 |
| DNA gyrase subunit A | Escherichia coli K-12 | IC50 (µMol) | 0.5000 | 0.0239 | 0.5629 | 5.2300 | AID262137; AID271586 |
| DNA gyrase subunit B | Escherichia coli K-12 | IC50 (µMol) | 0.5000 | 0.0050 | 0.4398 | 5.2300 | AID262137; AID271586 |
| DNA topoisomerase 4 subunit A | Staphylococcus aureus | IC50 (µMol) | 1.2000 | 0.3000 | 3.5579 | 9.1600 | AID262138 |
| DNA gyrase subunit A | Mycobacterium tuberculosis H37Rv | IC50 (µMol) | 27.1333 | 0.0150 | 3.4773 | 10.0000 | AID532977; AID532978; AID532979 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 (µMol) | 129.1187 | 0.0009 | 1.9014 | 10.0000 | AID161281; AID243151; AID243188; AID408340; AID420668; AID51930; AID576612; AID755684 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 (µMol) | 133.0000 | 2.4100 | 6.3433 | 10.0000 | AID1473739 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| streptokinase A precursor | Streptococcus pyogenes M1 GAS | EC50 (µMol) | 0.6680 | 0.0600 | 8.9128 | 130.5170 | AID1902 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| DNA gyrase subunit B | Staphylococcus aureus | CC50 | 0.7000 | 0.7000 | 2.8500 | 5.0000 | AID1626596 |
| DNA topoisomerase 4 subunit B | Staphylococcus aureus | CC50 | 0.2000 | 0.2000 | 0.3000 | 0.4000 | AID1626595 |
| DNA topoisomerase 4 subunit A | Staphylococcus aureus | CC50 | 0.2000 | 0.2000 | 0.3000 | 0.4000 | AID1626595 |
| DNA gyrase subunit A | Staphylococcus aureus | CC50 | 12.2333 | 0.7000 | 2.8500 | 5.0000 | AID1626596; AID1626598; AID530629 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1347167 | Vero cells viability qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347169 | Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347168 | HepG2 cells viability qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347149 | Furin counterscreen qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347161 | Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508628 | Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508629 | Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347153 | Confirmatory screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508627 | Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347152 | Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID342246 | Increase in toxin level in epidemic Clostridium difficile BI6-8-17 infected CF1 mouse at 0.2 mg/day, sc for 4 days assessed after 2 days of last treatment | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID279293 | Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parE D435N and gyrA E85K mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. |
| AID559055 | Antibacterial activity against Lancefield Streptococcus sp. 'group C' by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID286112 | Bactericidal activity against Staphylococcus aureus ATCC 49619 at fAUC/MIC of 67 after 24 to 96 hrs in pharmacodynamic model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID64580 | Minimum inhibitory concentration against Escherichia coli, strain ES142 | 2003 | Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17 | Discovery of (3S)-amino-(4R)-ethylpiperidinyl quinolones as potent antibacterial agents with a broad spectrum of activity and activity against resistant pathogens. |
| AID271587 | Antibacterial activity against Escherichia coli EC1-10 | 2006 | Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22 | 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. |
| AID530626 | Activity at Staphylococcus aureus wild-type DNA topoisomerase 4 subunit ParC | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. |
| AID285739 | Antibacterial activity against beta-lactamase positive Moraxella catarrhalis | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID562828 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-0930 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID558902 | Antimicrobial activity against Clostridium difficile CD5b harboring GyrB Ser416Ala mutant gene selected after 2 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID1237407 | Antibacterial activity against Escherichia coli CCARM 1356 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety. |
| AID625284 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID342079 | Effect on growth of epidemic Clostridium difficile BI6-8-17 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.375 mg/day, sc for 4 days assessed after 2 days of last treatment | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID559065 | Antibacterial activity against Streptococcus mitis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID442254 | Antimalarial activity against Plasmodium falciparum 3D7 | 2009 | Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24 | Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach. |
| AID342063 | Antimicrobial activity against nonepidemic Clostridium difficile J29 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID1237406 | Antibacterial activity against Escherichia coli KCTC 1924 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety. |
| AID559511 | Antibacterial activity against Lancefield Streptococcus sp. group F assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID580998 | Renal excretion in healthy human at 400 mg/kg, po administered as single dose | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. |
| AID286048 | Peak free concentration at 200 mg/24 hrs regimen in vitro PK model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID324754 | Antibacterial activity in Mycobacterium leprae infected mouse foot-pad model assessed as parasite killing after 9 months | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones. |
| AID613792 | Antibacterial activity against Enterococcus faecalis 08-12 after 18 to 24 hrs by NCCLS M100-S11 two fold serial dilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives. |
| AID408340 | Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique | 2008 | Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11 | Support vector machines classification of hERG liabilities based on atom types. |
| AID542508 | Antimicrobial activity against Escherichia coli K-12 harboring gyrA L83, N87 and parC R80, V84 mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. |
| AID286115 | Bactericidal activity against Staphylococcus aureus BSP-2443 with parC S52G, N91D mutation at fAUC/MIC of 51 after 72 hrs in pharmacodynamic model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID278253 | Antimicrobial activity against Salmonella enterica serovar Typhimurium CS3 gyrA+ with GyrA S83F, D87N, ParC S80I mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID1391313 | Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate CCARM 3167 after 24 hrs by two-fold serial dilution method | 2018 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9 | Synthesis and evaluation of the antibacterial activities of aryl substituted dihydrotriazine derivatives. |
| AID425337 | Antibacterial activity against penicillin-resistant Streptococcus pneumoniae ATCC 49619 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID1626597 | Inhibition of FQ-resistant Staphylococcus aureus topoisomerase 4 ParC S80F mutant assessed as compound concentration causing 50% induction of cleavage of covalently closed DNA substrate | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14 | Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections. |
| AID428986 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 107 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID264952 | Inhibition of Mycobacterium tuberculosis DNA gyrase | 2006 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11 | Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase. |
| AID530345 | Antimicrobial activity against Escherichia coli BicA expressing blaTEM-1, blaCTX-M-15 and qepA2 gene by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID244996 | Minimum inhibitory concentration against Streptococcus pneumoniae ATCC 49619 | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID559535 | Antibacterial activity against Legionella pneumophila assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID563024 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0745 harboring gyrA Asp89Asn mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID244972 | Minimum inhibitory concentration against Streptococcus pyogenes ATCC 19615 | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID1600108 | Bactericidal activity against Pseudomonas aeruginosa ATCC 9027 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID532978 | Inhibition of DNA supercoiling activitysof Mycobacterium tuberculosis DNA gyrase subunit A A90V mutant | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates. |
| AID559489 | Antibacterial activity against Prevotella sp. by CLSI M11-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID429010 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT48 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID264951 | Antimycobacterial activity against multi-drug resistant Mycobacterium tuberculosis | 2006 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11 | Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase. |
| AID278268 | Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS38 with GyrA D87G mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID429037 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT76 harboring wild type DNA gyrase A assessed as decrease in bacterial population at 4 times MIC after 30 mins by time-kill analysis | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1240503 | Antibacterial activity against Pseudomonas aeruginosa DR4877 after 24 hrs by broth microdilution method | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16 | N-Lipidated Peptide Dimers: Effective Antibacterial Agents against Gram-Negative Pathogens through Lipopolysaccharide Permeabilization. |
| AID518797 | Antimycobacterial activity against quinolone-resistant multidrug-resistant Mycobacterium tuberculosis after 21 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species. |
| AID558915 | Antimicrobial activity against Clostridium difficile CD5i harboring GyrA Ala92Glu and GyrB Ser416Ala mutant genes selected after 8 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID613797 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 18 to 24 hrs by NCCLS M100-S11 two fold serial dilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives. |
| AID286045 | Peak free concentration at 100 mg/24 hrs regimen in vitro PK model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID285761 | Antibacterial activity against Pseudomonas aeruginosa | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID351295 | Antibacterial activity against Escherichia coli ATCC 25922 after 18 hrs by conventional agar dilution method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Synthesis and antibacterial activity of nitroaryl thiadiazole-gatifloxacin hybrids. |
| AID278062 | Suppression of TNF alpha-stimulated IL8 D-170 mutant promoter activity in human PC3 cells at 16 ug/ml dual luciferase reporter assay | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID285780 | Antibacterial activity against Prevotella oralis | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID518798 | Antimycobacterial activity against Mycobacterium kansasii after 7 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species. |
| AID1330192 | Antibacterial activity against Pseudomonas aeruginosa 2742 measured after 24 hrs by two-fold serial dilution method | 2016 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24 | Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties. |
| AID244995 | Minimum inhibitory concentration against Streptococcus agalactiae ATCC 13813 | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID625286 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID425545 | Antibacterial activity against Streptococcus pneumoniae HMC 2527 harboring S81Y mutation in quinolone-resistant determining regions of GyrA gene, S79F, K137N mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID394149 | Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected in CD1 mouse assessed as bacterial load in spleen at 50 mg/kg, ip administered 10 days postinfection for 10 days measured after 35 days of infection | 2009 | European journal of medicinal chemistry, Jan, Volume: 44, Issue:1 | Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids. |
| AID430966 | Antibacterial activity against Escherichia coli SKM9 containing gyrA L83, Y87 and parC L80 mutants assessed as increase in MIC by Etest relative to MIC for Escherichia coli 1596 containing gyrA L83 and parC I80 mutants | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli. |
| AID68675 | In vitro antibacterial activity was tested for Escherichia coli H560 | 1995 | Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22 | The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. |
| AID559494 | Antibacterial activity against Peptostreptococcus sp. assessed as percent susceptible isolates by CLSI M11-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1626612 | Antimicrobial activity against Staphylococcus aureus isogenic forms expressing rpoB H481Y mutant | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14 | Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections. |
| AID518801 | Antimycobacterial activity against Mycobacterium avium serovar 8 after 14 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species. |
| AID342257 | Effect on growth of fluoroquinolone-susceptible epidemic Clostridium difficile ATCC 9689 in CF1 mouse assessed as increase in bacterial density in cecal content dosed sc for 5 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID310323 | Antimycobacterial activity against Mycobacterium smegmatis ATCC 14468 by agar dilution method | 2007 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23 | An atom efficient, solvent-free, green synthesis and antimycobacterial evaluation of 2-amino-6-methyl-4-aryl-8-[(E)-arylmethylidene]-5,6,7,8-tetrahydro-4H-pyrano[3,2-c]pyridine-3-carbonitriles. |
| AID425356 | Antibacterial activity against Streptococcus pneumoniae HMC 1059 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79F, K137N mutation in QRDR of ParC gene and I460N mutation in QRDR of ParE gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID559068 | Antibacterial activity against Streptococcus sanguinis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID271605 | Antibacterial activity against vancomycin-resistant Enterococcus faecium EF4-3489 | 2006 | Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22 | 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. |
| AID373141 | Antimycobacterial activity against Mycobacterium avium complex N084 infected C57BL/6J mouse assessed as spleen bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID278237 | Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-2 gyrA+ with ParC S80I mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID285723 | Antibacterial activity against Enterococcus faecalis | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID425576 | Antibacterial activity against macrolide-, quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 100 harboring S79Y mutation in quinolone-resistant determining regions of ParC gene after 34 passages with gemifloxacin measured afte | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID530636 | Antimicrobial activity against Staphylococcus aureus CB370 harboring rifampin-resistant rpoB H481Y mutant gene by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. |
| AID559046 | Antibacterial activity against non-ciprofloxacin-susceptible and methicillin-susceptible Staphylococcus aureus by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID531857 | Tmax in tuberculosis patient at 400 mg/day, po administered for 7 days by HPLC | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. |
| AID425335 | Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae ATCC 49619 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID1888648 | Antibacterial activity against rifampicin resistant Staphylococcus aureus harboring RpoBH481Y mutant assessed as inhibition of bacterial growth | 2022 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 57 | Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics. |
| AID456050 | Inhibition of Staphylococcus aureus wild type DNA gyrase | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria. |
| AID1600104 | Bactericidal activity against Bacillus subtilis ATCC 6633 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID558907 | Antimicrobial activity against Clostridium difficile CD5d harboring GyrB Ser416Ala mutant gene selected after 4 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID519204 | Antibacterial activity against Streptococcus pneumoniae assessed as resistant isolates by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | In vitro activity of AR-709 against Streptococcus pneumoniae. |
| AID584115 | Antibacterial activity against Escherichia coli KAM32 harboring pSP72 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus. |
| AID1079935 | Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] | |||
| AID450458 | Antibacterial activity against Bacillus subtilis after 24 hrs by twofold serial dilution method | 2009 | Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15 | Interaction of drug based binuclear mixed-ligand complexes with DNA. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID425354 | Antibacterial activity against Streptococcus pneumoniae HMC 5041 harboring S81F and S79F mutation in quinolone-resistant determining regions of GyrA and ParC genes respectively by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID425547 | Antibacterial activity against Streptococcus pneumoniae HMC 4026 harboring S81Y mutation in quinolone-resistant determining regions of GyrA gene, S79F, K137N mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID559204 | Antibacterial activity against Streptococcus pneumoniae D001 harboring parC Ser79Phe and gyrA Gly85Lys mutant genes | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms. |
| AID563226 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0781 assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1391317 | Antibacterial activity against Pseudomonas aeruginosa 2742 after 24 hrs by two-fold serial dilution method | 2018 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9 | Synthesis and evaluation of the antibacterial activities of aryl substituted dihydrotriazine derivatives. |
| AID430964 | Antibacterial activity against Escherichia coli 1596 containing gyrA L83 and parC I80, G84 mutants assessed as increase in MIC by Etest relative to MIC for Escherichia coli 1608 containing gyrA mutant | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli. |
| AID556012 | Antibacterial activity against Helicobacter pylori harboring gyrA mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. |
| AID559242 | Antibacterial activity against Streptococcus pneumoniae S003 harboring wild-type parC and gyrA Ser81Phe mutant genes assessed as mutation prevention concentration after 48 hrs | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms. |
| AID1237427 | Bactericidal activity against methicillin-resistant Staphylococcus aureus CCARM 3506 after 24 hrs by agar plate method | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety. |
| AID1664938 | Antimalarial activity against CQ-sensitive Plasmodium falciparum 3D7 assessed as inhibition of parasite growth | 2020 | ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7 | Synthesis of Novel Ciprofloxacin-Based Hybrid Molecules toward Potent Antimalarial Activity. |
| AID759324 | Antibacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3167 after 24 hrs by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Synthesis and biological evaluation of rhodanine derivatives bearing a quinoline moiety as potent antimicrobial agents. |
| AID542518 | Antimicrobial activity against Escherichia coli ATCC 25922 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates. |
| AID1382069 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis by CLSI agar dilution method | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Ciprofloxacin derivatives and their antibacterial activities. |
| AID559396 | Antimicrobial activity against Clostridium difficile 630C selected after 4 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID318921 | Antimycobacterial activity against Mycobacterium smegmatis MC2 by agar dilution method | 2008 | Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6 | Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid. |
| AID558613 | Antimicrobial activity against Streptococcus pneumoniae isolate 2686 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID1237408 | Antibacterial activity against Pseudomonas aeruginosa 2742 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety. |
| AID563046 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0757 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID559537 | Antibacterial activity against Morganella morganii assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID625287 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID559143 | Antimicrobial activity against Clostridium difficile A422g harboring GyrA Asp81Asn mutant gene selected after 8 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID781329 | pKa (acid-base dissociation constant) as determined by other workers | 2014 | Pharmaceutical research, Apr, Volume: 31, Issue:4 | Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds. |
| AID285738 | Antibacterial activity against beta-lactamase negative Moraxella catarrhalis | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID286080 | fAUC/MIC ratio of Staphylococcus aureus ATCC 49610 at 200 mg | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID558604 | Antimicrobial activity against Streptococcus pneumoniae isolate 1055 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID428983 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate CT61 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID285747 | Antibacterial activity against Klebsiella pneumoniae | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID576612 | Inhibition of human ERG | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2 | Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model. |
| AID428987 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate nar 108 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID405818 | Antimicrobial activity against Acinetobacter sp. 5248 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID342075 | Effect on growth of epidemic Clostridium difficile BI6-8-17 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.2 mg/day, sc for 4 days assessed after 2 days of last treatment | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID285783 | Antibacterial activity against Neisseria meningitidis | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID565314 | Antibacterial activity against Mycoplasma genitalium TW10-6G by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID388877 | Protective effect against Staphylococcus aureus ATCC 13709-induced bone infection in CD rat at 10 mg/kg, iv administered as single dose 2 days before bacterial challenge | 2008 | Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20 | Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis. |
| AID559501 | Antibacterial activity against non-ciprofloxacin-susceptible and methicillin-susceptible Staphylococcus aureus assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID303468 | Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected CD1 mouse assessed as lung bacterial count at 50 mg/kg, ip after 35 days post infection | 2007 | Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24 | Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid. |
| AID285776 | Antibacterial activity against Prevotella bivia | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID278047 | Suppression of PMA-stimulated IL8 secretion in human PC3 cells | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID559049 | Antibacterial activity against Staphylococcus haemolyticus by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID559045 | Antibacterial activity against ciprofloxacin-susceptible and methicillin-resistant Staphylococcus aureus by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID558921 | Antimicrobial activity against Clostridium difficile CD5i harboring GyrA Ala118Ser, Thr82Ala and GyrB Ser416Ala mutant genes selected after 8 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID388878 | Protective effect against Staphylococcus aureus ATCC 13709-induced bone infection in CD rat at 10 mg/kg, iv administered as single dose 1 hr before bacterial challenge | 2008 | Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20 | Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis. |
| AID558630 | Antimicrobial activity against Streptococcus pneumoniae isolate 4747 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID285338 | Antimicrobial activity against streptomycin-resistant Escherichia coli J53 transconjugant with qnrA1 producing urinary specimen isolate 13.52 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America. |
| AID279286 | Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parC S79F and gyrA S81Y mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. |
| AID559157 | Antimicrobial activity against Clostridium difficile 630f selected after 4 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID286047 | Peak free concentration at 175 mg/24 hrs regimen in vitro PK model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID278252 | Antimicrobial activity against Salmonella enterica serovar Typhimurium CS3 with GyrA S83F, D87N, ParC S80I mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID265977 | Cytotoxicity against Vero cell line | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 | Discovery of new antitubercular oxazolyl thiosemicarbazones. |
| AID1199292 | Antimicrobial activity against Staphylococcus aureus ATCC 29213 by broth macrodilution method | 2015 | Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2 | Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections. |
| AID324747 | Antibacterial activity against Mycobacterium leprae at 5 ug/mL after 11 to 18 days | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones. |
| AID542511 | Antimicrobial activity against Escherichia coli K-12 harboring gyrA L83,N87,gyrB V456, parC I80 and parE A458 mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. |
| AID542499 | Antimicrobial activity against Escherichia coli K-12 harboring gyrA A83 mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. |
| AID285766 | Antibacterial activity against Bacteroides thetaiotaomicron | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID279262 | Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3665 after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID425733 | Apparent total clearance in mouse at 10 to 100 mg/kg, ip | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. |
| AID428998 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT144 harboring DNA gyrase A D87G mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID286078 | fAUC/MIC ratio of Staphylococcus aureus ATCC 49610 at 150 mg | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID559378 | Antimicrobial activity against Clostridium difficile A422C selected after 4 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID698997 | Antimycobacterial activity against Mycobacterium tuberculosis infected in human assessed as log reduction of bacterial count at 400 mg, qd measured up to 2 days | 2012 | European journal of medicinal chemistry, May, Volume: 51 | Tuberculosis: the drug development pipeline at a glance. |
| AID1079946 | Presence of at least one case with successful reintroduction. [column 'REINT' in source] | |||
| AID342078 | Effect on growth of epidemic Clostridium difficile BI9 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.375 mg/day, sc for 4 days assessed after 2 days of last treatment | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID425552 | Antibacterial activity against penicillin-, macrolide-susceptible and quinolone-resistant Streptococcus pneumoniae HMC 1074 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79F mutation in QRDR of ParC gene and I460V mutat | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID558891 | Antimicrobial activity against Clostridium difficile C253f selected after 4 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID559060 | Antibacterial activity against Streptococcus pyogenes by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID425543 | Antibacterial activity against Streptococcus pneumoniae HMC 1156 harboring S81F and S79F mutation in quinolone-resistant determining regions of GyrA and ParC genes respectively showing efflux to ciprofloxacin, gemifloxacin by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID429017 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG7 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID559191 | Antimicrobial activity against Clostridium difficile CD5A harboring GyrB Ser416Ala mutant gene selected after 4 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID559066 | Antibacterial activity against Streptococcus oralis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1488561 | Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay | |||
| AID571172 | Antimicrobial activity against Clostridium difficile harboring ribotype 027 by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. |
| AID559377 | Antimicrobial activity against Clostridium difficile A422B selected after 4 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID425349 | Antibacterial activity against Streptococcus pneumoniae HMC 1076 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, D83N mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID559515 | Antibacterial activity against Streptococcus pyogenes assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID558612 | Antimicrobial activity against Streptococcus pneumoniae isolate 2617 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID279272 | Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 37 with GyrA S81Y, GyrB E474K and ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID559167 | Antimicrobial activity against Clostridium difficile BI2a harboring GyrB Arg447Lys mutant gene selected after 2 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID528514 | Bactericidal activity against levofloxacin-sensitive and methicillin-resistant Staphylococcus aureus at 8 times MIC after 24 hrs by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID285737 | Antibacterial activity against Legionella pneumophila | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID286107 | Bactericidal activity against Staphylococcus aureus ATCC 49619 at fAUC/MIC of 60 after 24 hrs in pharmacodynamic model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID285757 | Antibacterial activity against Shigella sonnei | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID69639 | Minimum inhibitory concentration against Escherichia coli | 2000 | Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6 | Artificial neural network applied to prediction of fluorquinolone antibacterial activity by topological methods. |
| AID456045 | Antibacterial activity against vancomycin-resistant Enterococcus faecalis after 18 hrs by twofold microbroth dilution method | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria. |
| AID558913 | Antimicrobial activity against Clostridium difficile CD5 1-g harboring GyrA Ala92Glu and GyrB Ser416Ala mutant genes selected after 8 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID285721 | Antibacterial activity against penicillin-resistant Streptococcus pneumoniae | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID285759 | Antibacterial activity against Acinetobacter sp. | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID206650 | Antibacterial activity was determined against clinically isolated Levofloxacin-methicillin resistant Staphylococcus aureus (LVFX-r MRSA) strains (74 strains) | 2003 | Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6 | Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents. |
| AID518799 | Antimycobacterial activity against Mycobacterium fortuitum after 3 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species. |
| AID394146 | Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay | 2009 | European journal of medicinal chemistry, Jan, Volume: 44, Issue:1 | Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids. |
| AID456031 | Antibacterial activity against Enterococcus faecalis ATCC 19433 after 18 hrs by twofold microbroth dilution method | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria. |
| AID159910 | In vitro inhibitory activity against hepatic stages of Plasmodium yoelii yoelii 265 BY; No data | 2004 | Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11 | Synthesis of new fluoroquinolones and evaluation of their in vitro activity on Toxoplasma gondii and Plasmodium spp. |
| AID425770 | Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 3583 expressing mefA after 46 passages by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID420669 | Lipophilicity, log D at pH 7.0 | 2009 | European journal of medicinal chemistry, May, Volume: 44, Issue:5 | GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers. |
| AID425342 | Antibacterial activity against Streptococcus pneumoniae HMC 1149 harboring S81F and S79Y mutation in quinolone-resistant determining regions of GyrA and ParC genes respectively showing efflux to ciprofloxacin, gemifloxacin by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID699004 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv | 2012 | European journal of medicinal chemistry, May, Volume: 51 | Tuberculosis: the drug development pipeline at a glance. |
| AID285735 | Antibacterial activity against beta-lactamase negative Haemophilus influenzae | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID430963 | Antibacterial activity against Escherichia coli 1608 containing gyrA L83, L87 mutants assessed as increase in MIC by Etest relative to MIC for wild type Escherichia coli 1609 | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli. |
| AID601703 | Antibacterial activity against 10'4 CFU Staphylococcus aureus ATCC 25923 after 18 hrs by CLSI agar dilution method | 2011 | European journal of medicinal chemistry, Jun, Volume: 46, Issue:6 | Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives. |
| AID1601848 | Antibacterial activity against Escherichia coli CMCC 44568 measured after 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Mar-15, Volume: 166 | Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety. |
| AID425725 | Apparent total clearance in human | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. |
| AID558629 | Antimicrobial activity against Streptococcus pneumoniae isolate 3791 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID285771 | Antibacterial activity against Fusobacterium sp. | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID278244 | Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-4 with GyrA S83F, ParC S80I mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID279269 | Antibacterial activity against levofloxacin resistance selected Streptococcus pneumoniae 19 with GyrA S81Y and ParC D83Y mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID563016 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0810 harboring gyrA Asp94Tyr mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID565315 | Antibacterial activity against Mycoplasma genitalium TW48-5G by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID565326 | Antibacterial activity against Mycoplasma genitalium M6090 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID429009 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT47 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID559145 | Antimicrobial activity against Clostridium difficile A422i harboring GyrA Asp81Asn mutant gene selected after 8 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID1600099 | Antibacterial activity against Staphylococcus epidermidis ATCC 14990 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID565327 | Antibacterial activity against Mycoplasma genitalium M6151 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID429002 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT3 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID433404 | Inhibition of Mycobacterium leprae wild type DNA gyrase A2B2 assessed as formation of DNA cleavable complex | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones? |
| AID601791 | Antibacterial activity against 10'4 CFU Pseudomonas aeruginosa ATCC 27853 after 18 hrs by CLSI agar dilution method | 2011 | European journal of medicinal chemistry, Jun, Volume: 46, Issue:6 | Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives. |
| AID1626615 | Antimicrobial activity against Staphylococcus aureus isogenic forms expressing rpoB H481Y and gyrA S84L mutant | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14 | Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections. |
| AID285718 | Antibacterial activity against Streptococcus sanguis | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID342255 | Effect on growth of fluoroquinolone-resistant epidemic Clostridium difficile NAP1 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.2 mg/day, sc for 5 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID286110 | Bactericidal activity against Staphylococcus aureus ATCC 49619 with S79Y Parc mutation and S81F gyrA mutation at fAUC/MIC of 60 after 96 hrs in pharmacodynamic model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID278264 | Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS18 with GyrA S38F mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID559047 | Antibacterial activity against ciprofloxacin-susceptible and methicillin-resistant Staphylococcus epidermidis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID530629 | Activity at Staphylococcus aureus wild-type GyrA S84L mutant | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. |
| AID528513 | Bactericidal activity against high level levofloxacin and methicillin-resistant Staphylococcus aureus at 8 times MIC after 24 hrs by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID1600111 | Antibacterial activity against methicillin resistant Staphylococcus aureus 6347 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID262133 | Antimicrobial activity against Escherichia coli ATCC 25922 | 2006 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5 | Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells. |
| AID293152 | Antibacterial activity against Streptococcus pneumoniae by agar dilution method | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4 | Synthesis and antibacterial activities of new quinolone derivatives utilizing 1-azabicyclo[1.1.0]butane. |
| AID425553 | Antibacterial activity against penicillin- and quinolone-susceptible Streptococcus pneumoniae HMC 5055 expressing mefA by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID558884 | Antimicrobial activity against Clostridium difficile C253b selected after 2 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID1491401 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 3 to 7 days by rapid direct susceptibility test | |||
| AID759327 | Antibacterial activity against Staphylococcus aureus KCTC 209 after 24 hrs by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Synthesis and biological evaluation of rhodanine derivatives bearing a quinoline moiety as potent antimicrobial agents. |
| AID325857 | Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected in CD1 mouse assessed as bacterial load in lungs at 50 mg/kg, ip after 10 days | 2008 | Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5 | Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids. |
| AID425578 | Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 228 expressing ermB and harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79Y mutation in QRDR of ParC gene and I460 | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID563216 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0815 harboring gyrA Thr80Ala and Ala90Gly mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID519205 | Antibacterial activity against Streptococcus pneumoniae by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | In vitro activity of AR-709 against Streptococcus pneumoniae. |
| AID559202 | Antibacterial activity against Streptococcus pneumoniae S003 harboring wild-type parC and gyrA Ser81Phe mutant genes | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms. |
| AID1664939 | Antimalarial activity against CQ-resistant Plasmodium falciparum NF54-R assessed as inhibition of parasite growth | 2020 | ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7 | Synthesis of Novel Ciprofloxacin-Based Hybrid Molecules toward Potent Antimalarial Activity. |
| AID1264464 | Antimycobacterial activity against non-replicating streptomycin starved Mycobacterium tuberculosis 18b after 7 days by REMA method | 2015 | ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10 | Nitrofuranyl Methyl Piperazines as New Anti-TB Agents: Identification, Validation, Medicinal Chemistry, and PK Studies. |
| AID285732 | Antibacterial activity against Listeria monocytogenes | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID1551290 | Antibacterial activity against Staphylococcus aureus RN4220 assessed as reduction in bacterial cell growth incubated for 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Jun-15, Volume: 172 | Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents. |
| AID559503 | Antibacterial activity against non-ciprofloxacin-susceptible and methicillin-susceptible Staphylococcus epidermidis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID456052 | Selectivity ratio of IC50 for Staphylococcus aureus DNA gyrase Ser84Leu mutant to IC50 for Staphylococcus aureus wild type DNA gyrase | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria. |
| AID425344 | Antibacterial activity against Streptococcus pneumoniae HMC 1058 harboring S79F, K137N mutation in quinolone-resistant determining regions of ParC gene and 460V mutation in QRDR of ParE gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID278060 | Suppression of TNF alpha-stimulated IL8 D-240 mutant promoter activity in human PC3 cells at 16 ug/ml dual luciferase reporter assay | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID425347 | Antibacterial activity against Streptococcus pneumoniae HMC 1070 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, D83N mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID69933 | Antibacterial activity was determined against Escherichia coli NIHJ strain after incubation at 37 degrees C for 18 h | 2003 | Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6 | Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents. |
| AID285734 | Antibacterial activity against Corynebacterium sp. | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID625280 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID425549 | Antibacterial activity against Streptococcus pneumoniae HMC 1068 harboring E85K mutation in quinolone-resistant determining regions of GyrA gene, S79Y, K137N mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene showing efflux to ciproflox | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID428982 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate CT29 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1067073 | Antimicrobial activity against Candida albicans 7535 after 20 hrs by two-fold serial dilution technique | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives. |
| AID559073 | Antibacterial activity against Citrobacter koseri by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID425730 | Apparent peripheral volume of distribution in mouse at 10 to 100 mg/kg, ip | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. |
| AID559056 | Antibacterial activity against Lancefield Streptococcus sp. group F by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID563020 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-0319 harboring gyrA Asp94Ala mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID429015 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG5 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID528510 | Bactericidal activity against high level levofloxacin and methicillin-resistant Staphylococcus aureus at 4 times MIC after 24 hrs by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID394147 | Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected in CD1 mouse assessed as bacterial load in lungs at 50 mg/kg, ip administered 10 days postinfection for 10 days measured after 35 days of infection | 2009 | European journal of medicinal chemistry, Jan, Volume: 44, Issue:1 | Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids. |
| AID530347 | Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M carrying blaCTX-M-15 and pQep plasmid carrying qepA2 gene by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID601790 | Antibacterial activity against 10'4 CFU Klebsiella pneumoniae 09-23 after 18 hrs by CLSI agar dilution method | 2011 | European journal of medicinal chemistry, Jun, Volume: 46, Issue:6 | Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives. |
| AID1473739 | Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID563034 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0764 by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID285711 | Antibacterial activity against Staphylococcus haemolyticus | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID558890 | Antimicrobial activity against Clostridium difficile C253e selected after 4 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID1600113 | Antibacterial activity against methicillin resistant Staphylococcus epidermidis ATCC 13199 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID1382075 | Antibacterial activity against Escherichia coli NCDC 134 after overnight incubation by single disc method | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Ciprofloxacin derivatives and their antibacterial activities. |
| AID278246 | Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-4 acrAB::Kan with GyrA S83F, ParC S80I mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID565308 | Antibacterial activity against Mycoplasma genitalium by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID279257 | Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3009 after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID285746 | Antibacterial activity against Klebsiella oxytoca | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID1524622 | Antibacterial activity against Staphylococcus aureus RN4220 after 24 hrs by microtiter ELISA | 2019 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9 | Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents. |
| AID601780 | Antibacterial activity against 10'4 CFU methicillin-sensitive Staphylococcus epidermidis 09-6 after 18 hrs by CLSI agar dilution method | 2011 | European journal of medicinal chemistry, Jun, Volume: 46, Issue:6 | Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives. |
| AID558587 | Antimicrobial activity against Streptococcus pneumoniae 19A by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID1626618 | Antimicrobial activity against Staphylococcus aureus isogenic forms expressing rpoB H481Y and parC S80F mutant | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14 | Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections. |
| AID556015 | Antibacterial activity against Helicobacter pylori infected in human assessed as bacterial eradication rate at 20 mg, po BID for 7 days | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. |
| AID1557287 | Antibacterial activity against Enterococcus by agar diffusion method | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID562824 | Antimycobacterial activity against Mycobacterium tuberculosis 00-0715 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID558614 | Antimicrobial activity against Streptococcus pneumoniae isolate 2688 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID559061 | Antibacterial activity against Streptococcus anginosus by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID405817 | Antimicrobial activity against Pseudomonas putida 12346 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID698999 | Tmax in human at 400 mg, po | 2012 | European journal of medicinal chemistry, May, Volume: 51 | Tuberculosis: the drug development pipeline at a glance. |
| AID342094 | Increase in toxin level in epidemic Clostridium difficile BI9 infected CF1 mouse at 2 mg/day, sc for 4 days assessed after 2 days of last treatment | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID558581 | Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID563208 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-0319 harboring gyrA Asp94Ala mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID293153 | Antibacterial activity against Moraxella catarrhalis by agar dilution method | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4 | Synthesis and antibacterial activities of new quinolone derivatives utilizing 1-azabicyclo[1.1.0]butane. |
| AID285754 | Antibacterial activity against Salmonella enterica serovar Typhi | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID342254 | Effect on growth of fluoroquinolone-resistant epidemic Clostridium difficile NAP1 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.375 mg/day, sc for 5 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID559199 | Antimicrobial activity against Clostridium difficile CD5F harboring GyrB Ser416Ala mutant gene selected after 8 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID209612 | In vitro antibacterial activity was tested for Streptococcus pyogenes C203 | 1995 | Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22 | The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. |
| AID425566 | Antibacterial activity against macrolide-, quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 100 after 50 passages by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID559062 | Antibacterial activity against Streptococcus bovis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID285756 | Antibacterial activity against Shigella flexneri | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID559198 | Antimicrobial activity against Clostridium difficile CD5E harboring GyrB Ser416Ala mutant gene selected after 8 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID286106 | Bactericidal activity against Staphylococcus aureus ATCC 49619 with Parc S79Y mutation and gyrA S81F mutation at fAUC/MIC of 35 after 96 hrs in pharmacodynamic model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID298871 | Antibacterial activity against vancomycin-resistant Enterococcus faecalis ATCC 700802 by micro-broth dilution method | 2007 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7 | Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones. |
| AID563048 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0790 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID558611 | Antimicrobial activity against Streptococcus pneumoniae isolate 1564 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID558625 | Antimicrobial activity against Streptococcus pneumoniae isolate 3458 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID528496 | Antimicrobial activity against high level levofloxacin and methicillin-resistant Staphylococcus aureus JCSC 6765 expressing gyrA Ser84Leu, norA T389C and grlA Ser80Phe/Glu84Lys mutants by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID293156 | Antibacterial activity against Escherichia coli with AcrAB efflux system by agar dilution method | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4 | Synthesis and antibacterial activities of new quinolone derivatives utilizing 1-azabicyclo[1.1.0]butane. |
| AID285728 | Antibacterial activity against VanA-resistant Enterococcus faecium | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID1382076 | Antibacterial activity against Pseudomonas aeruginosa NCDC105 after overnight incubation by single disc method | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Ciprofloxacin derivatives and their antibacterial activities. |
| AID433582 | Selectivity index, ratio of IC50 for Mycobacterium leprae DNA gyrase subunit A A91V mutant to IC50 for Mycobacterium leprae wild type DNA gyrase A2B2 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones? |
| AID1237429 | Bactericidal activity against quinolone-resistant Staphylococcus aureus CCARM 3519 after 24 hrs by agar plate method | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety. |
| AID279202 | Antibacterial activity against Streptococcus pneumoniae 3009 by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID565317 | Antibacterial activity against Mycoplasma genitalium M2282 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID1557280 | Antibacterial activity against Pseudomonas aeruginosa by agar diffusion method | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID278261 | Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS14 gyrA+ with GyrA D87G mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID565325 | Antibacterial activity against Mycoplasma genitalium M6328 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID244953 | Minimum inhibitory concentration against Staphylococcus aureus ATCC 25923 | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID528507 | Bactericidal activity against low level levofloxacin and methicillin-resistant Staphylococcus aureus at 8 times MIC after 120 mins by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID1626609 | Antimicrobial activity against Staphylococcus aureus isogenic forms expressing gyrA S84L and parC S80F mutant | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14 | Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections. |
| AID559512 | Antibacterial activity against Lancefield Streptococcus sp. 'group G' assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID425361 | Antibacterial activity against Streptococcus pneumoniae HMC 1078 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79F mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID285765 | Antibacterial activity against Bacteroides ovatus | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID558596 | Antimicrobial activity against Streptococcus pneumoniae 8 by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID1264492 | Antimicrobial activity against nonreplicating Mycobacterium tuberculosis 18b by resazurin microtiter assay | 2015 | ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10 | Synthesis and Biological Evaluation of Polar Functionalities Containing Nitrodihydroimidazooxazoles as Anti-TB Agents. |
| AID528515 | Bactericidal activity against low level levofloxacin and methicillin-resistant Staphylococcus aureus at 16 times MIC after 24 hrs by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID530627 | Activity at Staphylococcus aureus DNA topoisomerase 4 subunit ParC S80F mutant | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. |
| AID1524628 | Antibacterial activity against quinolone-resistant Staphylococcus aureus CCARM 3505 after 24 hrs by microtiter ELISA | 2019 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9 | Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents. |
| AID1079948 | Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] | |||
| AID565291 | Antimicrobial activity against Mycoplasma hominis by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis. |
| AID528501 | Antimicrobial activity against levofloxacin-sensitive and methicillin-resistant Staphylococcus aureus JCSC 6770 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID559054 | Antibacterial activity against Streptococcus agalactiae by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID285714 | Antibacterial activity against Alloiococcus otitidis | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID563227 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0782 assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID559500 | Antibacterial activity against ciprofloxacin-susceptible and methicillin-resistant Staphylococcus aureus assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1254067 | Antibacterial activity against Staphylococcus aureus RN4220 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22 | Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents. |
| AID278258 | Antimicrobial activity against Salmonella enterica serovar Typhimurium CS9 acrAB::Kan with GyrA S83F, D87N, ParC S80I mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID558607 | Antimicrobial activity against Streptococcus pneumoniae isolate 1384 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID559197 | Antimicrobial activity against Clostridium difficile CD5D harboring GyrB Ser416Ala mutant gene selected after 8 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID563035 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0774 by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID580860 | Oral bioavailability in healthy human at 400 mg/kg, po | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. |
| AID542515 | Antimicrobial activity against Escherichia coli K-12 harboring gyrA L83, Y87, parC I80 and parE A458 mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. |
| AID601704 | Antibacterial activity against 10'4 CFU methicillin-sensitive Staphylococcus aureus 08-1 after 18 hrs by CLSI agar dilution method | 2011 | European journal of medicinal chemistry, Jun, Volume: 46, Issue:6 | Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives. |
| AID279261 | Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3665 with GyrA S81Y mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID518803 | Antimycobacterial activity against Mycobacterium chelonae after 3 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species. |
| AID425069 | Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae M7943 bearing qnrB10 gene with aac(6)-Ib-cr-blaOXA-30 catB3-arr-3 integron in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID428977 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate D43 harboring DNA gyrase A S83Y mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1254079 | Antibacterial activity against quinolone-resistant Staphylococcus aureus CCARM 3505 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22 | Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents. |
| AID271597 | Antibacterial activity against Staphylococcus aureus UC-76 SA-1 | 2006 | Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22 | 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. |
| AID1524624 | Antibacterial activity against Escherichia coli KCTC 1924 after 24 hrs by microtiter ELISA | 2019 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9 | Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents. |
| AID429042 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT144 harboring DNA gyrase A D87G mutation assessed as complete cell killing at 4 times MIC after 6 hrs by time-kill analysis | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID563007 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0785 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID285719 | Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID372992 | Antimycobacterial activity against Mycobacterium intracellular JATA52-01 infected C57BL/6J mouse assessed as spleen bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last do | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID372981 | Antimycobacterial activity against Mycobacterium avium complex N018 after 14 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID285748 | Antibacterial activity against beta-lactamase positive Klebsiella pneumoniae | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID1551296 | Antifungal activity against Candida albicans 7535 assessed as reduction in bacterial cell growth incubated for 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Jun-15, Volume: 172 | Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents. |
| AID1600118 | Bactericidal activity against Serratia marcescens ATCC 12795 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID559390 | Antimicrobial activity against Clostridium difficile A422I harboring GyrA Thr82Ile and GyrB Leu451Phe mutant genes selected after 8 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID285769 | Antibacterial activity against Fusobacterium nucleatum | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID1600116 | Bactericidal activity against Streptococcus pneumoniae cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID559395 | Antimicrobial activity against Clostridium difficile 630B selected after 4 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID278064 | Decrease in IL8 secretion in human prostatic myofibroblast cells at 16 ug/ml | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID563056 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0810 harboring gyrA Asp94Tyr mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1079944 | Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] | |||
| AID1524629 | Antibacterial activity against quinolone-resistant Staphylococcus aureus CCARM 3519 after 24 hrs by microtiter ELISA | 2019 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9 | Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents. |
| AID429004 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT15 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID559401 | Antimicrobial activity against Clostridium difficile 630E harboring GyrA Ala118Val mutant gene selected after 8 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID285778 | Antibacterial activity against Prevotella corporis | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID1600101 | Antibacterial activity against Enterococcus hirae ATCC 1052 cultured in BHI medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID368422 | Antimicrobial activity against Escherichia coli KAM32 pSTVqepA containing qepA gene ligated to pSTV28 plasmid by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. |
| AID559490 | Antibacterial activity against Propionibacterium acnes by CLSI M11-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1254073 | Antibacterial activity against Pseudomonas aeruginosa 2742 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22 | Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents. |
| AID1888652 | Antibacterial activity against Escherichia coli assessed as inhibition of bacterial growth | 2022 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 57 | Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics. |
| AID278265 | Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS18 gyrA+ with GyrA S38F mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID298866 | Antibacterial activity against Staphylococcus aureus ATCC 29213 by micro-broth dilution method | 2007 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7 | Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones. |
| AID563021 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-0172 harboring gyrA Asp94Ala mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID279266 | Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 3243 with L22 insertion 93SFRPRA94 mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID558606 | Antimicrobial activity against Streptococcus pneumoniae isolate 1147 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID1330194 | Antibacterial activity against methicillin-resistant Staphylococcus aureus 3167 measured after 24 hrs by two-fold serial dilution method | 2016 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24 | Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties. |
| AID530594 | Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr6 carrying Smqnr gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia. |
| AID1254074 | Antibacterial activity against Pseudomonas aeruginosa 2004 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22 | Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents. |
| AID278242 | Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-3 acrAB::Kan with GyrA S83F, ParC S80I mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID285717 | Antibacterial activity against Streptococcus bovis | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID558600 | Antimicrobial activity against Streptococcus pneumoniae 12 by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID530589 | Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr1 carrying Smqnr gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia. |
| AID563027 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0794 harboring gyrA Thr80Ala mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1601846 | Antibacterial activity against Bacillus subtilis CMCC 63501 measured after 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Mar-15, Volume: 166 | Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety. |
| AID559486 | Antibacterial activity against Clostridium perfringens by CLSI M11-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID342077 | Effect on growth of nonepidemic Clostridium difficile J29 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.375 mg/day, sc for 4 days assessed after 2 days of last treatment | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID613785 | Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 09-3 after 18 to 24 hrs by NCCLS M100-S11 two fold serial dilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives. |
| AID285716 | Antibacterial activity against Streptococcus agalactiae | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID279236 | Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 3009 after 14 passages by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID559051 | Antibacterial activity against Staphylococcus lugdunensis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID342076 | Effect on growth of nonepidemic Clostridium difficile ATCC 9689 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.375 mg/day, sc for 4 days assessed after 2 days of last treatment | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID1330185 | Antibacterial activity against Staphylococcus aureus 503 measured after 24 hrs by two-fold serial dilution method | 2016 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24 | Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties. |
| AID528502 | Antimicrobial activity against levofloxacin-sensitive and methicillin-resistant Staphylococcus aureus JCSC 6822 harboring mutation in norA gene by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID1551292 | Antibacterial activity against Staphylococcus aureus KCTC503 assessed as reduction in bacterial cell growth incubated for 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Jun-15, Volume: 172 | Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents. |
| AID1237409 | Antibacterial activity against Pseudomonas aeruginosa 2004 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety. |
| AID1600110 | Bactericidal activity against Proteus vulgaris NCTC 4635 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID558933 | Antimicrobial activity against Clostridium difficile A422f selected after 4 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID1601853 | Antibacterial activity against multidrug-resistant Escherichia coli ATCC BAA-196 measured after 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Mar-15, Volume: 166 | Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety. |
| AID428993 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 51 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1079939 | Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] | |||
| AID1510745 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus by two fold dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Nitroimidazole-containing compounds and their antibacterial and antitubercular activities. |
| AID1551295 | Antibacterial activity against Pseudomonas aeruginosa 2742 assessed as reduction in bacterial cell growth incubated for 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Jun-15, Volume: 172 | Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents. |
| AID563039 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0782 by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID372983 | Antimycobacterial activity against Mycobacterium avium complex after 14 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID207831 | Minimum inhibitory concentration against Staphylococcus aureus - methicillin resistant Ciprofloxacin sensitive strain MI300 | 2003 | Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17 | Discovery of (3S)-amino-(4R)-ethylpiperidinyl quinolones as potent antibacterial agents with a broad spectrum of activity and activity against resistant pathogens. |
| AID559244 | Antibacterial activity against Streptococcus pneumoniae D001 harboring parC Ser79Phe and gyrA Gly85Lys mutant genes assessed as mutation prevention concentration after 48 hrs | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms. |
| AID405457 | Antibacterial activity against Escherichia coli C600Rif in presence of 50 ug/ml efflux pump inhibitor phenyl-arginine-beta-naphthylamide by Etest | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. |
| AID559078 | Antibacterial activity against Klebsiella oxytoca by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID563030 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0769 harboring gyrA putative promoter mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID372982 | Antimycobacterial activity against Mycobacterium avium complex N084 after 14 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID558601 | Antimicrobial activity against Streptococcus pneumoniae isolate 24 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID342062 | Antimicrobial activity against nonepidemic Clostridium difficile ATCC 9689 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID245029 | Minimum inhibitory concentration against Staphylococcus haemolyticus ATCC 29970 | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID1600097 | Antibacterial activity against methicillin resistant Staphylococcus aureus N315 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID565290 | Antimicrobial activity against Mycoplasma pneumoniae by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis. |
| AID601789 | Antibacterial activity against 10'4 CFU Klebsiella pneumoniae 09-22 after 18 hrs by CLSI agar dilution method | 2011 | European journal of medicinal chemistry, Jun, Volume: 46, Issue:6 | Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives. |
| AID372980 | Antimycobacterial activity against Mycobacterium avium complex N016 after 14 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID1557279 | Antibacterial activity against Escherichia coli by agar diffusion method | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID1237411 | Antifungal activity against Candida albicans 7535 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety. |
| AID542512 | Antimicrobial activity against Escherichia coli K-12 harboring gyrA L83, Y87 mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. |
| AID558602 | Antimicrobial activity against Streptococcus pneumoniae isolate 33 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID1600136 | Resistance index, ratio of MIC for Proteus vulgaris NCTC 4635 measured after 5 dilution steps to MIC for Proteus vulgaris NCTC 4635 measured after 48 hrs incubation by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID405454 | Antibacterial activity against Escherichia coli C600Rif by Etest | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. |
| AID580865 | Plasma protein binding in healthy human at 400 mg/kg, po | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. |
| AID285729 | Antibacterial activity against VanB-resistant Enterococcus faecium | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID456033 | Antibacterial activity against Klebsiella pneumoniae type 2 after 18 hrs by twofold microbroth dilution method | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria. |
| AID559414 | Antimicrobial activity against Clostridium difficile BI2F harboring GyrB Glu466Lys mutant gene selected after 8 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID279254 | Antibacterial activity against levofloxacin resistance selected Streptococcus pneumoniae 3009 with GyrA S81Y and ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID563218 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0769 harboring gyrA putative promoter mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID699001 | Bioavailability in human | 2012 | European journal of medicinal chemistry, May, Volume: 51 | Tuberculosis: the drug development pipeline at a glance. |
| AID1237422 | Antibacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3167 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety. |
| AID1600109 | Antibacterial activity against Proteus vulgaris NCTC 4635 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID279280 | Antimicrobial activity against Streptococcus pneumoniae R6 transformants with gyrA S81Y mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. |
| AID528506 | Bactericidal activity against low level levofloxacin and methicillin-resistant Staphylococcus aureus at 4 times MIC after 120 mins by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID1240502 | Antibacterial activity against Pseudomonas aeruginosa DR5790 after 24 hrs by broth microdilution method | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16 | N-Lipidated Peptide Dimers: Effective Antibacterial Agents against Gram-Negative Pathogens through Lipopolysaccharide Permeabilization. |
| AID372985 | Antimycobacterial activity against Mycobacterium avium JATA51-01 infected C57BL/6J mouse assessed as liver bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID207483 | Antibacterial activity was determined against Staphylococcus aureus FDA 209-P strain after incubation at 37 degrees C for 18 h | 2003 | Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6 | Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents. |
| AID206629 | Antibacterial activity was determined against clinically isolated Levofloxacin-methicillin resistant Staphylococcus aureus (LVFX-r MRSA) strains (74 strains) | 2003 | Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6 | Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents. |
| AID322982 | Antimicrobial activity against macrolide-susceptible Mycoplasma pneumoniae FH | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae. |
| AID559238 | Antibacterial activity against Streptococcus pneumoniae W001 harboring wild-type parC and gyrA genes assessed as mutation prevention concentration after 48 hrs | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms. |
| AID613791 | Antibacterial activity against Enterococcus faecalis 08-10 after 18 to 24 hrs by NCCLS M100-S11 two fold serial dilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives. |
| AID405459 | Antibacterial activity against Escherichia coli C600Rif containing pIP1206 plasmid in presence of 40 ug/ml efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine by Etest | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. |
| AID1483976 | Ratio of MIC for Staphylococcus aureus ATCC 29213 after and before 15 serial passages | 2017 | Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4 | Symmetrically Substituted Xanthone Amphiphiles Combat Gram-Positive Bacterial Resistance with Enhanced Membrane Selectivity. |
| AID456047 | Inhibition of Staphylococcus aureus wild type DNA topoisomerase 4 | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria. |
| AID278269 | Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS38 gyrA+ with GyrA D87G mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID1491403 | Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay | |||
| AID394145 | Antibacterial activity against Mycobacterium smegmatis ATCC 14468 by agar dilution method | 2009 | European journal of medicinal chemistry, Jan, Volume: 44, Issue:1 | Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids. |
| AID429008 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT42 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID285770 | Antibacterial activity against Fusobacterium necrophorum | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID285727 | Antibacterial activity against Enterococcus faecium | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID429014 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate AG3 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID278271 | Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS38 tolC::Kan with GyrA D87G mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID1240498 | Antibacterial activity against Pseudomonas aeruginosa DM4150R after 24 hrs by broth microdilution method | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16 | N-Lipidated Peptide Dimers: Effective Antibacterial Agents against Gram-Negative Pathogens through Lipopolysaccharide Permeabilization. |
| AID1626599 | Inhibition of human DNA topoisomerase 2-alpha assessed as compound concentration causing 50% induction of cleavage of covalently closed DNA substrate | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14 | Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections. |
| AID559510 | Antibacterial activity against Lancefield Streptococcus sp. 'group C' assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID530628 | Activity at Staphylococcus aureus wild-type GyrA | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. |
| AID559487 | Antibacterial activity against Fusobacterium sp. by CLSI M11-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID558901 | Antimicrobial activity against Clostridium difficile CD5a harboring GyrB Ser416Ala mutant gene selected after 2 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID433402 | Inhibition of Mycobacterium leprae DNA gyrase subunit A A91V mutant assessed as DNA supercoiling inhibition | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones? |
| AID558619 | Antimicrobial activity against Streptococcus pneumoniae isolate 3275 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID285740 | Antibacterial activity against Neisseria gonorrhoeae | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID558903 | Antimicrobial activity against Clostridium difficile CD5c harboring GyrB Ser416Ala mutant gene selected after 2 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID1601854 | Antibacterial activity against multidrug-resistant Pseudomonas aeruginosa ATCC BAA-2111 measured after 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Mar-15, Volume: 166 | Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety. |
| AID213599 | Clonogenic cytotoxicity against Chinese hamster V-79 cells | 1995 | Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22 | The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. |
| AID1557288 | Antibacterial activity against Clostridium perfringens by agar diffusion method | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID613800 | Antibacterial activity against Pseudomonas aeruginosa 09-34 after 18 to 24 hrs by NCCLS M100-S11 two fold serial dilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives. |
| AID1626604 | Antimicrobial activity against wild type Staphylococcus aureus | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14 | Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections. |
| AID559520 | Antibacterial activity against Streptococcus mitis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID584113 | Ratio of LD99 for Escherichia coli K-12 DM4100 to MIC for Escherichia coli K-12 DM4100 | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Effect of N-1/c-8 ring fusion and C-7 ring structure on fluoroquinolone lethality. |
| AID278249 | Antimicrobial activity against Salmonella enterica serovar Typhimurium CS1 gyrA+ with GyrA S83F, D87N, ParC S80I mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID571174 | Antimicrobial activity against Clostridium difficile harboring other ribotypes by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. |
| AID558582 | Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID429022 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG152 harboring DNA gyrase A S83F and D87G mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID575944 | Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates. |
| AID286044 | Susceptibility of Streptococcus pneumoniae BSP-2443 by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID285733 | Antibacterial activity against Corynebacterium jeikeium | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID540211 | Fraction unbound in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID559509 | Antibacterial activity against Streptococcus agalactiae assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1524627 | Antibacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3506 after 24 hrs by microtiter ELISA | 2019 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9 | Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents. |
| AID411949 | Antitubercular activity against Mycobacterium tuberculosis H37Rv after 14 days by turbidimetric assay | 2008 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24 | Peptide deformylase inhibitors of Mycobacterium tuberculosis: synthesis, structural investigations, and biological results. |
| AID558595 | Antimicrobial activity against Streptococcus pneumoniae 7 by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID342074 | Effect on growth of epidemic Clostridium difficile BI9 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.2 mg/day, sc for 4 days assessed after 2 days of last treatment | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID265986 | Activity against Mycobacterium tuberculosis H37Rv infected in CD1 mouse assessed as decrease in bacterial load relative to control in spleen at 50 mg/kg, ip | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 | Discovery of new antitubercular oxazolyl thiosemicarbazones. |
| AID244988 | Minimum inhibitory concentration against Streptococcus pneumoniae ATCC 6303 | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID285720 | Antibacterial activity against penicillin-intermediate resistant Streptococcus pneumoniae | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID559536 | Antibacterial activity against Moraxella catarrhalis assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID613799 | Antibacterial activity against Pseudomonas aeruginosa 09-33 after 18 to 24 hrs by NCCLS M100-S11 two fold serial dilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives. |
| AID278041 | Cytotoxicity against human PC3 cells at 16 ug/ml relative to control | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID1524626 | Antibacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3167 after 24 hrs by microtiter ELISA | 2019 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9 | Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents. |
| AID425341 | Antibacterial activity against quinolone-resistant Streptococcus pneumoniae ATCC 49619 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID425546 | Antibacterial activity against Streptococcus pneumoniae HMC 2536 harboring S81Y mutation in quinolone-resistant determining regions of GyrA gene, S79F, K137N mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID520108 | Antimicrobial activity against Mycobacterium tuberculosis H37Rv at assessed as growth inhibition at 10 mg/kg following 24 days oxygen depletion by Wayne method relative to control | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo. |
| AID1551299 | Antibacterial activity against Quinolone-resistant Staphylococcus aureus CCARM 3505 assessed as reduction in bacterial cell growth incubated for 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Jun-15, Volume: 172 | Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents. |
| AID405819 | Antimicrobial activity against Acinetobacter sp. 5227 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID518796 | Antimycobacterial activity against drug-susceptible Mycobacterium tuberculosis after 21 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species. |
| AID565319 | Antibacterial activity against Mycoplasma genitalium M2321 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID1382077 | Antibacterial activity against Paenibacillus polymyxa NCDC 64 after overnight incubation by single disc method | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Ciprofloxacin derivatives and their antibacterial activities. |
| AID1557304 | AUC in human at 0.4 g, po | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID698998 | AUC in human at 400 mg, po | 2012 | European journal of medicinal chemistry, May, Volume: 51 | Tuberculosis: the drug development pipeline at a glance. |
| AID1601845 | Antibacterial activity against Enterococcus faecalis CMCC 29212 measured after 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Mar-15, Volume: 166 | Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety. |
| AID559050 | Antibacterial activity against Staphylococcus hominis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID279285 | Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parC S79F and gyrA S81F mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. |
| AID559063 | Antibacterial activity against Streptococcus constellatus by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1915654 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as reduction in bacterial growth incubated for 72 hrs by two-fold dilution method | 2021 | European journal of medicinal chemistry, Jan-15, Volume: 210 | An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review. |
| AID160372 | In vitro antibacterial activity was tested for Propion acnes PA5-1 | 1995 | Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22 | The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. |
| AID278045 | Reduction of peptidoglycan-stimulated IL8 secretion in human PC3 cells | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID520615 | Antimicrobial activity against Nocardia brasiliensis HUJEG-1 infected in BALB/c mouse assessed as decrease in number of lesions on foot-pad at 100 mg/kg, sc TID for 4 weeks | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | In vivo therapeutic effect of gatifloxacin on BALB/c mice infected with Nocardia brasiliensis. |
| AID286079 | fAUC/MIC ratio of Staphylococcus aureus ATCC 49610 at 175 mg | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID534771 | Antimicrobial activity against Acinetobacter baumannii-calcoaceticus obtained from war-wounded patient assessed as susceptible isolates | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center. |
| AID390113 | Protective effect against Staphylococcus aureus ATCC 13709-induced bone infection in CD rat at 20 mg/kg, iv administered as single dose 2 days before bacterial challenge | 2008 | Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21 | Linking bisphosphonates to the free amino groups in fluoroquinolones: preparation of osteotropic prodrugs for the prevention of osteomyelitis. |
| AID428990 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 45 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID559064 | Antibacterial activity against Streptococcus intermedius by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1237410 | Antibacterial activity against Salmonella typhimurium 2421 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety. |
| AID286062 | Half life at 200 mg/24 hrs regimen in vitro PK model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID285785 | Antibacterial activity against Streptococcus mitis | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID558583 | Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID528503 | Bactericidal activity against methicillin-resistant Staphylococcus aureus at 4 times MIC upto 60 mins by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID563009 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0791 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID625289 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID559506 | Antibacterial activity against Staphylococcus lugdunensis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID425551 | Antibacterial activity against penicillin-, macrolide- and quinolone-susceptible Streptococcus pneumoniae HMC 63 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID318925 | Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected in CD1 mouse assessed as bacterial load in spleen at 50 mg/kg, ip after 10 days | 2008 | Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6 | Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid. |
| AID558617 | Antimicrobial activity against Streptococcus pneumoniae isolate 3260 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID563209 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-0172 harboring gyrA Asp94Ala mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID279264 | Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3676 after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID781330 | pKa (acid-base dissociation constant) as determined by potentiometric titration | 2014 | Pharmaceutical research, Apr, Volume: 31, Issue:4 | Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds. |
| AID430967 | Antibacterial activity against Escherichia coli SKM18 containing gyrA L83, Y87 and parC L80, G84 mutants assessed as increase in MIC by Etest relative to MIC for Escherichia coli SKM9 containing gyrA L83, Y87 and parC L80 mutants | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli. |
| AID588210 | Human drug-induced liver injury (DILI) modelling dataset from Ekins et al | 2010 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12 | A predictive ligand-based Bayesian model for human drug-induced liver injury. |
| AID540213 | Half life in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID613796 | Antibacterial activity against Klebsiella pneumoniae 09-22 after 18 to 24 hrs by NCCLS M100-S11 two fold serial dilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives. |
| AID558592 | Antimicrobial activity against Streptococcus pneumoniae 4 by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID601784 | Antibacterial activity against 10'4 CFU Enterococcus faecalis 08-12 after 18 hrs by CLSI agar dilution method | 2011 | European journal of medicinal chemistry, Jun, Volume: 46, Issue:6 | Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives. |
| AID1551297 | Antibacterial activity against Methicillin-resistant Staphylococcus aureus CCARM 3167 assessed as reduction in bacterial cell growth incubated for 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Jun-15, Volume: 172 | Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents. |
| AID559048 | Antibacterial activity against non-ciprofloxacin-susceptible and methicillin-susceptible Staphylococcus epidermidis by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID518802 | Antimycobacterial activity against Mycobacterium intracellular serovar 16 after 21 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species. |
| AID278059 | Suppression of TNF alpha-stimulated IL8 D-145 mutant promoter activity in human PC3 cells at 16 ug/ml by dual luciferase reporter assay | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID699000 | Half life in human at 400 mg, po | 2012 | European journal of medicinal chemistry, May, Volume: 51 | Tuberculosis: the drug development pipeline at a glance. |
| AID558597 | Antimicrobial activity against Streptococcus pneumoniae 9 by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID1600095 | Antibacterial activity against Staphylococcus aureus ATCC 6538 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID1240499 | Antibacterial activity against Pseudomonas aeruginosa DM23257 after 24 hrs by broth microdilution method | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16 | N-Lipidated Peptide Dimers: Effective Antibacterial Agents against Gram-Negative Pathogens through Lipopolysaccharide Permeabilization. |
| AID559205 | Antibacterial activity against Streptococcus pneumoniae D002 harboring parC Ser79Phe and gyrA Ser81Phe mutant genes | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms. |
| AID556010 | Antibacterial activity against Helicobacter pylori harboring gyrA mutant gene | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. |
| AID1916429 | Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 in C57BL/6 mouse model of bacterial keratitis assessed as log reduction in viable bacterial count in infected cornea at 0.3 % pre-infected with bacteria for 24 hrs followed by topical adminis | |||
| AID1488559 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 by two fold dilution method | |||
| AID565318 | Antibacterial activity against Mycoplasma genitalium M2300 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID559485 | Antibacterial activity against Bacteroides fragilis by CLSI M11-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID285749 | Antibacterial activity against Morganella morganii | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID558931 | Antimicrobial activity against Clostridium difficile A422d selected after 4 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID563222 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0764 assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID318924 | Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected in CD1 mouse assessed as bacterial load in lung at 50 mg/kg, ip after 10 days | 2008 | Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6 | Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid. |
| AID428980 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate A102 harboring DNA gyrase A S83Y mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID285750 | Antibacterial activity against Proteus mirabilis | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID342243 | Increase in toxin level in nonepidemic Clostridium difficile ATCC 9689 infected in CF1 mouse at 0.2 mg/day, sc for 4 days assessed after 2 days of last treatment | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID444050 | Fraction unbound in human plasma | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1079949 | Proposed mechanism(s) of liver damage. [column 'MEC' in source] | |||
| AID429001 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT2 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1557283 | Antibacterial activity against Haemophilus influenzae with horse blood by agar diffusion method | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID530588 | Antimicrobial activity against Escherichia coli TOP10 by Etest | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia. |
| AID298861 | Antibacterial activity against Enterococcus faecalis ATCC 29212 by micro-broth dilution method | 2007 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7 | Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones. |
| AID563028 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0815 harboring gyrA Thr80Ala and Ala90Gly mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID528505 | Bactericidal activity against methicillin-resistant Staphylococcus aureus at 16 times MIC upto 60 mins by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID565329 | Antibacterial activity against Mycoplasma genitalium M6283 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID1264494 | Antimicrobial activity against multidrug-resistant Mycobacterium tuberculosis by resazurin microtiter assay | 2015 | ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10 | Synthesis and Biological Evaluation of Polar Functionalities Containing Nitrodihydroimidazooxazoles as Anti-TB Agents. |
| AID285743 | Antibacterial activity against Enterobacter aerogenes | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID293154 | Antibacterial activity against Haemophilus influenzae by agar dilution method | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4 | Synthesis and antibacterial activities of new quinolone derivatives utilizing 1-azabicyclo[1.1.0]butane. |
| AID285768 | Antibacterial activity against Clostridium perfringens | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID373140 | Antimycobacterial activity against Mycobacterium avium complex N084 infected C57BL/6J mouse assessed as liver bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID1079947 | Comments (NB not yet translated). [column 'COMMENTAIRES' in source] | |||
| AID157244 | In vitro antibacterial activity was tested for Pepto asac PA 3-1 | 1995 | Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22 | The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. |
| AID41263 | In vitro antibacterial activity against Bacteroides fragilis BFA | 1995 | Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22 | The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. |
| AID532979 | Inhibition of DNA supercoiling activity of Mycobacterium tuberculosis DNA gyrase subunit A D94G mutant | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates. |
| AID625282 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID278245 | Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-4 gyrA+ with ParC S80I mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID285755 | Antibacterial activity against Shigella dysenteriae | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID1557285 | Antibacterial activity against Streptococcus pneumoniae by agar diffusion method | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID1626607 | Antimicrobial activity against Staphylococcus aureus isogenic forms expressing parC S80F mutant | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14 | Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections. |
| AID405298 | Antimicrobial activity against Leptospira interrogans serovar Portlandvere infected golden Syrian hamster model of acute lethal leptospirosis assessed as survival at 25 mg/kg/day, ip once daily for 5 days administered 2 day after infection | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Efficacy of fluoroquinolones against Leptospira interrogans in a hamster model. |
| AID528497 | Antimicrobial activity against low level levofloxacin and methicillin-resistant Staphylococcus aureus JCSC 6766 expressing gyrA Glu84Lys and grlA Ser80Phe mutants by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID278057 | Inhibition of TNF alpha-stimulated IL8 mRNA expression in human PC3 cells at 16 ug/ml after 48 hrs | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID303466 | Antimycobacterial activity against multi-drug-resistant Mycobacterium tuberculosis by agar dilution method | 2007 | Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24 | Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid. |
| AID613798 | Antibacterial activity against Pseudomonas aeruginosa 09-32 after 18 to 24 hrs by NCCLS M100-S11 two fold serial dilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives. |
| AID286077 | fAUC/MIC ratio of Staphylococcus aureus ATCC 49610 at 100 mg | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID444051 | Total clearance in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID278267 | Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS18 tolC::Kan with GyrA S38F mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID298863 | Antibacterial activity against Klebsiella pneumoniae ATCC 10031 by micro-broth dilution method | 2007 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7 | Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones. |
| AID559156 | Antimicrobial activity against Clostridium difficile 630e selected after 4 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID1079936 | Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] | |||
| AID279267 | Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3243 with 23S rRNA A2059T mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID559239 | Antibacterial activity against Streptococcus pneumoniae W002 harboring wild-type parC and gyrA genes assessed as mutation prevention concentration after 48 hrs | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms. |
| AID310322 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis by agar dilution method | 2007 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23 | An atom efficient, solvent-free, green synthesis and antimycobacterial evaluation of 2-amino-6-methyl-4-aryl-8-[(E)-arylmethylidene]-5,6,7,8-tetrahydro-4H-pyrano[3,2-c]pyridine-3-carbonitriles. |
| AID1067080 | Antimicrobial activity against Streptococcus mutans 3065 after 20 hrs by two-fold serial dilution technique | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives. |
| AID341089 | Antimicrobial activity against Clostridium difficile clinical isolates by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. |
| AID351292 | Antibacterial activity against Bacillus subtilis ATCC 6051 after 18 hrs by conventional agar dilution method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Synthesis and antibacterial activity of nitroaryl thiadiazole-gatifloxacin hybrids. |
| AID271589 | Antibacterial activity against Klebsiella pneumonia ESBL KP3729 | 2006 | Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22 | 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. |
| AID425340 | Antibacterial activity against quinolone-susceptible Streptococcus pneumoniae ATCC 49619 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID298869 | Antibacterial activity against linezolid-resistant Staphylococcus aureus NRS 119 by microbroth dilution method | 2007 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7 | Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones. |
| AID559052 | Antibacterial activity against Staphylococcus saprophyticus by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID558618 | Antimicrobial activity against Streptococcus pneumoniae isolate 3263 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID699003 | Antimycobacterial activity against Mycobacterium tuberculosis clinical isolate | 2012 | European journal of medicinal chemistry, May, Volume: 51 | Tuberculosis: the drug development pipeline at a glance. |
| AID558919 | Antimicrobial activity against Clostridium difficile CD5 2-g harboring GyrA Ala118Ser, Thr82Ala and GyrB Ser416Ala mutant genes selected after 8 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID559081 | Antibacterial activity against Moraxella catarrhalis by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID601782 | Antibacterial activity against 10'4 CFU Streptococcus pneumoniae 08-4 after 18 hrs by CLSI agar dilution method | 2011 | European journal of medicinal chemistry, Jun, Volume: 46, Issue:6 | Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives. |
| AID542519 | Antimicrobial activity against fluoroquinolone-sensitive Escherichia coli clinical isolate by Etest | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates. |
| AID1888649 | Antibacterial activity against wild type Staphylococcus aureus assessed as inhibition of bacterial growth | 2022 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 57 | Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics. |
| AID559382 | Antimicrobial activity against Clostridium difficile A422D harboring GyrB Leu451Phe mutant gene selected after 8 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID245697 | Mutant prevention concentration aganist methicillin resistant Staphylococcus aureus-5023 done for 48 hr at 37 degree C with compound | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID584111 | Bacteriostatic activity against Escherichia coli K-12 DM4100 | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Effect of N-1/c-8 ring fusion and C-7 ring structure on fluoroquinolone lethality. |
| AID613822 | Antibacterial activity against Klebsiella pneumoniae 09-23 after 18 to 24 hrs by NCCLS M100-S11 two fold serial dilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives. |
| AID165206 | In vitro antibacterial activity was tested for Pseudomonas aeruginosa UI-18 | 1995 | Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22 | The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. |
| AID429026 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate AG182 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID498191 | Antibacterial activity against Stenotrophomonas maltophilia MBS101 containing plasmid encoded Smqnr gene by epsilon test | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia. |
| AID279265 | Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3243 after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID625288 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID425579 | Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 3583 expressing mefA and harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, D83N mutation in QRDR of ParC gene and I46 | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID68676 | In vitro antibacterial activity was tested for Escherichia coli Vogel | 1995 | Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22 | The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. |
| AID285782 | Antibacterial activity against Propionibacterium acnes | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID559067 | Antibacterial activity against Streptococcus salivarius by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID285764 | Antibacterial activity against Bacteroides fragilis | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID559168 | Antimicrobial activity against Clostridium difficile BI2b harboring GyrB Arg447Lys mutant gene selected after 2 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID556011 | Antibacterial activity against Helicobacter pylori harboring gyrA mutant gene assessed as resistant isolates | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. |
| AID425336 | Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae ATCC 49619 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID1557286 | Antibacterial activity against Streptococcus pyogenes by agar diffusion method | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID285730 | Antibacterial activity against Enterococcus casseliflavus | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID528516 | Bactericidal activity against high level levofloxacin and methicillin-resistant Staphylococcus aureus at 16 times MIC after 24 hrs by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID1254075 | Antibacterial activity against Salmonella typhimurium 2421 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22 | Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents. |
| AID303467 | Antimicrobial activity against Mycobacterium smegmatis by agar dilution method | 2007 | Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24 | Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid. |
| AID293151 | Antibacterial activity against Enterococcus faecalis by agar dilution method | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4 | Synthesis and antibacterial activities of new quinolone derivatives utilizing 1-azabicyclo[1.1.0]butane. |
| AID318920 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis by agar dilution method | 2008 | Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6 | Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid. |
| AID625285 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID425575 | Antibacterial activity against macrolide-, quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 100 harboring S81Y mutation in quinolone-resistant determining regions of GyrA gene after 22 passages with moxifloxacin measured afte | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID285760 | Antibacterial activity against Burkholderia cepacia | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID285741 | Antibacterial activity against Citrobacter diversus | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID285722 | Antibacterial activity against levofloxacin-resistant Streptococcus pneumoniae | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID559080 | Antibacterial activity against Legionella pneumophila by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID450459 | Antibacterial activity against Serratia marcescens after 24 hrs by twofold serial dilution method | 2009 | Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15 | Interaction of drug based binuclear mixed-ligand complexes with DNA. |
| AID342067 | Antimicrobial activity against fluoroquinolone-susceptible nonepidemic Clostridium difficile strain6 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID563217 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0773 harboring gyrA Pro8Ala mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID558932 | Antimicrobial activity against Clostridium difficile A422e selected after 4 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID559161 | Antimicrobial activity against Clostridium difficile 630g harboring GyrB Asp26Val mutant gene selected after 8 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID558889 | Antimicrobial activity against Clostridium difficile C253d selected after 4 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID1557281 | Antibacterial activity against Klebsiella by agar diffusion method | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID285706 | Antibacterial activity against oxacillin-resistant Staphylococcus aureus | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID368419 | Antimicrobial activity against Escherichia coli KAM32 expressing deltaacrB ydhE hsd gene by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. |
| AID429038 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate HTD 798 harboring DNA gyrase A S83F mutation assessed as decrease in bacterial population at 4 times MIC after 30 mins by time-kill analysis | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID285744 | Antibacterial activity against Enterobacter cloacae | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID563044 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-1647 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1330188 | Antibacterial activity against Streptococcus mutans 3065 measured after 24 hrs by two-fold serial dilution method | 2016 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24 | Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties. |
| AID285337 | Antimicrobial activity against Escherichia coli qnrA1 producing urinary specimen isolate 13.52 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America. |
| AID425577 | Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 228 expressing ermB and harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, D83N mutation in QRDR of ParC gene and I460 | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID1888651 | Antibacterial activity against Staphylococcus aureus harboring RpoBH481Y/ParCS80F/GyrAS84L triple mutant assessed as inhibition of bacterial growth | 2022 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 57 | Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics. |
| AID278238 | Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-2 acrAB::Kan with GyrA S83F, ParC S80I mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID558920 | Antimicrobial activity against Clostridium difficile CD5h harboring GyrA Ala118Ser, Thr82Ala and GyrB Ser416Ala mutant gene selected after 8 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID425070 | Antimicrobial activity against multidrug-resistant Escherichia coli M7943-TC2 bearing qnrB10 gene with aac(6)-Ib-cr-blaOXA-30 catB3-arr-3 integron in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID285762 | Antibacterial activity against Stenotrophomonas maltophilia | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID279268 | Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 19 with GyrA S81F mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID405466 | Antibacterial activity against Escherichia coli TOP10 containing pIP1206 plasmid in presence of 50 ug/ml efflux pump inhibitor phenyl-arginine-beta-naphthylamide by Etest | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. |
| AID1254077 | Antibacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3167 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22 | Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents. |
| AID456044 | Antibacterial activity against penicillin-intermediate resistant Streptococcus pneumoniae after 18 hrs by twofold microbroth dilution method | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria. |
| AID561399 | Antibacterial activity against quinolone-susceptible Bordetella pertussis BP117 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Emergence of quinolone-resistant Bordetella pertussis in Japan. |
| AID445446 | Oral bioavailability in human | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. |
| AID285777 | Antibacterial activity against Prevotella buccae | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID1237403 | Antibacterial activity against Staphylococcus aureus KCTC 209 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety. |
| AID285745 | Antibacterial activity against Escherichia coli | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID456051 | Inhibition of Staphylococcus aureus DNA gyrase Ser84Leu mutant | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria. |
| AID559203 | Antibacterial activity against Streptococcus pneumoniae S004 harboring wild-type parC and gyrA Gly85Asn mutant genes | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms. |
| AID429030 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate BL 21801 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID298858 | Antibacterial activity against Bacillus subtilis ATCC 6633 by micro-broth dilution method | 2007 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7 | Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones. |
| AID208294 | Minimum inhibitory concentration against Streptococcus pneumoniae - penicillin sensitive, strain STP64 | 2003 | Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17 | Discovery of (3S)-amino-(4R)-ethylpiperidinyl quinolones as potent antibacterial agents with a broad spectrum of activity and activity against resistant pathogens. |
| AID285736 | Antibacterial activity against beta-lactamase positive Haemophilus influenzae | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID528509 | Bactericidal activity against low level levofloxacin and methicillin-resistant Staphylococcus aureus at 4 times MIC after 24 hrs by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID279282 | Antimicrobial activity against Streptococcus pneumoniae R6 transformants with gyrA S81F mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. |
| AID342242 | Increase in toxin level in epidemic Clostridium difficile BI6-8-17 infected CF1 mouse at 1.4 mg/day, sc for 4 days assessed after 2 days of last treatment | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID278039 | Cytotoxicity against human PC3 cells at 2 ug/ml relative to control | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID425358 | Antibacterial activity against Streptococcus pneumoniae HMC 1072 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79Y mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID278247 | Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-4 tolC::Kan with GyrA S83F, ParC S80I mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID318919 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method | 2008 | Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6 | Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid. |
| AID542506 | Antimicrobial activity against Escherichia coli K-12 harboring gyrA L83, N87, parC I80 and parE A548 mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. |
| AID450461 | Antibacterial activity against Escherichia coli after 24 hrs by twofold serial dilution method | 2009 | Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15 | Interaction of drug based binuclear mixed-ligand complexes with DNA. |
| AID558610 | Antimicrobial activity against Streptococcus pneumoniae isolate 1424 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID565309 | Antibacterial activity against Mycoplasma genitalium by quantitative TaqMan PCR method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID342066 | Antimicrobial activity against fluoroquinolone-resistant epidemic Clostridium difficile NAP1 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID563023 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0787 harboring gyrA Asp94His mutant gene and deletion of codons 678 and 679 in gyrB mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID278236 | Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-2 with GyrA S83F, ParC S80I mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID556014 | Antibacterial activity against Helicobacter pylori infected in human assessed as bacterial eradication rate at 1 g, po BID for 7 days | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. |
| AID565311 | Antibacterial activity against Mycoplasma genitalium M30 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID561388 | Antibacterial activity against quinolone-susceptible Bordetella pertussis CCUG 30837 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Emergence of quinolone-resistant Bordetella pertussis in Japan. |
| AID1473738 | Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID322984 | Antimicrobial activity against macrolide-susceptible Mycoplasma pneumoniae M129 | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae. |
| AID342096 | Increase in toxin level in nonepidemic Clostridium difficile ATCC 9689 infected in CF1 mouse at 1.4 mg/day, sc for 4 days assessed after 2 days of last treatment | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID262137 | Inhibitory activity against wild type Escherichia coli gyrase | 2006 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5 | Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells. |
| AID518804 | Antimycobacterial activity against Mycobacterium abscessus after 3 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species. |
| AID1237425 | Antibacterial activity against quinolone-resistant Staphylococcus aureus CCARM 3519 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety. |
| AID565331 | Antibacterial activity against Mycoplasma genitalium M6287 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID1551300 | Antibacterial activity against Quinolone-resistant Staphylococcus aureus CCARM 3519 assessed as reduction in bacterial cell growth incubated for 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Jun-15, Volume: 172 | Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents. |
| AID558896 | Antimicrobial activity against Clostridium difficile C253h harboring GyrA Ala118Ser mutant gene selected after 8 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID559519 | Antibacterial activity against Streptococcus intermedius assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID559384 | Antimicrobial activity against Clostridium difficile A422F harboring GyrB Leu451Phe mutant gene selected after 8 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID559174 | Antimicrobial activity against Clostridium difficile BI2e harboring GyrB Arg447Lys and Asp426Asn mutant gene selected after 32 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID613793 | Antibacterial activity against Escherichia coli ATCC 25922 after 18 to 24 hrs by NCCLS M100-S11 two fold serial dilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives. |
| AID278051 | Suppression IL8 secretion in human PC3 cells at 16 ug/ml added simultaneously with TNF alpha | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID559187 | Antimicrobial activity against Clostridium difficile C253F selected after 8 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID208611 | Antibacterial activity was determined against clinically isolated penicillin resistant Streptococcus pneumoniae (PRSP) strains (50 strains) | 2003 | Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6 | Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents. |
| AID271593 | Antibacterial activity against Escherichia coli EC2549 | 2006 | Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22 | 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. |
| AID530633 | Antimicrobial activity against Staphylococcus aureus CB811 harboring quinolone-resistant gyrA S84L mutant gene by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. |
| AID733004 | Inhibition of Mycobacterium leprae wild type DNA gyrase GyrA/GyrB G89C mutant-mediated DNA cleavable complex formation assessed as compound concentration inducing 25% DNA cleavage using relaxed pBR322 DNA substrate incubated for 1 hr at 30 degC by agarose | 2013 | Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4 | Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis. |
| AID279292 | Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parE D435N and gyrA S81Y mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. |
| AID405460 | Antibacterial activity against Escherichia coli C600Rif containing pIP1206 plasmid in presence of 50 ug/ml efflux pump inhibitor phenyl-arginine-beta-naphthylamide by Etest | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. |
| AID542510 | Antimicrobial activity against Escherichia coli K-12 harboring gyrA L83, N87, parC I80, K84 and parE D460 mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. |
| AID285800 | Antimicrobial activity against Bacteroides distasonis | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID559517 | Antibacterial activity against Streptococcus bovis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID285731 | Antibacterial activity against Enterococcus gallinarum | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID588211 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID563008 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0790 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID584112 | Bactericidal activity against Escherichia coli K-12 DM4100 after 2 hrs in presence of protein synthesis inhibitor chloramphenicol treated 10 mins before compound challenge | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Effect of N-1/c-8 ring fusion and C-7 ring structure on fluoroquinolone lethality. |
| AID428996 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate CT118 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1601842 | Antibacterial activity against Staphylococcus aureus CMCC 25923 measured after 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Mar-15, Volume: 166 | Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety. |
| AID559400 | Antimicrobial activity against Clostridium difficile 630D harboring GyrA Ala118Val mutant gene selected after 8 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID425581 | Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 3583 expressing mefA and harboring I460V mutation in QRDR of ParE gene after 41 passages with gemifloxacin measured after 10 daily antibiotic-free s | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID368423 | Antimicrobial activity against Escherichia coli KAM32 pSTVdeltaqepA containing disrupted qepA gene by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. |
| AID1600102 | Bactericidal activity against Enterococcus hirae ATCC 1052 cultured in BHI medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID1626602 | Antimicrobial activity against Staphylococcus aureus isogenic forms expressing gyrA S84L mutant | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14 | Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections. |
| AID556017 | Antibacterial activity against Helicobacter pylori harboring gyrA mutant gene infected in human assessed as bacterial eradication rate after 7 days | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. |
| AID1570241 | Cytotoxicity against African green monkey Vero cells incubated for 72 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains. |
| AID429016 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG6 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID601785 | Antibacterial activity against 10'4 CFU Enterococcus faecium 08-2 after 18 hrs by CLSI agar dilution method | 2011 | European journal of medicinal chemistry, Jun, Volume: 46, Issue:6 | Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives. |
| AID278256 | Antimicrobial activity against Salmonella enterica serovar Typhimurium CS9 with GyrA S83F, D87N, ParC S80I mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID559155 | Antimicrobial activity against Clostridium difficile 630d selected after 4 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID249970 | Ratio of MPC to MIC against methicillin resistant Staphylococcus aureus-5023 | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID528519 | Bactericidal activity against high level levofloxacin and methicillin-resistant Staphylococcus aureus at 2048 ug/ml after 24 hrs by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID561397 | Antibacterial activity against quinolone-susceptible Bordetella pertussis BP58 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Emergence of quinolone-resistant Bordetella pertussis in Japan. |
| AID425350 | Antibacterial activity against Streptococcus pneumoniae HMC 1146 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, and D435N mutation in QRDR of ParE gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID428988 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate ipt 2 harboring DNA gyrase A D87G mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1585704 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis after 3 to 7 days by rapid direct susceptibility test | 2019 | European journal of medicinal chemistry, Jan-15, Volume: 162 | Fluoroquinolone-isatin hybrids and their biological activities. |
| AID563026 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2834 by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID571173 | Antimicrobial activity against Clostridium difficile harboring ribotype 001 by CLSI agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. |
| AID542502 | Antimicrobial activity against Escherichia coli K-12 harboring gyrA L83, N87 mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. |
| AID279263 | Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3676 with GyrA E85G, GyrB S478I and ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID563019 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-2399 harboring gyrA Asp94Tyr mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID558622 | Antimicrobial activity against Streptococcus pneumoniae isolate 3374 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID249968 | Ratio of MPC to MIC aganist methicillin resistant Staphylococcus aureus-32 | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID540209 | Volume of distribution at steady state in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID368424 | Ratio of MIC for Escherichia coli KAM32 pSTVqepA mutant to MIC for Escherichia coli KAM32 pSTV28 mutant | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. |
| AID325858 | Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected in CD1 mouse assessed as bacterial load in spleen at 50 mg/kg, ip after 10 days | 2008 | Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5 | Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids. |
| AID285715 | Antibacterial activity against Streptococcus pyogenes | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID318922 | Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay | 2008 | Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6 | Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid. |
| AID428985 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 104 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID278233 | Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-1 gyrA+ | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID285752 | Antibacterial activity against Salmonella enterica serovar Paratyphi | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID580863 | Tmax in patients with pulmonary tuberculosis at 400 mg/kg, po | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. |
| AID425559 | Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 228 expressing ermB by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID559057 | Antibacterial activity against Lancefield Streptococcus sp. 'group G' by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1240500 | Antibacterial activity against Pseudomonas aeruginosa DM23376 after 24 hrs by broth microdilution method | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16 | N-Lipidated Peptide Dimers: Effective Antibacterial Agents against Gram-Negative Pathogens through Lipopolysaccharide Permeabilization. |
| AID298865 | Antibacterial activity against Staphylococcus aureus ATCC 25923 by micro-broth dilution method | 2007 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7 | Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones. |
| AID237457 | Partition coefficient (logD2.0) | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID613787 | Antibacterial activity against Streptococcus pneumoniae 08-2 after 18 to 24 hrs by NCCLS M100-S11 two fold serial dilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives. |
| AID368418 | Antimicrobial activity against multidrug-resistant Escherichia coli C316 pHPA containing mutated GyrA gene by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. |
| AID444053 | Renal clearance in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1237405 | Antibacterial activity against Streptococcus mutans 3065 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety. |
| AID559408 | Antimicrobial activity against Clostridium difficile BI2C selected after 4 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID210029 | Antibacterial activity was determined against Streptococcus pneumoniae J-24 strain after incubation at 37 degrees C for 18 h | 2003 | Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6 | Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents. |
| AID342256 | Effect on growth of fluoroquinolone-resistant epidemic Clostridium difficile NAP1 in CF1 mouse assessed as increase in bacterial density in cecal content at 2.0 mg/day, sc for 5 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID1524623 | Antibacterial activity against Streptococcus mutans 3289 after 24 hrs by microtiter ELISA | 2019 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9 | Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents. |
| AID1626596 | Inhibition of wild type Staphylococcus aureus gyrase assessed as compound concentration causing 50% induction of cleavage of covalently closed DNA substrate | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14 | Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections. |
| AID286060 | Half life at 100 mg/24 hrs regimen in vitro PK model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID1557305 | Half life in human at 0.4 g, po | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID285786 | Antibacterial activity against Streptococcus viridans | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID405465 | Antibacterial activity against Escherichia coli TOP10 containing pIP1206 plasmid in presence of 40 ug/ml efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine by Etest | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. |
| AID1600096 | Bactericidal activity against Staphylococcus aureus ATCC 6538 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID278259 | Antimicrobial activity against Salmonella enterica serovar Typhimurium CS9 tolC::Kan with GyrA S83F, D87N, ParC S80I mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID286049 | Peak free concentration at 400 mg/24 hrs regimen in vitro PK model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID498192 | Antibacterial activity against Stenotrophomonas maltophilia MBS100 deficient in Smqnr gene by epsilon test | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia. |
| AID209232 | In vitro antibacterial activity was tested for Streptococcus faecalis MGH-2 | 1995 | Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22 | The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. |
| AID278234 | Antimicrobial activity against Salmonella enterica serovar Typhimurium GyrA S21-1 acrAB::Kan with GyrA S83F mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID438298 | Inhibition of penicillin-resistant Streptococcus pneumoniae 5204 PBP2X preincubated for 4 hrs before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid | 2009 | Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19 | Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening. |
| AID278043 | Decrease in IL8 secretion in human PC3 cells at 4 ug/ml | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID558926 | Antimicrobial activity against Clostridium difficile A422b selected after 2 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID1605844 | Antibacterial activity against vancomycin-resistant Enterococcus faecalis 1010 assessed as reduction in bacterial growth measured after 24 hrs by broth microdilution method | 2020 | Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7 | Rational Substitution of ε-Lysine for α-Lysine Enhances the Cell and Membrane Selectivity of Pore-Forming Melittin. |
| AID1254071 | Antibacterial activity against Escherichia coli KCTC 1924 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22 | Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents. |
| AID1601841 | Antibacterial activity against Staphylococcus aureus CMCC(B) 26003 measured after 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Mar-15, Volume: 166 | Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety. |
| AID293148 | Antibacterial activity against quinoline-susceptible methicillin-resistant Staphylococcus aureus by agar dilution method | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4 | Synthesis and antibacterial activities of new quinolone derivatives utilizing 1-azabicyclo[1.1.0]butane. |
| AID563214 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2834 by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID425564 | Antibacterial activity against quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 5048 expressing mefA after 50 passages by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID285712 | Antibacterial activity against Staphylococcus saprophyticus | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID286081 | fAUC/MIC ratio of Staphylococcus aureus ATCC 49610 at 400 mg | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID206764 | In vitro antibacterial activity was tested for Staphylococcus aureus H228 | 1995 | Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22 | The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. |
| AID1254078 | Antibacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3506 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22 | Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents. |
| AID456032 | Antibacterial activity against Escherichia coli NIHJ after 18 hrs by twofold microbroth dilution method | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria. |
| AID561402 | Antibacterial activity against quinolone-susceptible Bordetella pertussis BP122 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Emergence of quinolone-resistant Bordetella pertussis in Japan. |
| AID278257 | Antimicrobial activity against Salmonella enterica serovar Typhimurium CS9 gyrA+ with GyrA S83F, D87N, ParC S80I mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID1428626 | Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 by broth microdilution method | 2017 | European journal of medicinal chemistry, Feb-15, Volume: 127 | Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis. |
| AID161281 | Inhibition of human Potassium channel HERG expressed in mammalian cells | 2003 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16 | Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. |
| AID625279 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID285725 | Antibacterial activity against VanB-resistant Enterococcus faecalis | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID389912 | Antibacterial activity against Staphylococcus aureus ATCC 13709 after 24 hrs by microdilution method | 2008 | Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21 | Linking bisphosphonates to the free amino groups in fluoroquinolones: preparation of osteotropic prodrugs for the prevention of osteomyelitis. |
| AID558605 | Antimicrobial activity against Streptococcus pneumoniae isolate 1146 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID208626 | Antibacterial activity was determined against clinically isolated penicillin resistant Streptococcus pneumoniae (PRSP) strains (50 strains) | 2003 | Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6 | Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents. |
| AID542509 | Antimicrobial activity against Escherichia coli K-12 harboring gyrA L83, N87, gyrB T471 and parC I80, G84 mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. |
| AID1557303 | Cmax in human at 0.4 g, po | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID559528 | Antibacterial activity against Citrobacter koseri assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID521103 | Antimicrobial activity against Streptococcus sp. 'group B' isolate 1 harboring gyrA Glu85Lys mutant, parC Ser79Tyr mutant and parE Ileu495Leu mutant gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan. |
| AID1605840 | Ratio of MIC for vancomycin-resistant Enterococcus faecalis 1010 to MIC for Mel-5-resistant vancomycin-resistant Enterococcus faecalis 1010 incubated for 24 hrs by broth microdilution method | 2020 | Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7 | Rational Substitution of ε-Lysine for α-Lysine Enhances the Cell and Membrane Selectivity of Pore-Forming Melittin. |
| AID271598 | Antibacterial activity against Staphylococcus aureus SA2552 | 2006 | Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22 | 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. |
| AID271595 | Antibacterial activity against Moraxella catarrhalis BC-3531 | 2006 | Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22 | 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. |
| AID1240497 | Antibacterial activity against Pseudomonas aeruginosa DR18531 after 24 hrs by broth microdilution method | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16 | N-Lipidated Peptide Dimers: Effective Antibacterial Agents against Gram-Negative Pathogens through Lipopolysaccharide Permeabilization. |
| AID209591 | Antibacterial activity was determined against Streptococcus mitis IID685 strain after incubation at 37 degrees C for 18 h | 2003 | Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6 | Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents. |
| AID562826 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-2934 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID444055 | Fraction absorbed in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID303464 | Cytotoxicity against Vero cells after 72 hrs by MTT assay | 2007 | Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24 | Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid. |
| AID278270 | Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS38 acrAB::Kan with GyrA D87G mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID286108 | Bactericidal activity against Staphylococcus aureus ATCC 49619 at fAUC/MIC of 60 after 48 hrs in pharmacodynamic model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID561398 | Antibacterial activity against quinolone-susceptible Bordetella pertussis BP99 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Emergence of quinolone-resistant Bordetella pertussis in Japan. |
| AID351293 | Antibacterial activity against Enterococcus faecalis NCTC 6013 after 18 hrs by conventional agar dilution method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Synthesis and antibacterial activity of nitroaryl thiadiazole-gatifloxacin hybrids. |
| AID372996 | Antimycobacterial activity against Mycobacterium avium complex N016 infected C57BL/6J mouse assessed as lung bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID559082 | Antibacterial activity against Morganella morganii by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID528508 | Bactericidal activity against low level levofloxacin and methicillin-resistant Staphylococcus aureus at 16 times MIC after 120 mins by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID565316 | Antibacterial activity against Mycoplasma genitalium UTMB-10G by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID425339 | Antibacterial activity against azithromycin-resistant Streptococcus pneumoniae ATCC 49619 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID565328 | Antibacterial activity against Mycoplasma genitalium M6282 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID559185 | Antimicrobial activity against Clostridium difficile C253D selected after 8 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID1510743 | Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis by two fold dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Nitroimidazole-containing compounds and their antibacterial and antitubercular activities. |
| AID425352 | Antibacterial activity against Streptococcus pneumoniae HMC 1150 harboring S81C mutation in quinolone-resistant determining regions of GyrA gene, S79F mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID1237414 | Bactericidal activity against Staphylococcus aureus KCTC 503 after 24 hrs by agar plate method | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety. |
| AID561391 | Antibacterial activity against quinolone-susceptible Bordetella pertussis BP109 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Emergence of quinolone-resistant Bordetella pertussis in Japan. |
| AID563036 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0777 by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1330187 | Antibacterial activity against Staphylococcus aureus 209 measured after 24 hrs by two-fold serial dilution method | 2016 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24 | Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties. |
| AID565324 | Antibacterial activity against Mycoplasma genitalium M6286 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID298862 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by micro-broth dilution method | 2007 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7 | Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones. |
| AID429025 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG176 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID425338 | Antibacterial activity against azithromycin-susceptible Streptococcus pneumoniae ATCC 49619 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID733006 | Inhibition of Mycobacterium leprae wild type DNA gyrase GyrA/GyrB-mediated DNA cleavable complex formation assessed as compound concentration inducing 25% DNA cleavage using relaxed pBR322 DNA substrate incubated for 1 hr at 30 degC by agarose gel electro | 2013 | Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4 | Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis. |
| AID286105 | Bactericidal activity against Staphylococcus aureus ATCC 49619 with Parc S79Y mutation and gyrA S81F mutation at fAUC/MIC of 35 after 72 hrs in pharmacodynamic model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID563057 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0821 harboring gyrA Asp94Tyr mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID425072 | Antimicrobial activity against Escherichia coli DH10B expressing pCRQB10 in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID433583 | Selectivity index, ratio of CC25 for Mycobacterium leprae DNA gyrase subunit A A91V mutant to CC25 for Mycobacterium leprae wild type DNA gyrase A2B2 by DNA cleavage assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones? |
| AID425351 | Antibacterial activity against Streptococcus pneumoniae HMC 1147 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79F mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene showing efflux to gemifloxacin by | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID565312 | Antibacterial activity against Mycoplasma genitalium R32 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID286161 | Effect on efflux-mediatated resistance of Staphylococcus aureus ATCC 49619 mutant | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID279255 | Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 3009 after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID530595 | Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr7 carrying Smqnr gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia. |
| AID244721 | Frequency of resistance emergence for methicillin resistant Staphylococcus aureus-33 | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID264956 | Activity against Mycobacterium tuberculosis ATCC 35801 in CD1 mouse at 50 mg/kg assessed as decrease in bacterial load in spleen relative to control | 2006 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11 | Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase. |
| AID558590 | Antimicrobial activity against Streptococcus pneumoniae 2 by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID405456 | Antibacterial activity against Escherichia coli C600Rif in presence of 40 ug/ml efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine by Etest | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. |
| AID563211 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0787 harboring gyrA Asp94His mutant gene assessed as microbial susceptibility and deletion of codons 678 and 679 in gyrB mutant gene assessed as microbial susceptibility by agar proportion m | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID565323 | Antibacterial activity against Mycoplasma genitalium M6285 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID279283 | Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parC S79Y and gyrA S81F mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. |
| AID1382067 | Antibacterial activity against Staphylococcus epidermidis ATCC 12228 by CLSI agar dilution method | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Ciprofloxacin derivatives and their antibacterial activities. |
| AID530590 | Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr2 carrying Smqnr gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia. |
| AID1237426 | Bactericidal activity against methicillin-resistant Staphylococcus aureus CCARM 3167 after 24 hrs by agar plate method | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety. |
| AID405467 | Antibacterial activity against Escherichia coli TOP10 containing pAT851 plasmid by Etest | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. |
| AID1237402 | Antibacterial activity against Staphylococcus aureus RN4220 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety. |
| AID1254072 | Antibacterial activity against Escherichia coli CCARM 1356 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22 | Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents. |
| AID1391316 | Antibacterial activity against Escherichia coli 1924 after 24 hrs by two-fold serial dilution method | 2018 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9 | Synthesis and evaluation of the antibacterial activities of aryl substituted dihydrotriazine derivatives. |
| AID532977 | Inhibition of DNA supercoiling activity of wild type Mycobacterium tuberculosis DNA gyrase A | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates. |
| AID244968 | Minimum inhibitory concentration against Pseudomonas aeruginosa ATCC 27853 | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID1079933 | Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is | |||
| AID528500 | Antimicrobial activity against levofloxacin-sensitive and methicillin-resistant Staphylococcus aureus JCSC 6769 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID271596 | Antibacterial activity against Staphylococcus aureus SA1417 | 2006 | Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22 | 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. |
| AID559053 | Antibacterial activity against Staphylococcus warneri by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1605834 | In vivo antibacterial activity against Staphylococcus aureus ATCC 29213 infected in C57BL/6 mouse assessed as reduction in bacterial burden by measuring log10 CFU/cornea at 0.3% administered topically as two times on day 1, four times on day 2 and two tim | 2020 | Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7 | Rational Substitution of ε-Lysine for α-Lysine Enhances the Cell and Membrane Selectivity of Pore-Forming Melittin. |
| AID1600098 | Bactericidal activity against methicillin resistant Staphylococcus aureus N315 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID342081 | Effect on growth of nonepidemic Clostridium difficile J29 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.4 mg/day, sc for 4 days assessed after 2 days of last treatment | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID285705 | Antibacterial activity against oxacillin-susceptible Staphylococcus aureus | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID456046 | Antibacterial activity against vancomycin-resistant Enterococcus faecium after 18 hrs by twofold microbroth dilution method | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria. |
| AID433400 | Inhibition of Mycobacterium leprae wild type DNA gyrase A2B2 assessed as DNA supercoiling inhibition | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones? |
| AID425731 | Antimicrobial activity against Bacillus anthracis Ames after 18 hrs by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. |
| AID456043 | Antibacterial activity against ciprofloxacin, methicillin-resistant Staphylococcus aureus after 18 hrs by twofold microbroth dilution method | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria. |
| AID237034 | Dissociation constant (pKa) was determined | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID425732 | Apparent volume of distribution with respect to the bioavailability in mouse at 10 to 100 mg/kg, ip | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. |
| AID518800 | Antimycobacterial activity against Mycobacterium avium serovar 4 after 14 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species. |
| AID559179 | Antimicrobial activity against Clostridium difficile C253A selected after 4 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID1600112 | Bactericidal activity against methicillin resistant Staphylococcus aureus 6347 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID520617 | Antimicrobial activity against Nocardia brasiliensis HUJEG-1 by broth macrodilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | In vivo therapeutic effect of gatifloxacin on BALB/c mice infected with Nocardia brasiliensis. |
| AID285758 | Antibacterial activity against Serratia marcescens | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID563012 | Antimycobacterial activity against Mycobacterium tuberculosis 02-1975 harboring gyrA Asp94Gly mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID429040 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT76 harboring wild type DNA gyrase A assessed as complete cell killing at 4 times MIC after 6 hrs by time-kill analysis | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID563050 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0797 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID428899 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT18 harboring DNA gyrase A S83F and D87G mutation assessed as decrease in viable count at 16 times MIC after 4 hrs by time-kill analysis | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1393792 | Antibacterial activity against multidrug resistant Mycobacterium tuberculosis ATTC 27294 by Alamar Blue assay | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Fluoroquinolone derivatives and their anti-tubercular activities. |
| AID351442 | Cytotoxicity against mouse NIH/3T3 cells after 72 hrs by MTT assay | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Synthesis and antibacterial activity of nitroaryl thiadiazole-gatifloxacin hybrids. |
| AID613782 | Antibacterial activity against methicillin-resistant Staphylococcus aureus 08-1 after 18 to 24 hrs by NCCLS M100-S11 two fold serial dilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives. |
| AID96407 | In vitro antibacterial activity was tested for Klebsiella pneumoniae MGH-2 | 1995 | Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22 | The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. |
| AID278262 | Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS14 acrAB::Kan with GyrA D87G mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID286111 | Bactericidal activity against Staphylococcus aureus ATCC 49619 at fAUC/MIC of 66 after 24 to 96 hrs in pharmacodynamic model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID456029 | Antibacterial activity against Streptococcus pyogenes G-36 after 18 hrs by twofold microbroth dilution method | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria. |
| AID1391315 | Antifungal activity against Candida albicans 7535 after 24 hrs by two-fold serial dilution method | 2018 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9 | Synthesis and evaluation of the antibacterial activities of aryl substituted dihydrotriazine derivatives. |
| AID1570240 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv incubated for 7 days by rapid direct susceptibility test | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains. |
| AID342065 | Antimicrobial activity against epidemic Clostridium difficile BI6-8-17 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID278232 | Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-1 GyrA S83F mutant | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID425653 | Renal clearance in human | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Physicochemical determinants of human renal clearance. |
| AID1067077 | Antimicrobial activity against Pseudomonas aeruginosa 2742 after 20 hrs by two-fold serial dilution technique | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives. |
| AID285753 | Antibacterial activity against Salmonella enterica serovar Typhimurium | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID429027 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate AG258 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1601849 | Antibacterial activity against Pseudomonas aeruginosa CMCC 27853 measured after 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Mar-15, Volume: 166 | Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety. |
| AID278241 | Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-3 gyrA+ with ParC S80I mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID285781 | Antibacterial activity against Prevotella sp. | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID1067072 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus clinical isolate 3167 after 20 hrs by two-fold serial dilution technique | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives. |
| AID342064 | Antimicrobial activity against epidemic Clostridium difficile BI9 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID425348 | Antibacterial activity against Streptococcus pneumoniae HMC 1073 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, and I460V mutation in QRDR of ParE gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID285339 | Antimicrobial activity against streptomycin-resistant Escherichia coli J53 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant Escherichia coli strain in Latin America. |
| AID163740 | In vitro antibacterial activity was tested for Providencia rettgeri H1771 | 1995 | Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22 | The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. |
| AID322985 | Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae with 23S rRNA A2063G mutant isolate 1 | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae. |
| AID278240 | Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-3 with GyrA S83F, ParC S80I mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID66576 | Antibacterial activity was determined against clinically isolated vancomycin-A resistant enterococci (VRE) strains (33 strains) | 2003 | Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6 | Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents. |
| AID285774 | Antibacterial activity against Peptostreptococcus magnus | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID575948 | Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae assessed as resistant isolates by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates. |
| AID563215 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0794 harboring gyrA Thr80Ala mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID342245 | Increase in toxin level in epidemic Clostridium difficile BI9 infected CF1 mouse at 0.2 mg/day, sc for 4 days assessed after 2 days of last treatment | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID405825 | Antimicrobial activity against Acinetobacter baumannii 694 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID425775 | Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 228 expressing ermB after 28 passages by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID1601844 | Antibacterial activity against Streptococcus pneumoniae CMCC 31968 measured after 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Mar-15, Volume: 166 | Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety. |
| AID428997 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT142 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID67078 | Antibacterial activity was determined against Enterococcus faecalis ATCC 19433 strain after incubation at 37 degrees C for 18 h | 2003 | Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6 | Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents. |
| AID559200 | Antibacterial activity against Streptococcus pneumoniae S001 harboring parC Asp83Asn mutant and wild-type gyrA genes | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms. |
| AID559507 | Antibacterial activity against Staphylococcus saprophyticus assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID298873 | Antibacterial activity against penicillin-resistant Streptococcus pneumoniae ATCC 700904 by micro-broth dilution method | 2007 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7 | Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones. |
| AID265984 | Activity against Mycobacterium tuberculosis H37Rv infected in CD1 mouse assessed as decrease in bacterial load relative to control in lung at 50 mg/kg, ip | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 | Discovery of new antitubercular oxazolyl thiosemicarbazones. |
| AID1473741 | Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID561400 | Antibacterial activity against quinolone-susceptible Bordetella pertussis BP118 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Emergence of quinolone-resistant Bordetella pertussis in Japan. |
| AID558925 | Antimicrobial activity against Clostridium difficile A422a selected after 2 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID425357 | Antibacterial activity against Streptococcus pneumoniae HMC 1071 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene and S79F, K137N mutation in QRDR of ParC gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID1330196 | Antibacterial activity against quinolone-resistant Staphylococcus aureus 3505 measured after 24 hrs by two-fold serial dilution method | 2016 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24 | Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties. |
| AID563031 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0771 harboring gyrA putative promoter mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID558621 | Antimicrobial activity against Streptococcus pneumoniae isolate 3346 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID565313 | Antibacterial activity against Mycoplasma genitalium TW10-5G by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID1237417 | Fungicidal activity against Candida albicans 7535 after 24 hrs by agar plate method | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety. |
| AID237037 | Dissociation constant (pKa) was determined | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID265978 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 | Discovery of new antitubercular oxazolyl thiosemicarbazones. |
| AID279273 | Antibacterial activity against Streptococcus pneumoniae assessed as period of suppression of bacterial growth | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID243151 | Inhibitory concentration against potassium channel HERG | 2005 | Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11 | A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. |
| AID558877 | Antimicrobial activity against Clostridium difficile A422 expressing tcdA and tcdB gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID559245 | Antibacterial activity against Streptococcus pneumoniae D002 harboring parC Ser79Phe and gyrA Ser81Phe mutant genes assessed as mutation prevention concentration after 48 hrs | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms. |
| AID1067083 | Antimicrobial activity against Staphylococcus aureus RN4220 after 20 hrs by two-fold serial dilution technique | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives. |
| AID405299 | Antimicrobial activity against Leptospira interrogans serovar Portlandvere infected golden Syrian hamster model of acute lethal leptospirosis assessed as survival at 5 mg/kg/day, ip once daily for 5 days administered 2 day after infection | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Efficacy of fluoroquinolones against Leptospira interrogans in a hamster model. |
| AID1237415 | Bactericidal activity against Streptococcus mutans 3065 after 24 hrs by agar plate method | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety. |
| AID1067071 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus clinical isolate 3506 after 20 hrs by two-fold serial dilution technique | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives. |
| AID425073 | Antimicrobial activity against Escherichia coli DH10B expressing pCR2.1 in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID456034 | Antibacterial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by twofold microbroth dilution method | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria. |
| AID520613 | Cmax in BALB/c mouse serum at 100 mg/kg, sc TID for 4 weeks by HPLC method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | In vivo therapeutic effect of gatifloxacin on BALB/c mice infected with Nocardia brasiliensis. |
| AID530634 | Antimicrobial activity against Staphylococcus aureus CB808 harboring quinolone-resistant parC S80F mutant gene by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. |
| AID559175 | Antimicrobial activity against Clostridium difficile BI2f harboring GyrB Arg447Lys and Asp426Asn mutant gene selected after 32 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID428978 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate B111 harboring DNA gyrase A S83Y mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID436988 | Inhibition of human HeLa cell proliferation | 2009 | Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15 | 7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents. |
| AID530632 | Antimicrobial activity against Staphylococcus aureus CB190 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. |
| AID558908 | Antimicrobial activity against Clostridium difficile CD5e harboring GyrB Ser416Ala mutant gene selected after 4 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID405824 | Antimicrobial activity against Acinetobacter baumannii 696 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID425542 | Antibacterial activity against Streptococcus pneumoniae HMC 1139 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79F, K137N mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID298867 | Antibacterial activity against Staphylococcus aureus ATCC 33592 by micro-broth dilution method | 2007 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7 | Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones. |
| AID279277 | Antimicrobial activity agaisnt Streptococcus pneumoniae R6 transformants with parC S79Y mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. |
| AID278040 | Cytotoxicity against human PC3 cells at 4 ug/ml relative to control | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID1264463 | Antimycobacterial activity against rifamypicin-resistant Mycobacterium tuberculosis after 7 days by REMA method | 2015 | ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10 | Nitrofuranyl Methyl Piperazines as New Anti-TB Agents: Identification, Validation, Medicinal Chemistry, and PK Studies. |
| AID429019 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG15 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID528517 | Bactericidal activity against levofloxacin-sensitive and methicillin-resistant Staphylococcus aureus at 16 times MIC after 24 hrs by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID530350 | Antimicrobial activity against Escherichia coli TOP10 by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID559505 | Antibacterial activity against Staphylococcus hominis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID285772 | Antibacterial activity against Peptostreptococcus anaerobius | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID279203 | Antibacterial activity against Streptococcus pneumoniae 1076 by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID559488 | Antibacterial activity against Peptostreptococcus sp. by CLSI M11-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID542501 | Antimicrobial activity against Escherichia coli K-12 harboring parE A458 mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. |
| AID565320 | Antibacterial activity against Mycoplasma genitalium M2341 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID563038 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0781 by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID425074 | Antimicrobial activity against Escherichia coli DH10B in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID278050 | Suppression of 1 ng/ml LPS-stimulated IL8 secretion in human PC3 cells | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID563058 | Antimycobacterial activity against Mycobacterium tuberculosis 04-0649 harboring gyrA Asp94Asn mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID559495 | Antibacterial activity against Prevotella sp. assessed as percent susceptible isolates by CLSI M11-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID271600 | Antibacterial activity against Staphylococcus aureus SA2558 | 2006 | Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22 | 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. |
| AID559240 | Antibacterial activity against Streptococcus pneumoniae S001 harboring parC Asp83Asn mutant and wild-type gyrA genes assessed as mutation prevention concentration after 48 hrs | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms. |
| AID498188 | Antibacterial activity against Stenotrophomonas maltophilia MBS108 containing both chromosomally and plasmid encoded Smqnr gene by epsilon test | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia. |
| AID262134 | Antimicrobial activity against Staphylococcus aureus ATCC 29213 | 2006 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5 | Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells. |
| AID530593 | Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr5 carrying Smqnr gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia. |
| AID425556 | Antibacterial activity against quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 441 expressing ermB by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID1382078 | Antibacterial activity against Staphylococcus aureus NCDC 110 after overnight incubation by single disc method | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Ciprofloxacin derivatives and their antibacterial activities. |
| AID563212 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0745 harboring gyrA Asp89Asn mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID285763 | Antibacterial activity against Actinomyces sp. | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID325852 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method | 2008 | Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5 | Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids. |
| AID278046 | Reduction of Mycoplasma hominis-stimulated IL8 secretion in human PC3 cells | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID558598 | Antimicrobial activity against Streptococcus pneumoniae 10 by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID368421 | Antimicrobial activity against Escherichia coli KAM32 pSTV28 containing chloramphenicol-resistant vector by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. |
| AID565330 | Antibacterial activity against Mycoplasma genitalium M6284 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID1237404 | Antibacterial activity against Staphylococcus aureus KCTC 503 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety. |
| AID1067075 | Antimicrobial activity against Salmonella typhimurium 2421 after 20 hrs by two-fold serial dilution technique | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives. |
| AID1067070 | Antimicrobial activity against quinolone-resistant Staphylococcus aureus clinical isolate 3505 after 20 hrs by two-fold serial dilution technique | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives. |
| AID342093 | Increase in toxin level in nonepidemic Clostridium difficile J29 infected CF1 mouse at 2 mg/day, sc for 4 days assessed after 2 days of last treatment | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID285779 | Antibacterial activity against Prevotella melaninogenica | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID286117 | Bactericidal activity against Staphylococcus aureus BSP-2443 at fAUC/MIC of 62 after 24 to 96 hrs in pharmacodynamic model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID1551291 | Antibacterial activity against Staphylococcus aureus KCTC209 assessed as reduction in bacterial cell growth incubated for 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Jun-15, Volume: 172 | Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents. |
| AID425736 | Ratio of AUC (0 to 24 hrs) for Staphylococcus aureus infected ICR/Swiss mouse model to MIC for Staphylococcus aureus | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. |
| AID558627 | Antimicrobial activity against Streptococcus pneumoniae isolate 3587 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID542503 | Antimicrobial activity against Escherichia coli K-12 harboring gyrA L83, N87 and parC K84 mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. |
| AID559496 | Antibacterial activity against Propionibacterium acnes assessed as percent susceptible isolates by CLSI M11-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID558909 | Antimicrobial activity against Clostridium difficile CD5f harboring GyrB Ser416Ala mutant gene selected after 4 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID1240504 | Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 after 24 hrs by broth microdilution method | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16 | N-Lipidated Peptide Dimers: Effective Antibacterial Agents against Gram-Negative Pathogens through Lipopolysaccharide Permeabilization. |
| AID428995 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate ipt 33 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID279211 | Antibacterial activity against Streptococcus pneumoniae 37 by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID286113 | Bactericidal activity against Staphylococcus aureus ATCC 49619 at fAUC/MIC of 144 after 24 to 96 hrs in pharmacodynamic model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID558875 | Antimicrobial activity against Clostridium difficile C253 expressing tcdA and tcdB gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID1626595 | Inhibition of wild type Staphylococcus aureus topoisomerase 4 assessed as compound concentration causing 50% induction of cleavage of covalently closed DNA substrate | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14 | Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections. |
| AID429041 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate HTD 798 harboring DNA gyrase A S83F mutation assessed as complete cell killing at 4 times MIC after 6 hrs by time-kill analysis | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID425729 | Tlag in mouse at 10 to 100 mg/kg, ip | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. |
| AID271592 | Antibacterial activity against Escherichia coli EC2026 | 2006 | Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22 | 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. |
| AID558589 | Antimicrobial activity against Streptococcus pneumoniae 1 by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID559150 | Antimicrobial activity against Clostridium difficile 630b selected after 2 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID1330191 | Antibacterial activity against Salmonella typhimurium 1926 measured after 24 hrs by two-fold serial dilution method | 2016 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24 | Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties. |
| AID562829 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0757 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID588212 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID563051 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 99-1914 harboring gyrA Asp94Gly mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID373002 | Antimycobacterial activity against Mycobacterium avium complex N018 infected C57BL/6J mouse assessed as lung bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID50848 | In vitro antibacterial activity was tested for Clostridium diff CD1-1 | 1995 | Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22 | The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. |
| AID531858 | Tmax in tuberculosis patient at 4.59 ug/ml, po administered for 7 days by HPLC | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. |
| AID558608 | Antimicrobial activity against Streptococcus pneumoniae isolate 1394 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID325854 | Antimycobacterial activity against Mycobacterium smegmatis MC2 by agar dilution method | 2008 | Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5 | Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids. |
| AID279256 | Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3009 with GyrA S81F and ParC D83N mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID342092 | Increase in toxin level in nonepidemic Clostridium difficile ATCC 9689 infected in CF1 mouse at 2 mg/day, sc for 4 days assessed after 2 days of last treatment | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID1330193 | Antifungal activity against Candida albicans 7535 measured after 24 hrs by two-fold serial dilution method | 2016 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24 | Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties. |
| AID530639 | Antimicrobial activity against Staphylococcus aureus CB812 harboring rpoB H481Y, gyrA S84L and gyrA S80F mutant genes by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. |
| AID1601850 | Antibacterial activity against Pseudomonas aeruginosa CMCC 10104 measured after 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Mar-15, Volume: 166 | Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety. |
| AID278250 | Antimicrobial activity against Salmonella enterica serovar Typhimurium CS1 acrAB::Kan with GyrA S83F, D87N, ParC S80I mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID1254069 | Antibacterial activity against Staphylococcus aureus 503 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22 | Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents. |
| AID558616 | Antimicrobial activity against Streptococcus pneumoniae isolate 2880 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID613788 | Antibacterial activity against Streptococcus pneumoniae 08-4 after 18 to 24 hrs by NCCLS M100-S11 two fold serial dilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives. |
| AID429018 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG8 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID528520 | Bactericidal activity against levofloxacin-sensitive and methicillin-resistant Staphylococcus aureus at 2048 ug/ml after 24 hrs by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID559523 | Antibacterial activity against Streptococcus sanguinis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID558883 | Antimicrobial activity against Clostridium difficile C253a selected after 2 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID1557306 | Protein binding in human at 0.4 g, po | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID425570 | Antibacterial activity against penicillin-susceptible, quinolone-resistant Streptococcus pneumoniae HMC 1072 expressing ermB and harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79Y mutation in QRDR of ParC gene and I460V | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID530637 | Antimicrobial activity against Staphylococcus aureus CB812 harboring rpo B H481Y and gyrA S84L mutant genes by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. |
| AID285707 | Antibacterial activity against oxacillin and levofloxacin-resistant Staphylococcus aureus | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID542521 | Antimicrobial activity against fluoroquinolone-resistant Escherichia coli clinical isolate by Etest | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates. |
| AID429039 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT144 harboring DNA gyrase A D87G mutation assessed as decrease in bacterial population at 4 times MIC after 30 mins by time-kill analysis | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID405461 | Antibacterial activity against Escherichia coli TOP10 by Etest | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. |
| AID563013 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2614 harboring gyrA Asp94Gly mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1330197 | Antibacterial activity against quinolone-resistant Staphylococcus aureus 3519 measured after 24 hrs by two-fold serial dilution method | 2016 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24 | Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties. |
| AID1600106 | Bactericidal activity against Escherichia coli ATCC 8739 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID1067078 | Antimicrobial activity against Escherichia coli CCARM 1356 after 20 hrs by two-fold serial dilution technique | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives. |
| AID66578 | Antibacterial activity was determined against clinically isolated vancomycin-B resistant enterococci (VRE) strains (10 strains) | 2003 | Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6 | Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents. |
| AID1890606 | Antibacterial activity against beta-lactams, macrolide and fluoroquinolone resistant Streptococcus pneumoniae 718 infected in po dosed Swiss mouse septicemia model assessed as protective dose administered on 1 and 5 hrs post infection and measured on day | 2022 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 63 | WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections. |
| AID425726 | Half life in human | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. |
| AID563053 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2614 harboring gyrA Asp94Gly mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1330195 | Antibacterial activity against methicillin-resistant Staphylococcus aureus 3506 measured after 24 hrs by two-fold serial dilution method | 2016 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24 | Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties. |
| AID563052 | Antimycobacterial activity against Mycobacterium tuberculosis 02-1975 harboring gyrA Asp94Gly mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1585702 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 3 to 7 days by rapid direct susceptibility test | 2019 | European journal of medicinal chemistry, Jan-15, Volume: 162 | Fluoroquinolone-isatin hybrids and their biological activities. |
| AID519203 | Antibacterial activity against Streptococcus pneumoniae assessed as susceptible isolates by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | In vitro activity of AR-709 against Streptococcus pneumoniae. |
| AID1557282 | Antibacterial activity against Bacteroides fragilis by agar diffusion method | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID310321 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method | 2007 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23 | An atom efficient, solvent-free, green synthesis and antimycobacterial evaluation of 2-amino-6-methyl-4-aryl-8-[(E)-arylmethylidene]-5,6,7,8-tetrahydro-4H-pyrano[3,2-c]pyridine-3-carbonitriles. |
| AID530591 | Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr3 carrying Smqnr gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia. |
| AID1079943 | Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] | |||
| AID425548 | Antibacterial activity against Streptococcus pneumoniae HMC 1062 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79F mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID309398 | Antitubercular activity against Mycobacterium tuberculosis H37Rv | 2007 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 17, Issue:20 | Synthesis and antitubercular activity of lipophilic moxifloxacin and gatifloxacin derivatives. |
| AID563025 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-1234 harboring gyrA Asn533Thr gyrB mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1382068 | Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis by CLSI agar dilution method | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Ciprofloxacin derivatives and their antibacterial activities. |
| AID425071 | Antimicrobial activity against Escherichia coli J53-AzR in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID565310 | Antibacterial activity against Mycoplasma genitalium G37 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID428994 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate ipt 32 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1600100 | Bactericidal activity against Staphylococcus epidermidis ATCC 14990 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID530599 | Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr11 carrying Smqnr gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia. |
| AID540210 | Clearance in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID245040 | Minimum inhibitory concentration against Staphylococcus saprophyticus ATCC 15305 | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID558897 | Antimicrobial activity against Clostridium difficile C253i harboring GyrA Ala118Ser mutant gene selected after 8 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID531859 | Antimicrobial activity against Mycobacterium tuberculosis infected in patient at 400 mg/day, po administered for 7 days by HPLC | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. |
| AID530592 | Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr4 carrying Smqnr gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia. |
| AID245695 | Mutant prevention concentration against methicillin resistant Staphylococcus aureus-32 done for 48 h at 37 degree C with compound | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID1600103 | Antibacterial activity against Bacillus subtilis ATCC 6633 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID433579 | Inhibition of Mycobacterium leprae wild type DNA gyrase subunit A A91V mutant assessed as formation of DNA cleavable complex | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones? |
| AID244935 | Minimum inhibitory concentration against Klebsiella pneumoniae ATCC 10031 | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID1473740 | Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID209273 | Antibacterial activity was determined against Streptococcus pyogenes G-36 strain after incubation at 37 degrees C for 18 h | 2003 | Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6 | Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents. |
| AID351441 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 18 hrs by conventional agar dilution method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Synthesis and antibacterial activity of nitroaryl thiadiazole-gatifloxacin hybrids. |
| AID561393 | Antibacterial activity against quinolone-susceptible Bordetella pertussis BP112 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Emergence of quinolone-resistant Bordetella pertussis in Japan. |
| AID425652 | Total body clearance in human | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Physicochemical determinants of human renal clearance. |
| AID405297 | Antimicrobial activity against Leptospira interrogans serovar Portlandvere infected golden Syrian hamster model of acute lethal leptospirosis assessed as survival at 50 mg/kg/day, ip once daily for 5 days administered 2 day after infection | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Efficacy of fluoroquinolones against Leptospira interrogans in a hamster model. |
| AID1445729 | Ratio of MIC for Staphylococcus aureus ATCC 29213 after 15 passages to MIC for Staphylococcus aureus ATCC 29213 | 2017 | Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14 | Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA). |
| AID1601852 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 measured after 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Mar-15, Volume: 166 | Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety. |
| AID563223 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0774 assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID429023 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG168 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID271608 | Antibacterial activity against Streptococcus pyogenes C203 SP1-1 | 2006 | Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22 | 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. |
| AID563040 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0789 by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID425762 | Antibacterial activity against penicillin-, macrolide-susceptible and quinolone-resistant Streptococcus pneumoniae HMC 1074 harboring S81F, E85K mutation in quinolone-resistant determining regions of GyrA gene, S79F mutation in QRDR of ParC gene and I460V | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID279291 | Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parE D435N and gyrA S81F mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. |
| AID278251 | Antimicrobial activity against Salmonella enterica serovar Typhimurium CS1 tolC::Kan with GyrA S83F, D87N, ParC S80I mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID1254068 | Antibacterial activity against Staphylococcus aureus 209 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22 | Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents. |
| AID164393 | Antibacterial activity was determined against Pseudomonas aeruginosa PAO1 strain after incubation at 37 degrees C for 18 h | 2003 | Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6 | Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents. |
| AID425734 | Ratio of AUC (0 to 24 hrs) for Staphylococcus infected patient to MIC for Staphylococcus | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. |
| AID279270 | Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 24 with GyrA S81Y, GyrB P413S and ParC S79F mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID286114 | Bactericidal activity against Staphylococcus aureus BSP-2443 at fAUC/MIC of 51 after 24 to 48 hrs in pharmacodynamic model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID298859 | Antibacterial activity against Staphylococcus epidermidis ATCC 12228 by micro-broth dilution method | 2007 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7 | Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones. |
| AID425567 | Antibacterial activity against Streptococcus pneumoniae HMC 3041 after 50 passages by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID562825 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 03-0738 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID613790 | Antibacterial activity against Enterococcus faecium 08-7 after 18 to 24 hrs by NCCLS M100-S11 two fold serial dilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives. |
| AID563045 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-0930 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1601847 | Antibacterial activity against Escherichia coli CMCC 25922 measured after 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Mar-15, Volume: 166 | Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety. |
| AID279290 | Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parC D83Y and gyrA E85K mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. |
| AID563228 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0789 assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID420668 | Inhibition of human ERG in MCF7 cells | 2009 | European journal of medicinal chemistry, May, Volume: 44, Issue:5 | GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers. |
| AID262138 | Inhibitory activity against wild type Staphylococcus aureus topoisomerase 4 | 2006 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5 | Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells. |
| AID278248 | Antimicrobial activity against Salmonella enterica serovar Typhimurium CS1 with GyrA S83F, D87N, ParC S80I mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID324746 | Effect on Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as enhancement of supercoiled pBR322 DNA cleavage | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones. |
| AID279259 | Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 1076 with ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID351296 | Antibacterial activity against Salmonella typhi ATCC 19430 after 18 hrs by conventional agar dilution method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Synthesis and antibacterial activity of nitroaryl thiadiazole-gatifloxacin hybrids. |
| AID563022 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 04-0519 harboring gyrA Ala90Val and Asp94Asn mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID278263 | Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS14 tolC::Kan with GyrA D87G mutant | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID285767 | Antibacterial activity against Clostridium difficile | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID1600117 | Antibacterial activity against Serratia marcescens ATCC 12795 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID105998 | In vitro inhibitory activity on MRC5 fibroblast tissue cultures inoculated with virulent RH strain of Toxoplasma gondii | 2004 | Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11 | Synthesis of new fluoroquinolones and evaluation of their in vitro activity on Toxoplasma gondii and Plasmodium spp. |
| AID559376 | Antimicrobial activity against Clostridium difficile A422A selected after 4 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID278243 | Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-3 tolC::Kan with GyrA S83F, ParC S80I mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID293149 | Antibacterial activity against quinoline-intermediate methicillin-resistant Staphylococcus aureus by agar dilution method | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4 | Synthesis and antibacterial activities of new quinolone derivatives utilizing 1-azabicyclo[1.1.0]butane. |
| AID559407 | Antimicrobial activity against Clostridium difficile BI2B selected after 4 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID278266 | Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS18 acrAB::Kan with GyrA S38F mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID278054 | Inhibition of peptidoglycan-induced NF kappaB activation in human PC3 cells at 16 ug/ml | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID429029 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate HTD 798 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID699002 | Cmax in human at 400 mg, po | 2012 | European journal of medicinal chemistry, May, Volume: 51 | Tuberculosis: the drug development pipeline at a glance. |
| AID1079938 | Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] | |||
| AID1600114 | Bactericidal activity against methicillin resistant Staphylococcus epidermidis ATCC 13199 cultured in MH medium assessed as reduction in bacterial survival incubated for 48 hrs by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID530597 | Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr9 carrying Smqnr gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia. |
| AID759326 | Antibacterial activity against Staphylococcus aureus KCTC 503 after 24 hrs by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Synthesis and biological evaluation of rhodanine derivatives bearing a quinoline moiety as potent antimicrobial agents. |
| AID285799 | Antibacterial activity against Salmonella enterica serovar Enteritidis | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID342253 | Drug level in Clostridium difficile infected CF1 mouse stool at 0.2 mg/day for 4 days | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID588213 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID1254080 | Antibacterial activity against quinolone-resistant Staphylococcus aureus CCARM 3519 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22 | Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents. |
| AID249969 | Ratio of MPC to MIC against methicillin resistant Staphylococcus aureus-33 | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID351290 | Antibacterial activity against Staphylococcus epidermidis ATCC 4940 after 18 hrs by conventional agar dilution method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Synthesis and antibacterial activity of nitroaryl thiadiazole-gatifloxacin hybrids. |
| AID1237424 | Antibacterial activity against quinolone-resistant Staphylococcus aureus CCARM 3505 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety. |
| AID530596 | Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr8 carrying Smqnr gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia. |
| AID243188 | Inhibition of human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel) in open state | 2005 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6 | A two-state homology model of the hERG K+ channel: application to ligand binding. |
| AID563224 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0777 assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID322983 | Antimicrobial activity against macrolide-susceptible Mycoplasma pneumoniae Mac | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae. |
| AID1600105 | Antibacterial activity against Escherichia coli ATCC 8739 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID558878 | Antimicrobial activity against Clostridium difficile 630 expressing tcdA and tcdB gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID563032 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0746 by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID563210 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 04-0519 harboring gyrA Ala90Val and Asp94Asn mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID286075 | Half life at 175 mg/24 hrs regimen in vitro PK model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID264950 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv | 2006 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11 | Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase. |
| AID1254076 | Antifungal activity against Candida albicans 7535 by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22 | Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents. |
| AID467611 | Dissociation constant, pKa of the compound | 2009 | European journal of medicinal chemistry, Nov, Volume: 44, Issue:11 | Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data. |
| AID1626621 | Antimicrobial activity against Staphylococcus aureus isogenic forms expressing rpoB H481Y/gyrA S84L/parC S80F mutant | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14 | Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections. |
| AID428898 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT18 harboring DNA gyrase A S83F and D87G mutation assessed as decrease in viable count at 8 times MIC after 4 hrs by time-kill analysis | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID429020 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG16 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID425562 | Antibacterial activity against penicillin- and quinolone-susceptible Streptococcus pneumoniae HMC 5055 expressing mefA after 50 passages by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID342073 | Effect on growth of nonepidemic Clostridium difficile J29 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.2 mg/day, sc for 4 days assessed after 2 days of last treatment | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID428979 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate E86 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1491402 | Antimycobacterial activity against multidrug resistant Mycobacterium tuberculosis after 3 to 7 days by rapid direct susceptibility test | |||
| AID237458 | Partition coefficient (logD7.4) | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID285726 | Antibacterial activity against beta-lactamase positive Enterococcus faecalis | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID425560 | Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 3583 expressing mefA by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID558876 | Antimicrobial activity against Clostridium difficile CD25 expressing tcdA, tcdB gene and GyrB Ser416Ala mutant gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID733009 | Antimicrobial activity against Mycobacterium tuberculosis H37Rv assessed as drug concentration causing =<1% reduction in bacterial growth incubated for 21 to 30 days by proportion method | 2013 | Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4 | Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis. |
| AID1237416 | Bactericidal activity against Escherichia coli KCTC 1924 after 24 hrs by agar plate method | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety. |
| AID528499 | Antimicrobial activity against low level levofloxacin and methicillin-resistant Staphylococcus aureus JCSC 6768 expressing gyrA Glu84Lys and grlA Ser80Phe mutants by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID1079942 | Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] | |||
| AID285724 | Antibacterial activity against VanA-resistant Enterococcus faecalis | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID558609 | Antimicrobial activity against Streptococcus pneumoniae isolate 1397 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID285742 | Antibacterial activity against Citrobacter freundii | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID429013 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT60 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID429031 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate BL 21095 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1382072 | Antibacterial activity against methicillin-resistant Staphylococcus aureus by CLSI agar dilution method | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Ciprofloxacin derivatives and their antibacterial activities. |
| AID558623 | Antimicrobial activity against Streptococcus pneumoniae isolate 3412 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID429028 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate AG259 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID1330190 | Antibacterial activity against Escherichia coli 1356 measured after 24 hrs by two-fold serial dilution method | 2016 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24 | Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties. |
| AID1382066 | Antibacterial activity against Escherichia coli ATCC 700603 by CLSI agar dilution method | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Ciprofloxacin derivatives and their antibacterial activities. |
| AID278230 | Antimicrobial activity against Salmonella enterica serovar Typhimurium S21 acrAB::Kan | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID559169 | Antimicrobial activity against Clostridium difficile BI2c harboring GyrB Arg447Lys mutant gene selected after 2 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID444054 | Oral bioavailability in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID559508 | Antibacterial activity against Staphylococcus warneri assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID561390 | Antibacterial activity against quinolone-susceptible Bordetella pertussis BP106 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Emergence of quinolone-resistant Bordetella pertussis in Japan. |
| AID561395 | Antibacterial activity against quinolone-susceptible Bordetella pertussis BP115 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Emergence of quinolone-resistant Bordetella pertussis in Japan. |
| AID244934 | Minimum inhibitory concentration against Enterococcus faecalis ATCC 29212 | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID559389 | Antimicrobial activity against Clostridium difficile A422H harboring GyrA Thr82Ile and GyrB Leu451Phe mutant genes selected after 8 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID558927 | Antimicrobial activity against Clostridium difficile A422c selected after 2 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID1067069 | Antimicrobial activity against quinolone-resistant Staphylococcus aureus clinical isolate 3519 after 20 hrs by two-fold serial dilution technique | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives. |
| AID1570244 | Antimycobacterial activity against rifampicin-resistant Mycobacterium tuberculosis incubated for 7 days by rapid direct susceptibility test | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains. |
| AID498189 | Antibacterial activity against Stenotrophomonas maltophilia MBS109 containing chromosomally encoded Smqnr gene by epsilon test | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia. |
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID542505 | Antimicrobial activity against Escherichia coli K-12 harboring gyrA L83, N87, parC I80 and parE M464 mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. |
| AID559005 | Antibacterial activity against Streptococcus pneumoniae W002 harboring wild-type parC and gyrA genes | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms. |
| AID429007 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT40 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID208121 | In vitro antibacterial activity was tested for Streptococcus pneumoniae SV-1 | 1995 | Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22 | The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. |
| AID1551293 | Antibacterial activity against Streptococcus mutans KCTC3289 assessed as reduction in bacterial cell growth incubated for 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Jun-15, Volume: 172 | Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents. |
| AID1510744 | Antibacterial activity against methicillin-resistant Staphylococcus aureus by two fold dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Nitroimidazole-containing compounds and their antibacterial and antitubercular activities. |
| AID285713 | Antibacterial activity against Staphylococcus warneri | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID351291 | Antibacterial activity against Streptococcus pneumoniae ATCC 1240 after 18 hrs by conventional agar dilution method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Synthesis and antibacterial activity of nitroaryl thiadiazole-gatifloxacin hybrids. |
| AID271603 | Antibacterial activity against Enterococcus faecalis MGH2 EF1-1 | 2006 | Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22 | 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. |
| AID563042 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 03-0738 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID563043 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-2934 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID542520 | Antimicrobial activity against fluoroquinolone-resistant Escherichia coli clinical isolate by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates. |
| AID298868 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 700699 by micro-broth dilution method | 2007 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7 | Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones. |
| AID285709 | Antibacterial activity against oxacillin-susceptible Staphylococcus epidermidis | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID444057 | Fraction escaping hepatic elimination in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID278239 | Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-2 tolC::Kan with GyrA S83F, ParC S80I mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID559493 | Antibacterial activity against Fusobacterium sp. assessed as percent susceptible isolates by CLSI M11-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1570245 | Antimycobacterial activity against multidrug (isoniazid and rifampicin) resistant Mycobacterium tuberculosis 1 incubated for 7 days by rapid direct susceptibility test | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains. |
| AID575946 | Antimicrobial activity against erythromycin-resistant Streptococcus pneumoniae assessed as susceptible isolates by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates. |
| AID1570246 | Antimycobacterial activity against multidrug (isoniazid and rifampicin) resistant Mycobacterium tuberculosis 2 incubated for 7 days by rapid direct susceptibility test | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains. |
| AID425558 | Antibacterial activity against penicillin-, quinolone-resistant and macrolide-susceptible Streptococcus pneumoniae HMC 1058 harboring S79F, K137N mutation in quinolone-resistant determining regions of ParC gene and 460V mutation in QRDR of ParE gene by br | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID542500 | Antimicrobial activity against Escherichia coli K-12 harboring by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. |
| AID278260 | Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS14 with GyrA D87G mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID425343 | Antibacterial activity against Streptococcus pneumoniae HMC 1151 harboring D83N, K137N mutation in quinolone-resistant determining regions of ParC gene and I460V mutation in QRDR of ParE gene showing efflux to ciprofloxacin, gemifloxacin by agar dilution | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID1237412 | Bactericidal activity against Staphylococcus aureus RN4220 after 24 hrs by agar plate method | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety. |
| AID456027 | Antibacterial activity against Staphylococcus epidermidis 56500 after 18 hrs by twofold microbroth dilution method | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria. |
| AID388870 | Antibacterial activity against Staphylococcus aureus ATCC 13709 after 24 hrs by microdilution method | 2008 | Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20 | Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis. |
| AID1079945 | Animal toxicity known. [column 'TOXIC' in source] | |||
| AID558624 | Antimicrobial activity against Streptococcus pneumoniae isolate 3455 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID298864 | Antibacterial activity against Escherichia coli ATCC 25922 by micro-broth dilution method | 2007 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7 | Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones. |
| AID425554 | Antibacterial activity against macrolide-, quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 100 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID429021 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate AG17 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID625292 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID563220 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0746 assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID563049 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0791 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID559243 | Antibacterial activity against Streptococcus pneumoniae S004 harboring wild-type parC and gyrA Gly85Asn mutant genes assessed as mutation prevention concentration after 48 hrs | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms. |
| AID1330189 | Antibacterial activity against Escherichia coli 1924 measured after 24 hrs by two-fold serial dilution method | 2016 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24 | Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties. |
| AID425765 | Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 228 expressing ermB and harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79Y mutation in QRDR of ParC gene and I460 | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID429006 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT37 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID563015 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0744 harboring gyrA Asp94Tyr mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID425359 | Antibacterial activity against Streptococcus pneumoniae HMC 1074 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79F mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID293155 | Antibacterial activity against Escherichia coli without AcrAB efflux system by agar dilution method | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4 | Synthesis and antibacterial activities of new quinolone derivatives utilizing 1-azabicyclo[1.1.0]butane. |
| AID244926 | Minimum inhibitory concentration against Bacteroides vulgatus ATCC 29327 | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID563029 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0773 harboring gyrA Pro8Ala mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1067082 | Antimicrobial activity against Staphylococcus aureus 209 after 20 hrs by two-fold serial dilution technique | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives. |
| AID286093 | fAUC/MIC ratio of Staphylococcus aureus BSP-2443 at 235 mg | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID285751 | Antibacterial activity against Proteus vulgaris | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID613789 | Antibacterial activity against Enterococcus faecium 08-2 after 18 to 24 hrs by NCCLS M100-S11 two fold serial dilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives. |
| AID1079937 | Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] | |||
| AID559521 | Antibacterial activity against Streptococcus oralis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID584114 | Antibacterial activity against Escherichia coli KAM32 harboring Staphylococcus aureus cloned pSP72 lmrS by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus. |
| AID298872 | Antibacterial activity against vancomycin-resistant Enterococcus faecium ATCC 700221 by microbroth dilution method | 2007 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7 | Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones. |
| AID559163 | Antimicrobial activity against Clostridium difficile 630i harboring GyrB Asp26Val mutant gene selected after 8 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID561396 | Antibacterial activity against quinolone-susceptible Bordetella pertussis BP128 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Emergence of quinolone-resistant Bordetella pertussis in Japan. |
| AID271607 | Antibacterial activity against quinolone-resistant Streptococcus pneumonia SP3763 | 2006 | Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22 | 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. |
| AID279275 | Antimicrobial activity against Streptococcus pneumoniae R6 | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. |
| AID278229 | Antimicrobial activity against Salmonella enterica serovar Typhimurium S21 gyrA+ | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID372990 | Antimycobacterial activity against Mycobacterium intracellular JATA52-01 infected C57BL/6J mouse assessed as lung bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID563221 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0762 assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID342083 | Effect on growth of epidemic Clostridium difficile BI6-8-17 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.4 mg/day, sc for 4 days assessed after 2 days of last treatment | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID558879 | Antimicrobial activity against Clostridium difficile BI2 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID285710 | Antibacterial activity against oxacillin-resistant Staphylococcus epidermidis | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID562827 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-1647 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID625281 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1237413 | Bactericidal activity against Staphylococcus aureus KCTC 209 after 24 hrs by agar plate method | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety. |
| AID425544 | Antibacterial activity against Streptococcus pneumoniae HMC 1541 harboring S81Y mutation in quinolone-resistant determining regions of GyrA gene, S79F, K137N mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID279284 | Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parC S79Y and gyrA E85K mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. |
| AID1237423 | Antibacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3506 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety. |
| AID1067074 | Antimicrobial activity against Salmonella typhimurium 1926 after 20 hrs by two-fold serial dilution technique | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives. |
| AID1330186 | Antibacterial activity against Staphylococcus aureus 4220 measured after 24 hrs by two-fold serial dilution method | 2016 | Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24 | Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties. |
| AID1601843 | Antibacterial activity against Streptococcus pyogenes CMCC 32067 measured after 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Mar-15, Volume: 166 | Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety. |
| AID1916143 | Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 in C57BL/6 mouse model of bacterial keratitis assessed as log reduction in number of viable bacterial colonies in infected cornea at 3 mg/ml, TOP administered 4 times a day for 3 consecutive | |||
| AID286063 | Half life at 400 mg/24 hrs regimen in vitro PK model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID450457 | Antibacterial activity against Staphylococcus aureus after 24 hrs by twofold serial dilution method | 2009 | Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15 | Interaction of drug based binuclear mixed-ligand complexes with DNA. |
| AID1402093 | Antibacterial activity against Staphylococcus aureus | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | 4-Quinolone derivatives and their activities against Gram positive pathogens. |
| AID558885 | Antimicrobial activity against Clostridium difficile C253c selected after 2 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID1237428 | Bactericidal activity against quinolone-resistant Staphylococcus aureus CCARM 3505 after 24 hrs by agar plate method | 2015 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15 | Synthesis and antimicrobial evaluation of 5-aryl-1,2,4-triazole-3-thione derivatives containing a rhodanine moiety. |
| AID425355 | Antibacterial activity against Streptococcus pneumoniae HMC 1055 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79F, K137N mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID561389 | Antibacterial activity against quinolone-susceptible Bordetella pertussis BP101 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Emergence of quinolone-resistant Bordetella pertussis in Japan. |
| AID584116 | Ratio of MIC for Escherichia coli KAM32 harboring cloned pSP72 lmrS to MIC for Escherichia coli KAM32 harboring pSP72 | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus. |
| AID428992 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 50 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID428991 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 46 harboring DNA gyrase A D87G mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID433578 | Inhibition of Mycobacterium leprae wild type DNA gyrase subunit A G89A mutant assessed as formation of DNA cleavable complex | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones? |
| AID429005 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT18 harboring DNA gyrase A S83F and D87G mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID601783 | Antibacterial activity against 10'4 CFU Enterococcus faecalis 08-10 after 18 hrs by CLSI agar dilution method | 2011 | European journal of medicinal chemistry, Jun, Volume: 46, Issue:6 | Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives. |
| AID528512 | Bactericidal activity against low level levofloxacin and methicillin-resistant Staphylococcus aureus at 8 times MIC after 24 hrs by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID429024 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate AG169 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID542514 | Antimicrobial activity against Escherichia coli K-12 harboring gyrA L83, Y87 and parC I80 mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. |
| AID368420 | Antimicrobial activity against Escherichia coli KAM32 pHPA containing mutated GyrA gene by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. |
| AID271594 | Antibacterial activity against Haemophilus influenzae HI3542 | 2006 | Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22 | 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. |
| AID433580 | Inhibition of Mycobacterium leprae wild type DNA gyrase subunit B D205N mutant assessed as formation of DNA cleavable complex | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones? |
| AID559186 | Antimicrobial activity against Clostridium difficile C253E selected after 8 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID1600094 | Lipophilicity, log k of the compound at 100 ug/ml by micellar electrokinetic chromatography | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID351289 | Antibacterial activity against Staphylococcus aureus ATCC 25923 after 18 hrs by conventional agar dilution method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Synthesis and antibacterial activity of nitroaryl thiadiazole-gatifloxacin hybrids. |
| AID450460 | Antibacterial activity against Pseudomonas aeruginosa after 24 hrs by twofold serial dilution method | 2009 | Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15 | Interaction of drug based binuclear mixed-ligand complexes with DNA. |
| AID528518 | Bactericidal activity against low level levofloxacin and methicillin-resistant Staphylococcus aureus at 2048 ug/ml after 24 hrs by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID559491 | Antibacterial activity against Bacteroides fragilis assessed as percent susceptible isolates by CLSI M11-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID405464 | Antibacterial activity against Escherichia coli TOP10 containing pIP1206 plasmid by Etest | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. |
| AID563055 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0744 harboring gyrA Asp94Tyr mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID285775 | Antibacterial activity against Peptostreptococcus prevotii | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID759323 | Antibacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3506 after 24 hrs by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Synthesis and biological evaluation of rhodanine derivatives bearing a quinoline moiety as potent antimicrobial agents. |
| AID625283 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID556013 | Antibacterial activity against Helicobacter pylori infected in human assessed as bacterial eradication rate at 400 mg, po QD for 7 days | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. |
| AID528504 | Bactericidal activity against methicillin-resistant Staphylococcus aureus at 8 times MIC upto 60 mins by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID1888650 | Antibacterial activity against ciprofloxacin resistant Staphylococcus aureus harboring ParCS80F and GyrAS84L double mutant assessed as inhibition of bacterial growth | 2022 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 57 | Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics. |
| AID271586 | Inhibition of Escherichia coli gyrase | 2006 | Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22 | 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. |
| AID206765 | In vitro antibacterial activity was tested for Staphylococcus aureus UC-76 | 1995 | Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22 | The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. |
| AID445445 | Permeability at pH 6.5 by PAMPA method | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability. |
| AID1570242 | Selectivity index, ratio of CC50 for African green monkey Vero cells to MIC for Mycobacterium tuberculosis H37Rv | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains. |
| AID405462 | Antibacterial activity against Escherichia coli TOP10 in presence of 40 ug/ml efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine by Etest | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. |
| AID601779 | Antibacterial activity against 10'4 CFU methicillin-resistant Staphylococcus aureus 08-1 after 18 hrs by CLSI agar dilution method | 2011 | European journal of medicinal chemistry, Jun, Volume: 46, Issue:6 | Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives. |
| AID279281 | Antimicrobial activity against Streptococcus pneumoniae R6 transformants with gyrA E85K mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. |
| AID285784 | Antibacterial activity against Streptococcus salivarius | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID428984 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 102 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID425572 | Antibacterial activity against penicillin-, macrolide- and quinolone-susceptible Streptococcus pneumoniae HMC 63 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, D83Y mutation in QRDR of ParC gene and I460V mutation in QRDR | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID351299 | Antibacterial activity against Serratia marcescens PTCC 1111 after 18 hrs by conventional agar dilution method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Synthesis and antibacterial activity of nitroaryl thiadiazole-gatifloxacin hybrids. |
| AID279258 | Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 1076 with ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID425550 | Antibacterial activity against penicillin-susceptible, quinolone-resistant Streptococcus pneumoniae 1072 expressing ermB and harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79Y mutation in QRDR of ParC gene and I460V muta | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID372984 | Antimycobacterial activity against Mycobacterium avium JATA51-01 infected C57BL/6J mouse assessed as lung bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID530348 | Antimicrobial activity against azide-resistant Escherichia coli J53 by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID456030 | Antibacterial activity against Streptococcus mitis IID685 after 18 hrs by twofold microbroth dilution method | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria. |
| AID66574 | Antibacterial activity was determined against clinically isolated vancomycin-B resistant enterococci (VRE) strains (10 strains) | 2003 | Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6 | Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents. |
| AID563225 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0779 assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID558914 | Antimicrobial activity against Clostridium difficile CD5h harboring GyrA Ala92Glu and GyrB Ser416Ala mutant genes selected after 8 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID467613 | Volume of distribution at steady state in human | 2009 | European journal of medicinal chemistry, Nov, Volume: 44, Issue:11 | Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data. |
| AID429011 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT49 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID559492 | Antibacterial activity against Clostridium perfringens assessed as percent susceptible isolates by CLSI M11-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID425557 | Antibacterial activity against quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 5048 expressing mefA by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID563018 | Antimycobacterial activity against Mycobacterium tuberculosis 04-0649 harboring gyrA Asp94Asn mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID405823 | Antimicrobial activity against Acinetobacter baumannii 9043 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID1240505 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by broth microdilution method | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16 | N-Lipidated Peptide Dimers: Effective Antibacterial Agents against Gram-Negative Pathogens through Lipopolysaccharide Permeabilization. |
| AID563011 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 99-1914 harboring gyrA Asp94Gly mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID433403 | Inhibition of Mycobacterium leprae wild type DNA gyrase subunit B D205N mutant assessed as DNA supercoiling inhibition | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones? |
| AID1570243 | Inhibition of Mycobacterium tuberculosis DNA gyrase | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180 | Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains. |
| AID342095 | Increase in toxin level in epidemic Clostridium difficile BI6-8-17 infected CF1 mouse at 2 mg/day, sc for 4 days assessed after 2 days of last treatment | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID759321 | Antibacterial activity against quinolone-resistant Staphylococcus aureus CCARM 3519 after 24 hrs by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Synthesis and biological evaluation of rhodanine derivatives bearing a quinoline moiety as potent antimicrobial agents. |
| AID1067076 | Antimicrobial activity against Pseudomonas aeruginosa 2004 after 20 hrs by two-fold serial dilution technique | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives. |
| AID456048 | Inhibition of Staphylococcus aureus DNA topoisomerase 4 Ser80Phe mutant | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria. |
| AID428981 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate C152 harboring DNA gyrase A S83Y mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID559406 | Antimicrobial activity against Clostridium difficile BI2A selected after 4 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID558591 | Antimicrobial activity against Streptococcus pneumoniae 3 by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID271590 | Antibacterial activity against Providencia rettgeri PR9 | 2006 | Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22 | 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. |
| AID394143 | Antibacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method | 2009 | European journal of medicinal chemistry, Jan, Volume: 44, Issue:1 | Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids. |
| AID1626598 | Inhibition of FQ-resistant Staphylococcus aureus GyrA S84L mutant assessed as compound concentration causing 50% induction of cleavage of covalently closed DNA substrate | 2016 | Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14 | Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections. |
| AID372986 | Antimycobacterial activity against Mycobacterium avium JATA51-01 infected C57BL/6J mouse assessed as spleen bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID1254070 | Antibacterial activity against Streptococcus mutans 3065 after 24 hrs by two-fold serial dilution method | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22 | Synthesis and biological evaluation of 1,3-diaryl pyrazole derivatives as potential antibacterial and anti-inflammatory agents. |
| AID528495 | Antimicrobial activity against high level levofloxacin and methicillin-resistant Staphylococcus aureus JCSC 6764 expressing gyrA Ser84Leu, gyrB Asp437Glu norA T389C and grlA Ser80Phe/Glu84Lys mutants by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID531851 | Clearance in tuberculosis patient at 400 mg/day, po administered for 7 days measured after 24 hrs by HPLC | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. |
| AID278052 | Suppression of TNF alpha-stimulated IL8 secretion in human PC3 cells at 16 ug/ml added 30 mins after stimulation | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID601793 | Cytotoxicity against MDCK cells after 48 hrs by CPE assay | 2011 | European journal of medicinal chemistry, Jun, Volume: 46, Issue:6 | Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives. |
| AID372998 | Antimycobacterial activity against Mycobacterium avium complex N016 infected C57BL/6J mouse assessed as spleen bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID425360 | Antibacterial activity against Streptococcus pneumoniae HMC 1077 harboring S81Y and S79F mutation in quinolone-resistant determining regions of GyrA and ParC genes respectively by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID285773 | Antibacterial activity against Peptostreptococcus asaccharolyticus | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID286092 | fAUC/MIC ratio of Staphylococcus aureus BSP-2443 at 198 mg | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID405463 | Antibacterial activity against Escherichia coli TOP10 in presence of 50 ug/ml efflux pump inhibitor phenyl-arginine-beta-naphthylamide by Etest | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. |
| AID559413 | Antimicrobial activity against Clostridium difficile BI2E harboring GyrB Glu466Lys mutant gene selected after 8 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID298860 | Antibacterial activity against Staphylococcus aureus ATCC 33591 by micro-broth dilution method | 2007 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7 | Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones. |
| AID372978 | Antimycobacterial activity against Mycobacterium avium JATA51-01 after 14 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID563047 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0785 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID531860 | Ratio of fAUC in patient with tuberculosis at 400 mg/day, po administered for 7 days to MIC for Mycobacterium tuberculosis | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. |
| AID759322 | Antibacterial activity against quinolone-resistant Staphylococcus aureus CCARM 3505 after 24 hrs by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Synthesis and biological evaluation of rhodanine derivatives bearing a quinoline moiety as potent antimicrobial agents. |
| AID1391312 | Antibacterial activity against quinolone-resistant Staphylococcus aureus isolate CCARM 3505 after 24 hrs by two-fold serial dilution method | 2018 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9 | Synthesis and evaluation of the antibacterial activities of aryl substituted dihydrotriazine derivatives. |
| AID278042 | Decrease in IL8 secretion in human PC3 cells | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID1484396 | Antitubercular activity against Mycobacterium tuberculosis H37Rv | 2017 | European journal of medicinal chemistry, Jun-16, Volume: 133 | Isoniazid derivatives and their anti-tubercular activity. |
| AID158681 | In vitro inhibitory activity against chloroquine-resistant Plasmodium falciparum NF54-R in blood | 2004 | Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11 | Synthesis of new fluoroquinolones and evaluation of their in vitro activity on Toxoplasma gondii and Plasmodium spp. |
| AID444056 | Fraction escaping gut-wall elimination in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID286104 | Bactericidal activity against Staphylococcus aureus ATCC 49619 with Parc S79Y mutation and gyrA S81F mutation at fAUC/MIC of 35 after 48 hrs in pharmacodynamic model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID559412 | Antimicrobial activity against Clostridium difficile BI2D harboring GyrB Glu466Lys mutant gene selected after 8 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID559516 | Antibacterial activity against Streptococcus anginosus assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID278235 | Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-1 tolC::Kan with GyrA S83F mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID563059 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-2399 harboring gyrA Asp94Tyr mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID444052 | Hepatic clearance in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID286103 | Bactericidal activity against Staphylococcus aureus ATCC 49619 with Parc S79Y mutation at fAUC/MIC of 35 after 24 hrs in pharmacodynamic model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID405300 | Toxicity against Leptospira interrogans serovar Portlandvere infected golden Syrian hamster model of acute lethal leptospirosis assessed as induction of diarrhea at 50 mg/kg/day, ip once daily for 5 days administered 2 day after infection | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Efficacy of fluoroquinolones against Leptospira interrogans in a hamster model. |
| AID325855 | Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay | 2008 | Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5 | Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids. |
| AID425565 | Antibacterial activity against macrolide-, quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 99 after 50 passages by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID342098 | Increase in toxin level in epidemic Clostridium difficile BI9 infected CF1 mouse at 1.4 mg/day, sc for 4 days assessed after 2 days of last treatment | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID286116 | Bactericidal activity against Staphylococcus aureus BSP-2443 with parC S52G, N91D mutation and gyrA S114G mutation at fAUC/MIC of 51 after 96 hrs in pharmacodynamic model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID390106 | Binding affinity to bone assessed as drug level bound to cattle bone meal powder by fluorescence assay | 2008 | Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21 | Linking bisphosphonates to the free amino groups in fluoroquinolones: preparation of osteotropic prodrugs for the prevention of osteomyelitis. |
| AID580862 | Cmax in patients with pulmonary tuberculosis at 400 mg/kg, po | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. |
| AID279240 | Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 1076 with ParC S79Y mutation after 20 passages by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID542517 | Antimicrobial activity against Escherichia coli K-12 harboring gyrA L83, Y87, parC I80, G84 and parE A458 mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. |
| AID51930 | K+ channel blocking activity in Chinese hamster ovary cells expressing HERG Kv11.1 | 2002 | Journal of medicinal chemistry, Aug-29, Volume: 45, Issue:18 | Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. |
| AID68339 | In vitro antibacterial activity was tested for Enterobacter cloacae HA2646 | 1995 | Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22 | The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. |
| AID601781 | Antibacterial activity against 10'4 CFU methicillin-resistant Staphylococcus epidermidis 09-2 after 18 hrs by CLSI agar dilution method | 2011 | European journal of medicinal chemistry, Jun, Volume: 46, Issue:6 | Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives. |
| AID433401 | Inhibition of Mycobacterium leprae DNA gyrase subunit A G89C mutant assessed as DNA supercoiling inhibition | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones? |
| AID1391311 | Antibacterial activity against Staphylococcus aureus 4220 after 24 hrs by two-fold serial dilution method | 2018 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9 | Synthesis and evaluation of the antibacterial activities of aryl substituted dihydrotriazine derivatives. |
| AID530638 | Antimicrobial activity against Staphylococcus aureus CB812 harboring rpoB H481Y and gyrA S80F mutant genes by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. |
| AID278061 | Suppression of TNF alpha-stimulated IL8 D-188 mutant promoter activity in human PC3 cells at 16 ug/ml dual luciferase reporter assay | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID1601851 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 measured after 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Mar-15, Volume: 166 | Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety. |
| AID559522 | Antibacterial activity against Streptococcus salivarius assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID245696 | Mutant prevention concentration aganist methicillin resistant Staphylococcus aureus-33 done for 48 hr at 37 degree C with compound | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID303465 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by agar dilution method | 2007 | Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24 | Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid. |
| AID271602 | Antibacterial activity against ciprofolxacin-resistant Staphylococcus aureus SA2017 | 2006 | Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22 | 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. |
| AID1079934 | Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] | |||
| AID1557284 | Antibacterial activity against Staphylococcus aureus by agar diffusion method | 2019 | MedChemComm, Oct-01, Volume: 10, Issue:10 | Quinolone antibiotics. |
| AID558615 | Antimicrobial activity against Streptococcus pneumoniae isolate 2874 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID521102 | Antimicrobial activity against Streptococcus sp. 'group B' isolate 9 harboring gyrA Ser81Leu mutant, parC Ser79Tyr mutant and parE Ileu495Leu mutant gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan. |
| AID425766 | Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 3583 expressing mefA and harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, D83N mutation in QRDR of ParC gene and I46 | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID530635 | Antimicrobial activity against Staphylococcus aureus CB814 harboring fluoroquinolone-resistant gyrA S84L and parC S80F mutant genes by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. |
| AID425353 | Antibacterial activity against Streptococcus pneumoniae HMC 2538 harboring S81Y mutation in quinolone-resistant determining regions of GyrA gene, S79F, K137N mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene showing efflux to ciproflox | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID271601 | Antibacterial activity against methicillin-resistant Staphylococcus aureus SA1417 | 2006 | Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22 | 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. |
| AID1488560 | Antimycobacterial activity against isoniazid/rifampicin/ethambutol-resistant Mycobacterium tuberculosis 09710 by two fold dilution method | |||
| AID559388 | Antimicrobial activity against Clostridium difficile A422G harboring GyrA Thr82Ile and GyrB Leu451Phe mutant genes selected after 8 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID286043 | Susceptibility of Streptococcus pneumoniae ATCC 49619 by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID521101 | Antimicrobial activity against Streptococcus sp. 'group B' isolate 16 harboring gyrA Ser81Leu mutant, parC Ser79Tyr mutant and parE Ileu495Leu mutant gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan. |
| AID373004 | Antimycobacterial activity against Mycobacterium avium complex N018 infected C57BL/6J mouse assessed as spleen bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID442255 | Antimalarial activity against Plasmodium falciparum NF54 | 2009 | Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24 | Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach. |
| AID278053 | Suppression of TNF alpha-stimulated IL8 secretion in human PC3 cells at 16 ug/ml added 60 mins after stimulation | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID1067081 | Antimicrobial activity against Staphylococcus aureus 503 after 20 hrs by two-fold serial dilution technique | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives. |
| AID625291 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID278228 | Antimicrobial activity against Salmonella enterica serovar Typhimurium S21 | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID372979 | Antimycobacterial activity against Mycobacterium intracellular JATA52-01 after 14 days by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID429003 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT9 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID559402 | Antimicrobial activity against Clostridium difficile 630F harboring GyrA Ala118Val mutant gene selected after 8 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID286109 | Bactericidal activity against Staphylococcus aureus ATCC 49619 with parC S79Y mutation at fAUC/MIC of 60 after 72 hrs in pharmacodynamic model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID278049 | Suppression of 0.1 ng/ml LPS-stimulated IL8 secretion in human PC3 cells | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID342080 | Effect on growth of nonepidemic Clostridium difficile ATCC 9689 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.4 mg/day, sc for 4 days assessed after 2 days of last treatment | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID425727 | Half life in mouse at 10 to 100 mg/kg, ip | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. |
| AID559144 | Antimicrobial activity against Clostridium difficile A422h harboring GyrA Asp81Asn mutant gene selected after 8 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID559173 | Antimicrobial activity against Clostridium difficile BI2d harboring GyrB Arg447Lys and Asp426Asn mutant gene selected after 32 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID293157 | Antibacterial activity against Pseudomonas aeruginosa by agar dilution method | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4 | Synthesis and antibacterial activities of new quinolone derivatives utilizing 1-azabicyclo[1.1.0]butane. |
| AID456049 | Selectivity ratio of IC50 for Staphylococcus aureus DNA topoisomerase 4 Ser80Phe mutant to IC50 for Staphylococcus aureus wild type DNA topoisomerase 4 | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria. |
| AID498187 | Antibacterial activity against Stenotrophomonas maltophilia D457 containing chromosomally encoded Smqnr gene by epsilon test | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia. |
| AID563010 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0797 harboring gyrA Ala90Val mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1079931 | Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] | |||
| AID438297 | Inhibition of penicillin-sensitive Streptococcus pneumoniae R6 PBP2X preincubated for 1 hr before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid | 2009 | Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19 | Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening. |
| AID558593 | Antimicrobial activity against Streptococcus pneumoniae 5 by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID1079932 | Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] | |||
| AID759325 | Antibacterial activity against Escherichia coli CCARM 1356 after 24 hrs by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Synthesis and biological evaluation of rhodanine derivatives bearing a quinoline moiety as potent antimicrobial agents. |
| AID1382071 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus by CLSI agar dilution method | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Ciprofloxacin derivatives and their antibacterial activities. |
| AID755684 | Inhibition of human ERG current by patch clamp assay | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13 | The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel. |
| AID322988 | Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae with 23S rRNA A2064G mutant isolate 4 | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae. |
| AID278254 | Antimicrobial activity against Salmonella enterica serovar Typhimurium CS3 acrAB::Kan with GyrA S83F, D87N, ParC S80I mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID530349 | Antimicrobial activity against Escherichia coli TOP10 harboring pQep plasmid carrying qepA2 gene by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID324745 | Inhibition of Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as inhibition of pBR322 DNA supercoiling | 2007 | Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5 | Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones. |
| AID279288 | Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parC D83Y and gyrA S81F mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. |
| AID1067079 | Antimicrobial activity against Escherichia coli KCTC 1924 after 20 hrs by two-fold serial dilution technique | 2014 | European journal of medicinal chemistry, Mar-03, Volume: 74 | Synthesis and evaluation of the antimicrobial activities of 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)-2-thioxothiazolidin-4-one derivatives. |
| AID530346 | Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M plasmid carrying blaCTX-M-15 gene by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID405469 | Antibacterial activity against Escherichia coli TOP10 containing pAT851 in presence of 50 ug/ml efflux pump inhibitor phenyl-arginine-beta-naphthylamide by Etest | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. |
| AID588209 | Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset | 2010 | Chemical research in toxicology, Jul-19, Volume: 23, Issue:7 | Developing structure-activity relationships for the prediction of hepatotoxicity. |
| AID530630 | Ratio of CC50 for wild-type Staphylococcus aureus GyrA to CC50 for wild-type Staphylococcus aureus ParC | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. |
| AID1391314 | Antibacterial activity against Streptococcus mutans 3289 after 24 hrs by two-fold serial dilution method | 2018 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9 | Synthesis and evaluation of the antibacterial activities of aryl substituted dihydrotriazine derivatives. |
| AID558631 | Antimicrobial activity against Streptococcus pneumoniae isolate 4755 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID262135 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus 700699 | 2006 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5 | Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells. |
| AID559193 | Antimicrobial activity against Clostridium difficile CD5C harboring GyrB Ser416Ala mutant gene selected after 4 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID580856 | Antimicrobial activity against rifampicin-resistant Mycobacterium tuberculosis | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. |
| AID733005 | Inhibition of Mycobacterium leprae wild type DNA gyrase GyrA/GyrB A91V mutant-mediated DNA cleavable complex formation assessed as compound concentration inducing 25% DNA cleavage using relaxed pBR322 DNA substrate incubated for 1 hr at 30 degC by agarose | 2013 | Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4 | Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis. |
| AID286046 | Peak free concentration at 150 mg/24 hrs regimen in vitro PK model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID559504 | Antibacterial activity against Staphylococcus haemolyticus assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID279278 | Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parC D83Y mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. |
| AID559383 | Antimicrobial activity against Clostridium difficile A422E harboring GyrB Leu451Phe mutant gene selected after 8 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID561394 | Antibacterial activity against quinolone-susceptible Bordetella pertussis BP113 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Emergence of quinolone-resistant Bordetella pertussis in Japan. |
| AID601786 | Antibacterial activity against 10'4 CFU Enterococcus faecium 06-7 after 18 hrs by CLSI agar dilution method | 2011 | European journal of medicinal chemistry, Jun, Volume: 46, Issue:6 | Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives. |
| AID528511 | Bactericidal activity against levofloxacin-sensitive and methicillin-resistant Staphylococcus aureus at 4 times MIC after 24 hrs by time-kill assay | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID425345 | Antibacterial activity against Streptococcus pneumoniae HMC 1060 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79F, K137N mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID565322 | Antibacterial activity against Mycoplasma genitalium M6280 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID262136 | Cytotoxicity against human Hep2 laryngeal carcinoma cell line | 2006 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5 | Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells. |
| AID351294 | Antibacterial activity against Micrococcus luteus ATCC 1110 after 18 hrs by conventional agar dilution method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Synthesis and antibacterial activity of nitroaryl thiadiazole-gatifloxacin hybrids. |
| AID271591 | Antibacterial activity against Pseudomonas aeruginosa PA7 | 2006 | Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22 | 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. |
| AID279279 | Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parE D435N mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. |
| AID601788 | Antibacterial activity against 10'4 CFU Escherichia coli 08-21 after 18 hrs by CLSI agar dilution method | 2011 | European journal of medicinal chemistry, Jun, Volume: 46, Issue:6 | Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives. |
| AID559394 | Antimicrobial activity against Clostridium difficile 630A selected after 4 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID1600107 | Antibacterial activity against Pseudomonas aeruginosa ATCC 9027 cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID279253 | Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 37 with GyrA S81Y, GyrB E474K and ParC S79Y mutation after 14 passages by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID405820 | Antimicrobial activity against Acinetobacter baumannii 501 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID244722 | Frequency of resistance emergence for methicillin resistant Staphylococcus aureus-5023 | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID601792 | Antibacterial activity against 10'4 CFU Pseudomonas aeruginosa 09-32 after 18 hrs by CLSI agar dilution method | 2011 | European journal of medicinal chemistry, Jun, Volume: 46, Issue:6 | Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives. |
| AID759328 | Antibacterial activity against Staphylococcus aureus RN4220 after 24 hrs by broth microdilution method | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15 | Synthesis and biological evaluation of rhodanine derivatives bearing a quinoline moiety as potent antimicrobial agents. |
| AID558599 | Antimicrobial activity against Streptococcus pneumoniae 11 by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID279271 | Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 2527 after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID342072 | Effect on growth of nonepidemic Clostridium difficile ATCC 9689 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.2 mg/day, sc for 4 days assessed after 2 days of last treatment | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID625290 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID265979 | Antimycobacterial activity against multidrug resistant Mycobacterium tuberculosis | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 | Discovery of new antitubercular oxazolyl thiosemicarbazones. |
| AID559533 | Antibacterial activity against Klebsiella oxytoca assessed as percent susceptible isolates by CLSI M7-A7 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID1240501 | Antibacterial activity against Pseudomonas aeruginosa DU14476 after 24 hrs by broth microdilution method | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16 | N-Lipidated Peptide Dimers: Effective Antibacterial Agents against Gram-Negative Pathogens through Lipopolysaccharide Permeabilization. |
| AID1382073 | Antibacterial activity against Klebsiella pneumoniae ATCC 25922 by CLSI agar dilution method | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Ciprofloxacin derivatives and their antibacterial activities. |
| AID279260 | Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 1077 with 23S rRNA A2058G mutation after 10 antibiotic-free subcultures by macrodilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents. |
| AID433581 | Selectivity index, ratio of IC50 for Mycobacterium leprae DNA gyrase subunit A G89C mutant to IC50 for Mycobacterium leprae wild type DNA gyrase A2B2 | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones? |
| AID325853 | Antimycobacterial activity against multidrug resistant Mycobacterium tuberculosis by agar dilution method | 2008 | Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5 | Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids. |
| AID456028 | Antibacterial activity against Streptococcus pneumoniae J-24 after 18 hrs by twofold microbroth dilution method | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria. |
| AID206214 | Antibacterial activity was determined against Staphylococcus epidermis 56500 strain after incubation at 37 degrees C for 18 h | 2003 | Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6 | Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents. |
| AID373003 | Antimycobacterial activity against Mycobacterium avium complex N018 infected C57BL/6J mouse assessed as liver bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID405468 | Antibacterial activity against Escherichia coli TOP10 containing pAT851 in presence of 40 ug/ml efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine by Etest | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. |
| AID558620 | Antimicrobial activity against Streptococcus pneumoniae isolate 3282 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID542507 | Antimicrobial activity against Escherichia coli K-12 harboring gyrA L83, N87 and parC I80, G84 mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. |
| AID558628 | Antimicrobial activity against Streptococcus pneumoniae isolate 3681 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID278063 | Decrease in IL8 secretion in human prostatic myofibroblast cells at 4 ug/ml | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID733007 | Inhibition of Mycobacterium leprae DNA gyrase GyrA/GyrB assessed as reduction of enzyme supercoiling activity using relaxed pBR322 DNA substrate incubated for 2 hrs at 30 degC by ethidium bromide based gel electrophoresis | 2013 | Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4 | Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis. |
| AID278056 | Inhibition of TNF alpha-induced NF kappaB activation in human PC3 cells at 16 ug/ml | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID1510742 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis by two fold dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Nitroimidazole-containing compounds and their antibacterial and antitubercular activities. |
| AID425561 | Antibacterial activity against penicillin-, quinolone-resistant Streptococcus pneumoniae HMC 1541 harboring mutation in L4 protein by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID405458 | Antibacterial activity against Escherichia coli C600Rif containing pIP1206 plasmid by Etest | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. |
| AID244720 | Frequency of resistance emergence for methicillin resistant Staphylococcus aureus-32 | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID1551294 | Antibacterial activity against Escherichia coli 1924 assessed as reduction in bacterial cell growth incubated for 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Jun-15, Volume: 172 | Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents. |
| AID542504 | Antimicrobial activity against Escherichia coli K-12 harboring gyrA L83, N87 and parC I80 mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. |
| AID559004 | Antibacterial activity against Streptococcus pneumoniae W001 harboring wild-type parC and gyrA genes | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms. |
| AID96072 | Antibacterial activity was determined against Klebsiella pneumoniae type II strain after incubation at 37 degrees C for 18 h | 2003 | Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6 | Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents. |
| AID425574 | Antibacterial activity against macrolide-, quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 100 harboring S81Y and S79Y mutation in quinolone-resistant determining regions of GyrA and ParC genes respectively after 42 passages | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID559151 | Antimicrobial activity against Clostridium difficile 630c selected after 2 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID563033 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0762 by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID558895 | Antimicrobial activity against Clostridium difficile C253g harboring GyrA Ala118Ser mutant gene selected after 8 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID558594 | Antimicrobial activity against Streptococcus pneumoniae 6 by time-kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID322987 | Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae with 23S rRNA A2064G mutant isolate 2 | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae. |
| AID444058 | Volume of distribution at steady state in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID1382070 | Antibacterial activity against Staphylococcus aureus ATCC 29213 by CLSI agar dilution method | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Ciprofloxacin derivatives and their antibacterial activities. |
| AID428989 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate nar 28 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID278058 | Suppression of TNF alpha-stimulated IL8 promoter activity in human PC3 cells | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID286061 | Half life at 150 mg/24 hrs regimen in vitro PK model | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. |
| AID563041 | Antimycobacterial activity against Mycobacterium tuberculosis 00-0715 harboring gyrA Ala90Val mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1079941 | Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] | |||
| AID279287 | Antimicrobial activity agaisnt Streptococcus pneumoniae R6 transformants with parC S79F and gyrA E85K mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. |
| AID613794 | Antibacterial activity against Escherichia coli 08-21 after 18 to 24 hrs by NCCLS M100-S11 two fold serial dilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives. |
| AID372991 | Antimycobacterial activity against Mycobacterium intracellular JATA52-01 infected C57BL/6J mouse assessed as liver bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dos | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID322986 | Antimicrobial activity against macrolide-resistant Mycoplasma pneumoniae with 23S rRNA A2063G mutant isolate 6 | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae. |
| AID342244 | Increase in toxin level in nonepidemic Clostridium difficile J29 infected CF1 mouse at 0.2 mg/day, sc for 4 days assessed after 2 days of last treatment | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID293150 | Antibacterial activity against quinoline-resistant methicillin-resistant Staphylococcus aureus by agar dilution method | 2007 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4 | Synthesis and antibacterial activities of new quinolone derivatives utilizing 1-azabicyclo[1.1.0]butane. |
| AID425573 | Antibacterial activity against macrolide-, quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 99 harboring S81Y and S79Y mutation in quinolone-resistant determining regions of GyrA and ParC genes respectively after 41 passages | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID1264465 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis after 7 days by REMA method | 2015 | ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10 | Nitrofuranyl Methyl Piperazines as New Anti-TB Agents: Identification, Validation, Medicinal Chemistry, and PK Studies. |
| AID1600115 | Antibacterial activity against Streptococcus pneumoniae cultured in MH medium assessed as reduction in bacterial growth incubated for 48 hrs by microbroth dilution method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents. |
| AID207830 | Minimum inhibitory concentration against Staphylococcus aureus - methicillin resistant Ciprofloxacin resistant, strain MI339 | 2003 | Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17 | Discovery of (3S)-amino-(4R)-ethylpiperidinyl quinolones as potent antibacterial agents with a broad spectrum of activity and activity against resistant pathogens. |
| AID565321 | Antibacterial activity against Mycoplasma genitalium M6257 by broth dilution method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR. |
| AID1079940 | Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] | |||
| AID467612 | Fraction unbound in human plasma | 2009 | European journal of medicinal chemistry, Nov, Volume: 44, Issue:11 | Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data. |
| AID285708 | Antibacterial activity against vancomycin-intermediate Staphylococcus aureus | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. |
| AID530598 | Antimicrobial activity against Escherichia coli TOP10 harboring pSmQnr10 carrying Smqnr gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia. |
| AID425728 | Apparent distribution clearance in mouse at 10 to 100 mg/kg, ip | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. |
| AID542513 | Antimicrobial activity against Escherichia coli K-12 harboring gyrA L83, Y87 and parC K84 mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. |
| AID271606 | Antibacterial activity against Streptococcus pneumonia SVI SP3 | 2006 | Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22 | 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. |
| AID264955 | Activity against Mycobacterium tuberculosis ATCC 35801 in CD1 mouse at 50 mg/kg assessed as decrease in bacterial load in lung relative to control | 2006 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11 | Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase. |
| AID733008 | Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB assessed as reduction of enzyme supercoiling activity using relaxed pBR322 DNA substrate incubated for 1 hr at 37 degC by ethidium bromide based gel electrophoresis | 2013 | Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4 | Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis. |
| AID580864 | Half life in patients with pulmonary tuberculosis at 400 mg/kg, po | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. |
| AID424879 | Antimicrobial activity against multidrug-resistant Enterobacter cloacae E705 bearing qnrB10 gene with aac(6)-IId-aadA1a integron in presence of IPTG | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina. |
| AID559162 | Antimicrobial activity against Clostridium difficile 630h harboring GyrB Asp26Val mutant gene selected after 8 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID425346 | Antibacterial activity against Streptococcus pneumoniae HMC 1066 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79F mutation in QRDR of ParC gene and I460V mutation in QRDR of ParE gene by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID429032 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate BL 3769 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID271604 | Antibacterial activity against Enterococcus faecalis EF1-3524 | 2006 | Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22 | 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. |
| AID563017 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0821 harboring gyrA Asp94Tyr mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID162936 | Minimum inhibitory concentration against Pseudomonas aeruginosa, strain PS96 | 2003 | Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17 | Discovery of (3S)-amino-(4R)-ethylpiperidinyl quinolones as potent antibacterial agents with a broad spectrum of activity and activity against resistant pathogens. |
| AID429012 | Antimicrobial activity against multidrug-resistant Salmonella enterica Serovar Typhi isolate DT54 harboring DNA gyrase A S83F mutation by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID613795 | Antibacterial activity against Escherichia coli 08-22 after 18 to 24 hrs by NCCLS M100-S11 two fold serial dilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives. |
| AID559518 | Antibacterial activity against Streptococcus constellatus assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID278044 | Decrease in IL8 secretion in human PC3 cells at 16 ug/ml | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID1199294 | Antimicrobial activity against Staphylococcus aureus ATCC 29213 at 0.5 times MIC measured after 17 passages by multistep passage drug resistance selection study relative to wild type Staphylococcus aureus ATCC 29213 before passage | 2015 | Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2 | Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections. |
| AID1382074 | Antibacterial activity against Bacillus subtilis NCDC 71 after overnight incubation by single disc method | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Ciprofloxacin derivatives and their antibacterial activities. |
| AID540212 | Mean residence time in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID559181 | Antimicrobial activity against Clostridium difficile C253C selected after 4 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID50999 | In vitro antibacterial activity against Clostridium perfringens CP 3-1 | 1995 | Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22 | The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. |
| AID1488565 | Selectivity index, ratio of CC50 for African green monkey Vero cells to MIC for Mycobacterium tuberculosis H37Rv ATCC 27294 | |||
| AID559201 | Antibacterial activity against Streptococcus pneumoniae S002 harboring parC Ser79Phe mutant and wild-type gyrA genes | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms. |
| AID559192 | Antimicrobial activity against Clostridium difficile CD5B harboring GyrB Ser416Ala mutant gene selected after 4 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID298870 | Antibacterial activity against Enterococcus faecalis ATCC 14506 by microbroth dilution method | 2007 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7 | Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones. |
| AID559502 | Antibacterial activity against ciprofloxacin-susceptible and methicillin-resistant Staphylococcus epidermidis assessed as percent susceptible isolates by CLSI M100-S18 method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. |
| AID542516 | Antimicrobial activity against Escherichia coli K-12 harboring gyrA L83, Y87 and parC I80, G84 mutant gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. |
| AID279289 | Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parC D83Y and gyrA S81Y mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. |
| AID1551298 | Antibacterial activity against Methicillin-resistant Staphylococcus aureus CCARM 3506 assessed as reduction in bacterial cell growth incubated for 24 hrs by ELISA | 2019 | European journal of medicinal chemistry, Jun-15, Volume: 172 | Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents. |
| AID456026 | Antibacterial activity against Staphylococcus aureus FDA 209-P after 18 hrs by twofold microbroth dilution method | 2009 | Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19 | Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria. |
| AID351297 | Antibacterial activity against Shigella flexneri NCTC 8516 after 18 hrs by conventional agar dilution method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Synthesis and antibacterial activity of nitroaryl thiadiazole-gatifloxacin hybrids. |
| AID425555 | Antibacterial activity against macrolide-, quinolone-susceptible and penicillin-intermediate Streptococcus pneumoniae HMC 99 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID425580 | Antibacterial activity against penicillin-resistant and quinolone-susceptible Streptococcus pneumoniae HMC 3583 expressing mefA and harboring S81F mutation in quinolone-resistant determining regions of GyrA gene and I460V, D435N mutation in QRDR of ParE g | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID425563 | Antibacterial activity against penicillin-, macrolide- and quinolone-susceptible Streptococcus pneumoniae HMC 63 after 50 passages by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID558626 | Antimicrobial activity against Streptococcus pneumoniae isolate 3481 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID563014 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2230 harboring gyrA Asp94Gly mutant gene by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID1524625 | Antifungal activity against Candida albicans 7535 after 24 hrs by microtiter ELISA | 2019 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9 | Synthesis of novel dihydrotriazine derivatives bearing 1,3-diaryl pyrazole moieties as potential antibacterial agents. |
| AID1199313 | Antimicrobial activity against Staphylococcus aureus ATCC 29213 infected in mouse cornea infection model assessed as reduction in viable bacterial count at 0.3% solution applied topically 5 times/day dosed 1 day after infection relative to control | 2015 | Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2 | Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections. |
| AID613781 | Antibacterial activity against Staphylococcus aureus ATCC 25923 after 18 to 24 hrs by NCCLS M100-S11 two fold serial dilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives. |
| AID271588 | Antibacterial activity against Klebsiella pneumonia KP2 | 2006 | Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22 | 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. |
| AID279276 | Antimicrobial activity against Streptococcus pneumoniae R6 transformants with parC S79F mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. |
| AID1605818 | Antibacterial activity against Mel-5-resistant vancomycin-resistant Enterococcus faecalis 1010 assessed as reduction in bacterial growth measured after 24 hrs by broth microdilution method | 2020 | Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7 | Rational Substitution of ε-Lysine for α-Lysine Enhances the Cell and Membrane Selectivity of Pore-Forming Melittin. |
| AID563037 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 08-0779 by resazurin microtiter assay | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID278231 | Antimicrobial activity against Salmonella enterica serovar Typhimurium S21 tolC::Kan | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID303470 | Antimycobacterial activity against Mycobacterium tuberculosis ATCC 35801 infected CD1 mouse assessed as spleen bacterial count at 50 mg/kg, ip after 35 days post infection | 2007 | Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24 | Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid. |
| AID613784 | Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 09-4 after 18 to 24 hrs by NCCLS M100-S11 two fold serial dilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives. |
| AID351298 | Antibacterial activity against Klebsiella pneumoniae ATCC 10031 after 18 hrs by conventional agar dilution method | 2009 | European journal of medicinal chemistry, Mar, Volume: 44, Issue:3 | Synthesis and antibacterial activity of nitroaryl thiadiazole-gatifloxacin hybrids. |
| AID244957 | Minimum inhibitory concentration against Streptococcus sanguis ATCC 10556 | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID373008 | Antimycobacterial activity against Mycobacterium avium complex N084 infected C57BL/6J mouse assessed as lung bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID563219 | Antimycobacterial activity against Mycobacterium tuberculosis 08-0771 harboring gyrA putative promoter mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID561401 | Antibacterial activity against quinolone-susceptible Bordetella pertussis BP121 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Emergence of quinolone-resistant Bordetella pertussis in Japan. |
| AID559180 | Antimicrobial activity against Clostridium difficile C253B selected after 4 ug/ml of levofloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID271599 | Antibacterial activity against Staphylococcus aureus SA2554 | 2006 | Journal of medicinal chemistry, Nov-02, Volume: 49, Issue:22 | 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms. |
| AID425735 | Ratio of AUC (0 to 24 hrs) for Enterococcus infected patient to MIC for Enterococcus | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. |
| AID342097 | Increase in toxin level in nonepidemic Clostridium difficile J29 infected CF1 mouse at 1.4 mg/day, sc for 4 days assessed after 2 days of last treatment | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID530631 | Ratio of CC50 for Staphylococcus aureus ParC S80F mutant to CC50 for wild-type Staphylococcus aureus ParC | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. |
| AID563054 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 01-2230 harboring gyrA Asp94Gly mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID601787 | Antibacterial activity against 10'4 CFU Escherichia coli ATCC 25922 after 18 hrs by CLSI agar dilution method | 2011 | European journal of medicinal chemistry, Jun, Volume: 46, Issue:6 | Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives. |
| AID66572 | Antibacterial activity was determined against clinically isolated vancomycin-A resistant enterococci (VRE) strains (33 strains) | 2003 | Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6 | Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents. |
| AID425571 | Antibacterial activity against penicillin-, macrolide-susceptible and quinolone-resistant Streptococcus pneumoniae HMC 1074 harboring S81F mutation in quinolone-resistant determining regions of GyrA gene, S79F mutation in QRDR of ParC gene and I460V mutat | 2008 | Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1 | In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. |
| AID428999 | Antimicrobial activity against Salmonella enterica Serovar Typhi isolate CT145 harboring DNA gyrase A S83F mutation by disk diffusion method in presence of plasmid mediated quinolone-resistant gene qnrA and qnrS | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. |
| AID498190 | Antibacterial activity against Stenotrophomonas maltophilia MBS82 deficient in Smqnr gene by epsilon test | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia. |
| AID278055 | Inhibition of Mycoplasma hominis-induced NF kappaB activation in human PC3 cells at 16 ug/ml | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID528498 | Antimicrobial activity against low level levofloxacin and methicillin-resistant Staphylococcus aureus JCSC 6767 expressing gyrA Glu84Lys and grlA Ser80Phe mutants by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID372997 | Antimycobacterial activity against Mycobacterium avium complex N016 infected C57BL/6J mouse assessed as liver bacterial count at 100 mg/kg/day dosed through gavage route administered for 28 days post bacterial challenge measured 2 days after last dose | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. |
| AID244891 | Minimum inhibitory concentration against Escherichia coli ATCC 25922 | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus. |
| AID613783 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus 08-1 after 18 to 24 hrs by NCCLS M100-S11 two fold serial dilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives. |
| AID559241 | Antibacterial activity against Streptococcus pneumoniae S002 harboring parC Ser79Phe mutant and wild-type gyrA genes assessed as mutation prevention concentration after 48 hrs | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms. |
| AID563213 | Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis 02-1234 harboring gyrA Asn533Thr gyrB mutant gene assessed as microbial susceptibility by agar proportion method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. |
| AID559149 | Antimicrobial activity against Clostridium difficile 630a selected after 2 ug/ml of moxifloxacin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. |
| AID561392 | Antibacterial activity against quinolone-susceptible Bordetella pertussis BP111 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Emergence of quinolone-resistant Bordetella pertussis in Japan. |
| AID613786 | Antibacterial activity against methicillin-sensitive Staphylococcus epidermidis 09-6 after 18 to 24 hrs by NCCLS M100-S11 two fold serial dilution method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives. |
| AID558603 | Antimicrobial activity against Streptococcus pneumoniae isolate 37 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Comparative antipneumococcal activities of sulopenem and other drugs. |
| AID278048 | Suppression of TNF alpha-stimulated IL8 secretion in human PC3 cells | 2007 | Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1 | The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. |
| AID342082 | Effect on growth of epidemic Clostridium difficile BI9 in CF1 mouse assessed as increase in bacterial density in cecal content at 0.4 mg/day, sc for 4 days assessed after 2 days of last treatment | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. |
| AID531856 | Cmax in tuberculosis patient at 400 mg/day, po administered for 7 days by HPLC | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. |
| AID528494 | Antimicrobial activity against high level levofloxacin and methicillin-resistant Staphylococcus aureus JCSC 6763 expressing gyrA Ser84Leu/Ser85Pro and grlA Ser80Phe/Glu84Lys mutants by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcu |
| AID278255 | Antimicrobial activity against Salmonella enterica serovar Typhimurium CS3 tolC::Kan with GyrA S83F, D87N, parC S80I mutation | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials. |
| AID405821 | Antimicrobial activity against Acinetobacter baumannii 695 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID394144 | Antibacterial activity against multidrug-resistant Mycobacterium tuberculosis by agar dilution method | 2009 | European journal of medicinal chemistry, Jan, Volume: 44, Issue:1 | Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID493040 | Navigating the Kinome | 2011 | Nature chemical biology, Apr, Volume: 7, Issue:4 | Navigating the kinome. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 45 (4.50) | 18.2507 |
| 2000's | 629 (62.84) | 29.6817 |
| 2010's | 279 (27.87) | 24.3611 |
| 2020's | 48 (4.80) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (75.73) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 131 (12.51%) | 5.53% |
| Reviews | 56 (5.35%) | 6.00% |
| Case Studies | 83 (7.93%) | 4.05% |
| Observational | 4 (0.38%) | 0.25% |
| Other | 773 (73.83%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Controlled Research of the Application of Triple Antibiotic Paste in Primary Teeth With [NCT02196740] | 100 participants (Anticipated) | Interventional | 2013-06-30 | Active, not recruiting | |||
| Clinical Study of the Efficacy of the Ophthalmic Solution of Pazufloxacin 0.6% (PRO-157) for the Treatment of Acute Bacterial Conjunctivitis, Compared to the Ophthalmic Solution of Gatifloxacin 0.3%. [NCT03696342] | Phase 3 | 46 participants (Actual) | Interventional | 2018-10-01 | Terminated(stopped due to Sponsor's convenience) | ||
| Double-Masked, Randomized, Parallel Group Study for Evaluation of Non-Inferiority of 0.3%Gatifloxacin/1.0% Prednisolone Association Compared With Their Isolated Administration in the Prevention of Ocular Infection/Inflammation After LASIK Surgery [NCT01218737] | Phase 3 | 101 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240] | Early Phase 1 | 11 participants (Actual) | Interventional | 2014-03-06 | Terminated(stopped due to Not enough patient enrollment and lack of staffing) | ||
| Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis [NCT03625739] | 800 participants (Anticipated) | Observational [Patient Registry] | 2018-07-01 | Recruiting | |||
| A Randomized, Double Blind, Phase II Multicenter Trial to Evaluate the Safety and Efficacy of PRO-157 Ophthalmic Solution in Three Different Dosing Regimen Versus Moxifloxacin Versus Gatifloxacin in Patients With Bacterial Conjunctivitis. [NCT02980523] | Phase 2 | 150 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| [NCT00414011] | 40 participants (Actual) | Interventional | Completed | ||||
| A Single-Center, Randomized, Masked Study Comparing the Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After a Single Topical Instillation [NCT00905762] | Phase 1 | 119 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| [NCT00703313] | Phase 4 | 72 participants (Anticipated) | Interventional | 2008-05-31 | Completed | ||
| A Randomized Clinical Trial Comparing the Effect of Moxifloxacin Versus Gatifloxacin Following Pterygium Excision on Corneal Epithelial Healing and Epithelial Toxicity. [NCT00892918] | 40 participants (Anticipated) | Interventional | 2009-06-30 | Not yet recruiting | |||
| Swiss PACK-CXL (Photoactivated Chromophore for Infectious Keratitis Cross-linking) Multicenter Trial for the Treatment of Infectious Keratitis [NCT02717871] | Phase 3 | 35 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| Lessdrops™ Prophylactic Treatment After Routine Phacoemulsification Compared to Standard Drops Regimen [NCT03578276] | Phase 4 | 35 participants (Actual) | Interventional | 2018-06-22 | Completed | ||
| Randomized, Open Label, Multiple Dose Phase I Study of the Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, and Moxifloxacin in HIV-non-infected Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis [NCT00396084] | Phase 1/Phase 2 | 70 participants (Actual) | Interventional | 2004-02-10 | Completed | ||
| Effect of Gatifloxacin 0.3% and Moxifloxacin 0.5% on Epithelial Wound Healing After Photorefractive Keratectomy [NCT00569881] | 22 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| [NCT00651586] | Phase 2 | 129 participants (Actual) | Interventional | 2003-10-31 | Completed | ||
| The Effect of Preoperative Topical Gatifloxacin on Anterior Chamber Sample Cultures After Cataract Surgery. [NCT00335231] | 0 participants (Actual) | Interventional | 2006-06-30 | Withdrawn(stopped due to Protocol changes underway. Trial never started) | |||
| Randomized, Open-label, Superiority Trial of the Effectiveness of Gatifloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Enteric Fever. [NCT01421693] | Phase 4 | 300 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| [NCT00874887] | Phase 4 | 66 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| [NCT00433225] | Phase 4 | 0 participants | Interventional | Completed | |||
| Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-hour [NCT00466570] | 0 participants (Actual) | Interventional | 2007-04-30 | Withdrawn | |||
| An Open-Label, Randomized Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects After a Single Topical Dose [NCT00824070] | Phase 1 | 105 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Prospective Study Comparing the Effectiveness of Zymar and Vigamox for Preoperative Antibiotic Sterilization of the Ocular Surface After Loading Dose [NCT00347828] | Phase 4 | 40 participants | Interventional | 2006-06-30 | Active, not recruiting | ||
| [NCT00410891] | Phase 4 | 129 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| A Randomised Open-Label Controlled Trial of a 4-Month Gatifloxacin-Containing Regimen Versus Standard Regimen for the Treatment of Adult Patients With Pulmonary Tuberculosis [NCT00216385] | Phase 3 | 2,070 participants | Interventional | 2005-01-31 | Recruiting | ||
| [NCT00407017] | Phase 4 | 0 participants | Interventional | Completed | |||
| One Hour Preoperative Gatifloxacin [NCT00350363] | Phase 4 | 60 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [NCT00518089] | Phase 3 | 859 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| [NCT00509873] | Phase 3 | 578 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| [NCT00464438] | Phase 4 | 171 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| A Single-site, Single Masked, Prospective Comparison of Three Fluoroquinolone Topical Therapies (Besifloxacin 0.6% or Gatifloxacin 0.5% or Moxifloxacin 0.5%) in the Treatment of Infectious Corneal Ulcers. [NCT01928693] | Phase 2 | 2 participants (Actual) | Interventional | 2013-07-31 | Terminated(stopped due to study terminated due to slow accrual) | ||
| Evaluation of the Safety and Efficacy of Topical Besifloxacin Ophthalmic Suspension, 0.6% Compared With Gatifloxacin, 0.3% Ophthalmic Solution for the Treatment of Presumed Bacterial Conjunctivitis in Subjects From Birth to 31 Days of Age [NCT01330355] | Phase 3 | 33 participants (Actual) | Interventional | 2011-05-31 | Terminated(stopped due to Lack of enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||